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Synthesis and Computational Studies on Hiv-1 Integrase Inhibitors
Abstract
HIV-1 integrase (IN) is essential for viral replication and offers a promising target for the development of
anti-retroviral drugs. Two decades of extensive research has lead to the recent approval of raltegravir as
the first IN inhibitor. Advancement of drug candidate elvitegravir, which is currently in Phase III clinical
trial, has furthermore accelerated efforts against this potential target for combating HIV. However, the
emergence of resistance against raltegravir and elvitegravir demands exploration of novel chemical
scaffolds that could circumvent resistance against currently used HIV-1 IN inhibitors. With the goal of
discovering new agents targeting HIV, a novel structural class of HIV-IN inhibitors have been designed and
synthesized. Substantial computational studies were also performed that could aid the design and
development of potent HIV IN inhibitors. A part of this dissertation research, covered in Chapter 3, details
the design, synthesis, and biological evaluation of 3-keto salicylic acid chalcones as novel HIV-1 IN
inhibitors. In the chalcone series, the most active compound, 5-bromo-2-hydroxy-3-[3-(2,3,6-trichlorophenyl)- acryloyl]-2-hydroxybenzoic acid (96) was selectively active against IN strand transfer (ST) with
IC50 of 3.7 µM. While most of the compounds exhibit ST selectivity, a few were nonselective, such as
5-bromo-3-[3-(4-bromo-phenyl)-acryloyl]-2-hydroxybenzoic acid (86), which was active against both 3!processing (3!-P) and ST with IC50 values of 11 ± 4 and 5 ± 2 "M, respectively. The compounds also
inhibited HIV-1 replication with potencies comparable to their integrase inhibitory activities. Thus,
compounds 96 and 86 inhibited HIV-1 replication with EC50 values of 7.3 and 8.7 "M, respectively.
Chapter 4 describes the synthesis of structurally related amide derivatives which were designed by
modification of the chalcone moiety. In the amide series, the most active compound,
5-bromo-3-[(3-chloro-2,4-difluoro benzyl)- carbamoyl]-2-hydroxybenzoic acid (151), inhibited ST with an
IC50 of 4 µM. Chapter 5 discloses the synthesis, and biological studies of halogenated phenanthrene #diketo acids as novel HIV-1 IN inhibitors. The two most active compounds of the series,
4-(8-chlorophenanthren-3-yl)-2,4-dioxobutanoic acid (179) and
4-(6-chlorophenanthren-2-yl)-2,4-dioxobutanoic acid (177) had ST IC50 values of 1.2 and 1.3 "M,
respectively, and corresponding 3!-P values of 11.0 and 5.0 "M. In the last section of the dissertation
detailed in Chapter 6, computational studies were conducted with the aim of exploring the possible
binding modes of potent IN inhibitors and evaluating the structural requirements for IN inhibition. To
determine the physicochemical parameters important for ligand binding, in the first part of this chapter, a
PHASE pharmacophore hypothesis was developed and used for molecular alignments in the initial
comparative molecular field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA)
3D-quantitative structure activity relationship (3D-QSAR) modeling of the chalcone derivatives. A recent
breakthrough in the field of anti-HIV research was achieved with the crystallization and 3D structure
determination of a complete foamy virus IN-DNA complex. To take advantage of the power of structurebased drug design, in the second part of the computational studies, homology models of HIV-1 IN-DNA
were constructed based on the foamy virus IN-DNA complex X-ray crystal structure as template through
collaboration with the Oak Ridge National Laboratory. The binding modes of raltegravir and elvitegravir in
our homology models were in accordance with their binding modes in their complexes with the foamy
virus structure. The homology model was then used for docking and 3D-QSAR studies on our synthesized
inhibitors and other integrase inhibitors including the clinically available raltegravir and elvitegravir. Free
energy calculations using Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) methods
were carried out to rescore and validate the binding modes of HIV-1 integrase inhibitors. 3D-QSAR models
derived from this study provided detailed insights into the structural requirements for IN inhibition and
established predictive tools to guide further inhibitor design. Linear interaction energy (LIE) calculations
were also performed to derive energy parameters contributing to the binding free energies of the IN
inhibitors in the data set. These energy parameters were also analyzed to gain insight into the binding
modes of raltegravir and elvitegravir as well as to validate the conformations of our synthesized chalcone

and amide derivatives. The energy terms were then used as descriptors to develop a linear interaction
approximation (LIA) activity model for the inhibition of integration catalytic step. In the next section of the
chapter, lead optimization was attempted using structure- and ligand-based drug design tools. RACHEL, a
drug optimization software, was used to design an inhibitor with desired binding interactions with the IN
active site residues. The hit obtained from RACHEL was used to design a structurally related compound
(157), the synthesis and activity testing of which has been described in Chapter 4. Docking studies were
also performed on the phenanthrene derivatives synthesized in Chapter 5. The docking studies
predominantly revealed two binding poses that were distinct from the possible binding modes of clinically
used raltegravir and advanced IN inhibitor elvitegravir and, moreover, do not interact significantly with
some of the key amino acids (Q148 and N155) implicated in viral resistance. Therefore, this series of
compounds can further be investigated as IN inhibitors to circumvent resistance associated with current
clinically used HIV-1 IN inhibitors.
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ABSTRACT
HIV-1 integrase (IN) is essential for viral replication and offers a promising target
for the development of anti-retroviral drugs. Two decades of extensive research has lead
to the recent approval of raltegravir as the first IN inhibitor. Advancement of drug
candidate elvitegravir, which is currently in Phase III clinical trial, has furthermore
accelerated efforts against this potential target for combating HIV. However, the
emergence of resistance against raltegravir and elvitegravir demands exploration of novel
chemical scaffolds that could circumvent resistance against currently used HIV-1 IN
inhibitors. With the goal of discovering new agents targeting HIV, a novel structural class
of HIV-IN inhibitors have been designed and synthesized. Substantial computational
studies were also performed that could aid the design and development of potent HIV IN
inhibitors.
A part of this dissertation research, covered in Chapter 3, details the design,
synthesis, and biological evaluation of 3-keto salicylic acid chalcones as novel HIV-1 IN
inhibitors. In the chalcone series, the most active compound, 5-bromo-2-hydroxy-3-[3(2,3,6-trichloro-phenyl)-acryloyl]-2-hydroxybenzoic acid (96) was selectively active
against IN strand transfer (ST) with IC50 of 3.7 ȝM. While most of the compounds
exhibit ST selectivity, a few were nonselective, such as 5-bromo-3-[3-(4-bromo-phenyl)acryloyl]-2-hydroxybenzoic acid (86), which was active against both 3ƍ-processing (3ƍ-P)
and ST with IC50 values of 11 ± 4 and 5 ± 2 μM, respectively. The compounds also
inhibited HIV-1 replication with potencies comparable to their integrase inhibitory
activities. Thus, compounds 96 and 86 inhibited HIV-1 replication with EC50 values of
7.3 and 8.7 μM, respectively. Chapter 4 describes the synthesis of structurally related
amide derivatives which were designed by modification of the chalcone moiety. In the
amide series, the most active compound, 5-bromo-3-[(3-chloro-2,4-difluoro benzyl)carbamoyl]-2-hydroxy- benzoic acid (151), inhibited ST with an IC50 of 4 ȝM. Chapter 5
discloses the synthesis, and biological studies of halogenated phenanthrene ȕ-diketo acids
as novel HIV-1 IN inhibitors. The two most active compounds of the series, 4-(8chlorophenanthren-3-yl)-2,4-dioxobutanoic acid (179) and 4-(6-chlorophenanthren-2-yl)2,4-dioxobutanoic acid (177) had ST IC50 values of 1.2 and 1.3 μM, respectively, and
corresponding 3ƍ-P values of 11.0 and 5.0 μM.
In the last section of the dissertation detailed in Chapter 6, computational studies
were conducted with the aim of exploring the possible binding modes of potent IN
inhibitors and evaluating the structural requirements for IN inhibition. To determine the
physicochemical parameters important for ligand binding, in the first part of this chapter,
a PHASE pharmacophore hypothesis was developed and used for molecular alignments
in the initial comparative molecular field analysis (CoMFA) and comparative molecular
similarity analysis (CoMSIA) 3D-quantitative structure activity relationship (3D-QSAR)
modeling of the chalcone derivatives. A recent breakthrough in the field of anti-HIV
research was achieved with the crystallization and 3D structure determination of a
complete foamy virus IN-DNA complex. To take advantage of the power of structurebased drug design, in the second part of the computational studies, homology models of
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HIV-1 IN-DNA were constructed based on the foamy virus IN-DNA complex X-ray
crystal structure as template through collaboration with the Oak Ridge National
Laboratory. The binding modes of raltegravir and elvitegravir in our homology models
were in accordance with their binding modes in their complexes with the foamy virus
structure. The homology model was then used for docking and 3D-QSAR studies on our
synthesized inhibitors and other integrase inhibitors including the clinically available
raltegravir and elvitegravir. Free energy calculations using Molecular MechanicsGeneralized Born Surface Area (MM-GBSA) methods were carried out to rescore and
validate the binding modes of HIV-1 integrase inhibitors. 3D-QSAR models derived
from this study provided detailed insights into the structural requirements for IN
inhibition and established predictive tools to guide further inhibitor design. Linear
interaction energy (LIE) calculations were also performed to derive energy parameters
contributing to the binding free energies of the IN inhibitors in the data set. These energy
parameters were also analyzed to gain insight into the binding modes of raltegravir and
elvitegravir as well as to validate the conformations of our synthesized chalcone and
amide derivatives. The energy terms were then used as descriptors to develop a linear
interaction approximation (LIA) activity model for the inhibition of integration catalytic
step. In the next section of the chapter, lead optimization was attempted using structureand ligand-based drug design tools. RACHEL, a drug optimization software, was used to
design an inhibitor with desired binding interactions with the IN active site residues. The
hit obtained from RACHEL was used to design a structurally related compound (157),
the synthesis and activity testing of which has been described in Chapter 4. Docking
studies were also performed on the phenanthrene derivatives synthesized in Chapter 5.
The docking studies predominantly revealed two binding poses that were distinct from
the possible binding modes of clinically used raltegravir and advanced IN inhibitor
elvitegravir and, moreover, do not interact significantly with some of the key amino acids
(Q148 and N155) implicated in viral resistance. Therefore, this series of compounds can
further be investigated as IN inhibitors to circumvent resistance associated with current
clinically used HIV-1 IN inhibitors.
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CHAPTER 1.

INTRODUCTION

HIV/AIDS
Acquired Immunodeficiency syndrome (AIDS) is one of the most devastating
infections in human history.1 Since the first report of this syndrome in 1981, about 30
million people have died from the AIDS-related diseases.2 The Human
Immunodeficiency virus (HIV) was first identified as the causative agent of AIDS in
1983.3-8 The number of people infected with HIV has increased from 8 million in 1990 to
33 million today, with an addition of 2.6 million new HIV infections each year; making it
a major pandemic of the 21st century.9,10
There is still neither a cure nor a vaccine available for AIDS and it remains a
serious challenge to the scientific and healthcare community.11 Two decades of
tremendous effort has however led to major breakthroughs in combating this dreadful
menace.12-15 Before the discovery of its causative agent most patients died within 2 years
of infection. Today, the average longevity has exceeded 22 years due to the current
antiretroviral therapy and early diagnosis of patients with AIDS.16,17 Since the
identification of zidovudine (AZT) as the first drug against HIV, remarkable success has
been achieved.18-20 This is reflected by the fact that the number of clinically approved
drugs against HIV exceeds the number of drugs for all other viral infection, taken
together.21 Despite this unprecedented achievement, the issues of drug toxicity,22-27
compliance,28-30 and more importantly the emergence of drug resistance due to viral
mutations have rendered the current therapy ineffective.31-36 It is thus highly imperative to
stay ahead of the virus and develop drugs with novel scaffolds and different mechanisms
of action for achieving an effective and sustained success against AIDS/HIV.
The HIV-1 Life Cycle
HIV-1 belongs to the genus lentivirus and is a member of retroviridae, a family of
RNA viruses that use an intermediate DNA for replication.37 The life cycle of HIV
(shown in Figure 1-1) begins with the attachment of the virus to the host cell
membrane.38 This process involves specific interactions of the viral envelope
glycoprotein gp120 with CD4 receptors on the host cell surface. This interaction results
in conformational changes that expose the chemokine co-receptors CXCR4 or CCR5 to
the viral gp120. The gp120 protein binds to the co-receptors and further leads to
conformational changes that expose viral fusion protein gp41 which then fuses with the
host cell surface. After fusion and entry of the viral particle into the host cell, the virion is
decapsidated to release the viral RNA genetic material and core proteins in a
nucleoprotein complex. Viral enzyme reverse transcriptase (RT) then transcribes viral
single-stranded RNA to viral double-stranded DNA. Viral integrase (IN) thereafter
catalyzes the integration of the viral DNA into the host genome. The process of
integration occurs via two catalytic steps viz., the 3ƍ-processing (3ƍ-P) and the strand
transfer (ST) which involves integration of the viral DNA into the host genome. The
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Figure 1-1.

Life cycle of HIV-1

(Reproduced with permission from Nature Publishing Group: Pomerantz, R. J.; Horn, D.
L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9, 867-873.)17
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integrated viral DNA uses the host’s cellular machinery to transcribe viral RNA, which
then undergoes translation to give viral proteins.39 The viral genetic material and the gag
and gag-pol polyproteins are assembled together in the cytoplasm and the viral particle is
budded off from the cell. Finally, during assembly, the viral protease (PR) cleaves the
gag-pol polyprotein to generate a mature and functional virion capable of infecting
another host cell.
Current Therapy
There are currently 25 drugs approved for anti-HIV therapy. These drugs (shown
in Table 1-1) belong to seven different classes which include:
1) Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
2) Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
3) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
4) Protease Inhibitors (PIs)
5) Co-receptor Inhibitors (CRIs)
6) Fusion Inhibitors (FIs)
7) Integrase Inhibitors (INs)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Zidovudine (AZT, 1), a nucleoside analog, was the first anti-HIV drug approved
by the FDA.40 There are currently 7 NRTIs clinically available and 4 more are in
advanced Phase II/III clinical trials (Table 1-2). NRTIs, shown in Figure 1-2, exert their
anti-HIV effect by inhibiting the viral enzyme RT. These drugs are deoxyribonucleoside
mimic without the 3ƍ-OH group. They require in vivo phosphorylation to be transformed
to their active triphosphate form, which then acts as an alternate substrate and gets
incorporated into the growing DNA, resulting in chain termination.41
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
Tenofovir (8) is currently the only NtRTI (Figure 1-3) approved for the treatment
of HIV.42 It also inhibits the enzyme RT. However, it has a phosphonate group
incorporated into its structure and hence requires only two phosphorylations to be
converted to its active triphosphate form.
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Table 1-1.
Class
NRTIs

NtRTI
NNRTIs

PIs

Fusion
inhibitors
Entry
inhibitors
INIs

FDA-approved anti-HIV drugs
Generic name
Zidovudine
Didanosine
Zalcitabine
Stavudine
Lamivudine
Abacavir
Emtricitabine
Tenofovir disoproxil
Nevirapine
Delavirdine
Efavirenz
Etravirine
Saquinavir mesylate
Indinavir
Ritonavir
Saquinavir
Nelfinavir
Amprenavir
Lopinavir+Ritonavir
Fosamprenavir
Atazanavir
Tipranavir
Darunavir
Enfuvirtide

Brand name
Retrovir
Videx
Hivid
Zerit
Epivir
Ziagen
Emtriva
Viread
Viramune
Rescriptor
Sustiva
Intelence
Invirase
Crixivan
Norvir
Fortovase
Viracept
Agenerase
Kaletra
Lexiva
Reyataz
Aptivus
Prezista
Fuzeon

Approval year
1987
1991
1992
1994
1995
1998
2003
2001
1996
1997
1998
2008
1995
1996
1996
1997
1997
1999
2000
2003
2003
2005
2006
2003

Maraviroc

Selzentry

2007

Raltegravir

Isentress

2007

(Adapted with permission from Nature Publishing Group: Pommier, Y.; Johnson, A. A.;
Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4,
236-248.)96
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Table 1-2.
Class
NRTIs
NRTIs
NRTIs
NRTIs
NNRTIs
NNRTIs
NNRTIs
NNRTIs
NNRTIs
NNRTIs
CRIs
CRIs
CRIs
CRIs
CRIs
CRIs
CRIs
FIs
EIs
INIs
INIs

Clinically advanced anti-HIV agents
Drug
Apricitabine
Amdoxovir
Elvucitabine
Racivir
BILR 355 BS
(+)-Calanolide A
IDX899
MIV-150
RDEA806
Rilpivirine
AK-602
AMD070
HGS004
Ibalizumab (TNX-355)
PF-232798
VCH-286
Vicriviroc
PRO 140
SP01A
Elvitegravir
Dolutegravir

Clinical trials (Phases)
III
II
II
II
II
II
I/II
II
II
II
III
II
II
II
II
II
III
II
III
III
II

(Adapted with permission from American Chemical Society Publisher Ltd.: Mehellou,
Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and
where do we go? J. Med. Chem. 2010, 53, 521-538.)21
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Zidovudine (1)

Stavudine (2)

Didanosine (3)

Zalcitabine (4)

NH
N
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Abacavir (5)
Figure 1-2.

Lamivudine (6)

Emtricitabine (7)

Structures of nucleoside reverse transcriptase inhibitors
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Figure 1-3.

Structure of Tenofovir
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Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Nevirapine (9) was the first NNRTI approved in 1996. In contrast to the above
two classes, these are non-substrate analogs that bind to an adjacent allosteric site and
inhibit RT by a non-competitive mechanism. Three more NNRTIs including Delavirdine,
Efavirenz, and Etravirine (Figure 1-4) are approved as anti-HIV agents.43,44 In addition,
there are six NNRTIs that are currently under clinical development (see Table 1-2).
Protease Inhibitors (PIs)
HIV PR acts at a later stage of viral replication cycle and cleaves the gag and gagpol precursor polypetides to structural and functional proteins resulting in mature and
infectious virions. These drugs act by inhibiting HIV protease and thereby preventing the
formation of a mature and infectious viral particle. Protease inhibitors constitute the
largest class of HIV/AIDS drugs with 10 approved for anti-HIV therapy.45,46 The first
protease inhibitor approved was saquinavir mesylate (13) shown in Figure 1-5. Most of
these drugs are peptidomimetic transition state analogs and possess a hydroxyethylene
moiety as a non-scissile peptide bond isostere.
Co-Receptor Inhibitors (CRIs)
The first step in viral replication involves interactions of the viral glycoprotein
gp120 with chemokine receptors on the host cell membrane. Co-receptor inhibitors
prevent this interaction and inhibit the entry of virus into the cell.47 Although a large
number of small molecules antagonist have been discovered, maraviroc (Figure 1-6) is
currently the only approved CCR5 antagonist.
Fusion Inhibitors (FIs)
Synthetic peptides were derived from gp41and targeted as HIV fusion inhibitors.
A synthetic peptide, enfuvirtide, is the only fusion inhibitor currently approved. It
prevents the fusion of the viral fusogenic peptide gp41 to the host cell membrane thereby
preventing viral entry.48
Integrase Inhibitors (INIs)
HIV IN is an important enzyme involved in viral replication. It catalyzes the
insertion of the viral DNA into the host genome. Since IN has no homologue in human
cells, it offers a promising strategy for anti-retroviral drug development. ȕ-Diketo acids
and isosteres are the most advanced class to have shown promising HIV-1 IN inhibitory
activity.49 S-1360 (Figure 1-7) was the first IN inhibitor to enter clinical trials.50 Over the
last two decades, promising IN inhibitors were designed to incorporate bioisosteres of
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Nevirapine (9)

Efavirenz (10)

Etravirine (11)

Delavirdine (12)

Figure 1-4.

Structures of non-nucleotide reverse transcriptase inhibitors

Figure 1-5.

Structure of Saquinavir
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Figure 1-6.

Structure of Maraviroc

Figure 1-7.

Structure of S-1360
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diketo acid functionality. Raltegravir (16) shown in Figure 1-8 is currently the only IN
inhibitor approved by the FDA51 and 2 inhibitors elvitegravir and dolutegravir are in
Phase III and II clinical trials, respectively.
Resistance to anti-retroviral drugs results due to the high mutational rate of HIV
which in turn is caused by a low genetic barrier and a high turnover of the virus. To
circumvent viral resistance, the currently available anti-HIV regimens include a cocktails
of drugs from two or more classes. FDA-approved anti-HIV drug combinations are listed
in Table 1-3. The combination therapy called Highly Active Antiretroviral Therapy
(HAART), comprises of two NRTIs and one NNRTI and/or a PI. HAART though highly
successful in reducing morbidity and mortality, has failed to fully eradicate the virus.52-55
The emergence of multi-drug resistant viral stains demands development of drugs with
novel mechanisms of action. Towards this end, IN has emerged as a promising target
with the introduction of raltegravir for the clinical management of AIDS.
HIV Integrase: Structure and Function
Structure of HIV-1 IN
HIV-1 integrase, encoded by the pol gene, is an important enzyme in HIV
replication. IN is a 288 amino acid 32 kDa protein composed of three distinct domains
viz., the N-terminal domain (NTD), the central core domain (CCD), and the C-terminal
domain (CTD) (Figure 1-9), all of which are required for catalytic activity. The NTD
(1-50 amino acids) has a His-His-Cys-Cys (HHCC) zinc-finger motif, which is highly
conserved in the IN of retroviruses and retrotransposases. Coordination of this motif with
a Zn2+ ion stabilizes protein folding and multimerization, which in turn, is required for
normal enzymatic activity. The CCD (aa 51-212) contains a catalytic triad of acidic
amino acids that are conserved among the members of the super family of
polynucleotidyl transferases. The catalytic triad consists of residues D64, D116 and E152
which are involved in chelation with metal ions in the IN active site. Any mutation in any
of these residues and/or disruption of this coordination renders the enzyme inactive. It is
believed that two divalent ions, Mg2+ in vivo and Mg2+ or Mn2+ in vitro, are required for
catalysis. While D64 and D116 coordinate one Mg2+ ion, the second Mg2+ ion binds
residues D64 and E152. The CTD (aa 213-288) is the least conserved, and bears some
structural homology with SH3 DNA binding domains. This lysine-rich positively charged
domain has nonspecific but strong DNA binding function. All the three domains,
connected by flexible linkers, are prone to homodimerization. Recombinant IN exists in
dynamic equilibrium between monomers, dimmers, and tetramers in solution.56 Earlier
in vitro studies have reported that while the monomeric form of IN is inactive in vitro, the
isolated NTD, CCD, and CTD all exist as dimers. In the dimeric form, the IN is capable
of catalyzing 3ƍ-P and integration of one viral DNA end. In further studies, IN has been
isolated as a tetramer from human cells expressing HIV-1 IN. Electron microscopy,
single-particle image reconstruction studies and atomic force microscopy of intact
IN-DNA complex have also revealed that IN acts as a tetramer.57,58 Structural modeling
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Figure 1-8.

Structure of Raltegravir

Table 1-3.

FDA-approved anti-HIV combination therapies

Combination Components
Zidovudine (300 mg), Lamivudine (150mg)
Combivir
Abacavir (300 mg), Zidovudine (300 mg),
Trizivir
Lamivudine (150mg)
Abacavir (600 mg), Lamivudine (300mg)
Epzicom
Tenofovir disoproxil fumarate (TDF) (300
Truvada
mg), Emtricitabine (200 mg)
TDF (300 mg), Emtricitabine (200mg),
Atripla
Efavirenz (600 mg)

FDA approval year
1997
2000
2004
2004
2006

(Adapted with permission from American Chemical Society Publisher Ltd.: Mehellou,
Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and
where do we go? J. Med. Chem. 2010, 53, 521-538.)21
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Figure 1-9.

D64 D116 E152

CCD

Binds Mg2+/Mn2+

288

CTD

Binds DNA

Structure of HIV-1 integrase

(Adapted with permission from Nature Publishing Group: Pommier, Y.; Johnson, A. A.;
Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4,
236-248.)96
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further supports that the tetrameric form of IN catalyzes the insertion of two viral DNA
ends into the target DNA. It should be noted that because of the staggered cut, which
occurs 5 base pairs apart in a target helical B-form of DNA, the site of integration should
be separated by a corresponding distance of 15-18 Å. Thus the active site in a functional
integrase should also be separated by a similar distance. However, in the crystal structure
of the dimeric CCD, the active sites are found 35 Å apart. It was therefore concluded that
in order to maintain a distance of 35 Å at least one tetramer of IN is required to fulfill the
complete concerted ‘two-ended’ ST integration step.59 Moreover, studies on IN isolated
from a nuclear extract and its complex with lens epithelium-derived growth factor
(LEDGF) has further indicated that IN exists as a tetramer.60
3D structures of individual domains of recombinant HIV-1 IN have been reported
by either NMR or X-ray crystallography.61-80 Because of the poor solubility, full-length
wild type HIV-1 IN has yet not been crystallized. The F185K Mutation resulted in
substantial improvement in solubility and led to the first crystallization of the CCD. The
CCD has five-stranded mixed ȕ-sheet flanked by Į- helices. The crystal structures of
HIV-1 CCD have been solved for its apo form as well as with different metal-complexes.
The available structures however contain only single metal ion and no structure with two
metals have yet been reported. A crystal structure of a CCD-inhibitor (5-CITEP) complex
has also been reported. The inhibitor showed only indirect, water mediated, contact with
the active site Mg2+ and no interactions with either Asp64 or Asp116 were observed.
Later, it was confirmed that binding mode of 5-CITEP was affected by crystal
packing.81,82 Most of the structures of a CCD have partially resolved flexible loop region
(residues Gly140-Gln148). Only two crystal structures (chain B of 1BIS and chain C of
1BL3) have a completely resolved flexible loop, however, the conformations of the active
site residues in these structures were different. Although no X-ray crystal structures of the
CTD and NTD are available, the structures of these domains have been solved by
solution NMR spectroscopy. The solution structure of NTD of HIV-1 revealed that the
NTD exists as a homodimer, each monomer of which consists of 4 helices. The NMR
resolved structure of CTD also showed the presence of dimeric molecules in which each
monomer comprises 5 ȕ-strands, arranged in an antiparallel manner in a ȕ-barrel.
Interdomain (CCD-CTD or CCD-NTD) structures of HIV-1 IN have also been
crystallized. Table 1-4 summarizes the reported 3D structures of HIV-1 IN solved by
NMR and X-ray crystallography. One of the major limitations of the available structures
is that they have only partially resolved inter-domain linker conformations. Furthermore,
the absence of two metals in the IN active site and of a full-length HIV IN-DNA complex
make the structural information available limited and far from reality. Several studies
have been directed to exploring the binding interactions of IN with the viral DNA.83-88
HIV-1 IN-DNA models were constructed based on the solved two domain (CCDNTD/CCD-CTD) structures. Although IN is not very selective for the target DNA, it does
recognize viral DNA sequence-specifically. The terminal conserved CA dinucleotide is
shown to be important for IN binding and catalyzing 3ƍ-P and ST reactions. In addition,
in vitro mutational studies revealed a region centered 12 bases from the 3ƍ-terminus to be
essential in DNA binding in the presence of magnesium cofactor.89,90 Specific
photocrosslinking studies have identified Lys156 and Lys159 as important CCD residues
involved in interaction with the viral DNA.91
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Table 1-4.

Crystal structures of HIV-1 IN

Protein
NTD

PDB code
1WJA,
1WJB
NTD
1WJC,
1WJD
NTD
1WJE, 1WJF
CCD
1ITG
CCD
2ITG
CCD
1BHL
CCD
1BI4
CCD
1BL3
CCD
1BIS
CCD
1BIU
CCD
1BIZ
CCD
1B92
CCD
1B9D
CCD
1B9F
CCD
1QS4
CCD
1EXQ
CCD
1HYV
CCD
1HYZ
CTD
1IHV
CTD
1QMC
NTD-CCD
1K6Y
CCD-CTD
1EX4
CCD+LEDGF 2B4J
3LPT
CCD
3LPU
CCD
3L3U
CCD
3L3V
CCD
3NF6, 3NF8
CCD
3NF7
CCD
3NF9, 3NFA
CCD
a

Method
NMR

Resolution (Å) Year
N/Aa
1997

Ref.
62

NMR

N/A

1997

62

NMR
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
NMR
NMR
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray
X-ray

N/A
2.30
2.60
2.20
2.50
2.00
1.95
2.50
1.95
2.02
1.70
1.70
2.10
1.60
1.70
2.30
N/A
N/A
2.40
2.80
2.02
2.00
1.95
1.40
2.00
1.90
1.85
1.95

1998
1994
1996
1998
1998
1998
1998
1998
1998
1999
1999
1999
1999
2000
2001
2001
1995
1999
2001
2000
2005
2010
2010
2010
2010
2011
2011
2011

64
63
61
66
66
66
67
67
67
68
68
68
69
70
71
71
72
73
74
70
76
77
77
78
78
79
79
79

N/A = not available.

(Adapted with permission from John Wiley and Sons: Jaskolski, M.; Alexandratos, J. N.;
Bujacz, G.; Wlodawer, A. Piecing together the structure of retroviral integrase, an
important target in AIDS therapy. FEBS J. 2009, 276, 2926-2946.)80
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Since IN inhibitors target a DNA- IN complex and not a free protein, tremendous
efforts are underway to solve a complete HIV IN-DNA complex structure which would
accelerate the structure-based design of new HIV-IN inhibitors. In a recent breakthrough,
crystal structures of full-length IN from prototype foamy virus in complex with the
viral/host DNA (Figure 1-10) have been determined.92-94 Crystal structures of the foamy
virus IN-DNA-inhibitor (raltegravir or elvitegravir) complexes have also been
published.92 The structure revealed the retroviral IN as a tetramer tightly bound to the
viral DNA. This minimal IN-DNA complex within the pre integration complex (PIC)
capable of carrying 3ƍ-P and ST is referred to as intasome. Foamy virus and HIV both
belong to the family of retroviruses and super family of polynucleotidyl transferases.
They share a conserved triad of acidic residues in the active site and use two divalent
metals (Mg2+) for nucleophilic SN2 catalytic mechanism. A high level of sequence
identity in the active sites of the foamy virus and HIV provides a rationale for using the
foamy structure as a surrogate for HIV. This structure was used as template and sequence
aligned with the secondary structure of HIV-1 to build a model for HIV-1 intasome.95
The modeled intasome consisted of a pair of IN dimer (forming a tetramer) tightly bound
to a molecule of viral DNA. The outer CCDs of the two dimers serve an accessory role to
the complex; while the CCDs of the inner subunits of each dimer forms a pair of
functional active site which is involved in all protein-protein and protein- DNA
interactions. Residues of the active site loop (Gln140-Gln148) and Į4 helix are involved
in CCD-DNA contacts. Most of the contacts were observed with the backbone of the
nontransferred DNA strand, however few specific contacts with the bases are also
observed. Apart from the residues previously implicated in DNA binding, Arg20 and
Lys266 were identified as new residues which have role in DNA binding and
integration.95 Another crystal structure of the foamy virus intasome shows (Figure 1-11)
viral DNA-IN in association with the target DNA.94 Within the intasome, target DNA is
placed in a cleft between the two symmetric dimers of the IN. Severe bending of the
target DNA makes it possible to position its scissile phosphodiester into the intasome
active site, separated by a distance of ~ 27Å. While there are only few direct contacts
between target DNA and IN, the phosphodiester backbone is involved in 8 hydrogenbonds with the main chain amides of IN.94
Function and Putative Mechanism of IN
HIV-1 IN is one of the three enymes essential for viral replication, the other two
being HIV-1 reverse transcriptase and HIV-1 protease. It catalyzes the integration96 of the
viral DNA into the host genome by two catalytic steps, 3ƍ-P and ST (Figure 1-12).97 In
the 3ƍ-P reaction, which occurs in the cytoplasm of an infected cell within a preintegration complex (PIC), a site specific endonucleolytic activity removes a GT
dinucleotide from the long terminal repeat region (LTR) of the viral genome. The
terminal nucleotides removed are adjacent to the highly conserved CA dinucleotide at
each of the 3ƍ-end of the proviral DNA. Chemically, the reaction involves the
nucleophilic activation of a water molecule by the Mg2+ ion (coordinated with Glu152
and Asp64); the activated water molecule then subsequently attacks the phosphodiester
bond of the viral DNA to generate free 3ƍ-OH ends.
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Figure 1-10. Crystal structure of foamy virus integrase-viral DNA complex
The inner subunits of the IN tetramer, engaged with viral DNA, are blue and green; outer
IN chains are yellow. The reactive and non-transferred DNA strands are magenta and
orange, respectively. Side chains of Asp128, Asp185 and Glu221 active-site residues are
red sticks; Zn atoms are grey spheres.
(Reproduced with permission from Nature Publishing Group: Hare, S.; Gupta, S. S.;
Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition
of DNA strand transfer. Nature 2010, 464, 232-236.)93
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Figure 1-11. Crystal structure of foamy virus IN, viral and target DNA strand
transfer complex
Representations of the STC crystal structure, viewed along or perpendicular to the
crystallographic two-fold axis, respectively. IN active site carboxylates are shown in red.
(Reproduced with permission from Nature Publishing Group: Maertens, G. N.; Hare, S.;
Cherepanov, P. The mechanism of retroviral integration from X-ray structures of its key
intermediates. Nature 2010, 468, 326-329.)94
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Figure 1-12. Mechanism of integration
(I) Donor DNA; (II) integrase-catalyzed 3ƍ- processing; (III) integrase-catalyzed strand
transfer; (IV) product of strand transfer; (V) DNA repair by cellular enzymes.
(Open Access: Savarino, A. In-Silico docking of HIV-1 integrase inhibitors reveals a
novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007, 4,
21.)97
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The primed viral DNA in association with the viral protein, in a pre-integration
complex, then translocates into the nucleus of the host cell. Within the nucleus, viral IN
catalyzes the next step of integration, ST. In the process of ST, IN introduces a staggered
cut in the target DNA at sites separated by 5 base pairs resulting in overhangs with 5ƍ
phosphorylated ends. IN then performs strand transfer, also called as the 3ƍ -end joining
reaction wherein the primed 3ƍ-ends of the viral DNA are joined to the 5ƍ-ends of the
host/target DNA. Chemically, this involves a second nucleophilic attack, this time by the
3ƍ OH groups at the phosphodiester bond of the host DNA. Finally, host enzymes remove
the two mismatched nucleotides at each 5ƍ end of viral DNA, fill in the single stranded
gaps and ligate the remaining ends.
A putative mechanism for inhibition of integration has been proposed based on
the recently reported foamy virus crystal structures. For integration to occur, unpairing of
the donor DNA is required to expose the scissile phosphodiester bond (for 3ƍ-P) and
orient the 3ƍ OH (for ST) near the IN active site. The model suggests that the terminal
adenine (A17) of the reactive DNA strand dissociates from its base pair thymine (T3) in
the complementary nontransferred strand, as the terminal bases of the DNA interacts with
the CCD, CTD and CCD-CTD linker. The adenine 3ƍ OH end is then positioned into the
active site and is activated by the metal (coordinated between Asp64 and Asp116) to
undergo SN2 nucleophilic attack at the phosphodiester bond of the host DNA. Raltegravir
and other IN inhibitors have coplanar metal chelating hetero atoms that coordinate the
two divalent metals in the IN active site.98,99 Furthermore, a halogenated benzyl group
which is a common feature of IN inhibitors, according to the model, stacks against the
penultimate cytosine of the reactive DNA strand and thereby displaces the terminal
3ƍ-OH out of the active site away from the metal ions. Thus, any disruption of the
activation of the nucleophilic 3ƍ-OH or its displacement from the active site upon drug
binding inhibits ST step of retroviral integration.92,100
HIV-1 IN Inhibitors
HIV-IN does not have a human counterpart making it an attractive target for antiHIV therapy. During the last two decades of research, large numbers of IN inhibitors
have been discovered. However, only few have advanced to clinical trials and only one,
raltegravir, has been approved. IN inhibitors can be classified on the basis of those
targeting selectively the 3ƍ-P step, those that inhibit both 3ƍ-P and ST, and those that
selectively inhibit the ST catalytic step. The most advanced drugs selectively inhibit the
ST reaction and have two common structural features viz., a hydrophobic halo benzyl
group and a chelating motif capable of binding two Mg2+ ions.
In the early efforts, ribozymes were used to cleave HIV-1 IN and oligonucleotides
were designed to form triplex DNA to inhibit the integration process.101-103 These efforts
did not yield any potent inhibitor and were not pursued due to their significant risk of
toxicity. Nucleotide analogs based on AZT were among the early IN inhibitors
reported.104 Several di-, tri-, and tetra-nucleotides were then examined for their IN
inhibitory activities. A G-quartet oligonucleotide composed of deoxyguanosine and
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thymidine, zintevir, showed potent HIV-1 IN inhibitory activity and inhibition of viral
replication in cell culture.105 Zintevir, which progressed to Phase I/II clinical trials, was
later shown to inhibit viral gp120 binding and prevent viral entry into cells.
DNA-Binding Agents
Several DNA-binding agents were identified to inhibit HIV-1 IN by preventing
the interaction of viral DNA with the DNA-binding domain of the enzyme.
Benzimidazoles inhibited IN with an overall 50 % inhibitory concentration (IC50) of 5
μM.106 Minor groove binders like netropsin are also reported to interfere with viral DNAIN binding. Lexitropsins have also been shown to inhibit IN by binding at the conserved
AT sequence in HIV-1 LTR.107 The fluorescent dye Hoechst 33258 and its derivatives
bind in a site-specific and non-covalent manner to the minor groove of DNA. N,Nƍ(methylene-di-4,1-phenylene) bis-1-pyrrolidineacetamide was recently reported as novel
anti-HIV agent that competes with viral DNA for binding to the IN CCD dimer
interface.108
Peptides/Proteins
Polyamides prevent the binding of viral DNA to IN and subsequently inhibit IN
enzymatic activity. A hexamer peptide (HCKFWW) was identified to be an inhibitor of
HIV-1 IN with micromolar affinity.109 In another study, a 30-mer peptide which
corresponds to amino acids 147-175 of HIV-1 IN was shown to inhibit IN activity at a
millimolar concentrations but was not active in cell culture.110 MAP30, luffin, and
saporin which are members of the family of ribosome inactivating protein (RIP), have
also been reported to have antiviral and anti-IN inhibitory activity.111
Polyhydroxylated Aromatic Compounds
Polyhydroxylated aromatic compounds (Figure 1-13) were among the first small
molecule inhibitors of HIV-IN in vitro. They include both natural and synthetic
derivatives like flavones, tyrphostins, lignans, anthraquinones, catechols and biscatechols.112-116 These compounds possess two aryl groups which are separated by a
linker. At least one aryl unit contains two ortho-hydroxyl groups meant for chelation with
the IN active site metal ions. An example of a potent member of the class of bis-catechols
is ȕ-conidendrol (17), which selectively inhibited both steps of HIV-1 IN with an IC50 of
0.5 μM. However, when tested in cell cultures the in vitro inhibition did not translate into
antiviral activity. Dicaffeoylquinic acids (DCQAs) represented by L-chicoric acid (18)
and analogs were shown to be active against HIV-1 IN in vitro, and to also inhibit HIV-1
replication in tissue culture in the low μM concentration range.117 Other bis-catechol IN
inhibitors include the curcumin derivative rosmarinic acid (19).118 Curcumin analog
dicaffeoyl methane (20) inhibited ST activity with an IC50 of 3.1 μM.118 One
representative IN inhibitor of the catechol series, caffeic acid phenylethyl ester
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Figure 1-13. Structures of poly-hydroxylated HIV-1 integrase inhibitors
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(CAPE, 21) is shown in Figure 1-14.119 CAPE was the first selective (ten-folds
selectively against ST relative to 3ƍ-P) IN inhibitor that also showed weak antiviral
activity. From these studies it was inferred that at least one catechol group is required for
potent HIV IN inhibitory activity.119 Compounds without a catechol unit were also
investigated for their HIV-IN inhibitory activity. NSC 158393 (Figure 1-15, compound
22) contains four 4-hydroxycoumarin moieties with no catechol substructure and was
active against both HIV-1 PR and IN.120 The utility of polyhydroxylated aromatic
compounds as drug candidates is however limited by the fact that their catechol moiety is
prone to oxidation in situ to a reactive quinone species which may lead to covalent
protein modification.
Styryl Quinolines
A novel series of compounds in which a quinoline ring system is attached to a
hydroxyl containing aryl group by an ethylenic linker (Figure 1-16) was developed as
potent HIV-1 IN inhibitors.121 Although, highly active compounds of the series, including
FZ41 (23), have a catechol substituent, detailed structure activity relationship (SAR)
studies showed that a catechol group was not an absolute pharmacophoric requirement
for an IN inhibitor. These compounds were designed to chelate active site divalent metals
and were found to inhibit both 3ƍ-P and ST at sub-micromolar levels. They are believed to
be competitive inhibitors of the binding of viral DNA to IN. Another study has shown
that they prevented the nuclear import of recombinant IN.122
Pyranodipyrimidines
Pyranodipyrimidines (Figure 1-17) were reported to inhibit HIV-1 integration at
low μM concentrations. The most potent compound of the series V-165 (24) inhibited
recombinant integrase in vitro and also HIV-1 replication in cell cultures.123 V-165 was
more active against 3ƍ-P with IC50 of 0.17 μM as compared to ST inhibitory IC50 value of
16 μM. Time-of-addition experiments indicate that V-165 acts prior to the formation of
the pre-integration complex (PIC) suggesting that it prevented the formation of DNA-IN
complex by inhibiting the binding of IN to the viral DNA. It was however reported that
V-165 was not selective for IN and was found to be active against RT as well.
ȕ-Diketo Acids
The ȕ-Diketo acid pharmacophore was discovered from several fungi derived
natural products which were reported as HIV-1 IN inhibitors. These fungal compounds
contained a ȕ-hydroxy keto groups which were subsequently modified to a ȕ-diketo acid
and its structural analogs.49,124 Although, not sufficient for activity, the diketo acid
functionality was identified as an important requirement for an IN inhibitor. Extensive
research was thus directed to incorporate a ȕ-diketo acid functionality, which
subsequently became the first representative pharmacophore of potent IN inhibitors. The

23

Figure 1-14. Structure of caffeic acid phenyl ester (CAPE)

Figure 1-15. Structure of NSC 158393 HIV-1 integrase inhibitor
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Figure 1-16. Structure of styryl quinoline integrase inhibitors

Figure 1-17. Structure of pyranodipyrimidine, V-165

25

coplanar heteroatoms in the ȕ-diketo acid motif were perceived to chelate the divalent
metals in the IN active site.99 In pursuit of ȕ-diketo acid IN inhibitors shown in Figure
1-18, researchers at the Shionogi & Co. Ltd discovered 5-CITEP (25) which contained a
tetrazole as a bioisostere of carboxylic acid. 5-CITEP was highly selective for the ST
catalytic step (IC50s of 0.4-4.0 μM for ST vs. 35 μM for 3ƍ-P). Moreover, 5-CITEP was
found to be a more potent inhibitor (ST IC50 of 0.4 μM) in the presence of Mn2+ than
Mg2+ ( ST IC50 4.0 μM). It was also the first integrase inhibitor to have been cocrystallized with the CCD of IN. Subsequently, Merck also discovered ȕ-diketo acid IN
inhibitors; the most potent among them were L-731,988 (26) and L-708,906 (27), which
have an acid functionality instead of its isostere tetrazole that was present in 5CITEP.50,124 SAR studies have shown that replacement of the lesser acidic tetrazole
moiety with a carboxylate substantially improved the ST inhibitory activity in Mg2+
suggesting that a carboxylate might be important for metal coordination.50 L-731,988 and
L-708,906 were also highly selective (70-100 folds) for the ST reaction in vitro. L731,988 and L-708,906 have ST IC50s values of 80 nM and 150 nM, respectively, and
inhibited HIV-1 replication with micromolar 50 % effective concentration (EC50) values
in cell culture. It was again shown that IN inhibition can be divalent-cation dependent.
The IC50 of L-708,906 for 3ƍ-P was 2.5 μM and 22 μM in Mg2+ and Mn2+ respectively,
while its IC50 for ST was comparable with either metal. Another closely related
compound from Shionogi, S-1360 (see Figure 1-7) showed potent inhibition of integrase
in enzymatic assay and displayed antiviral activity in cell culture. Their antiviral activity
was proved to be the result of their inhibition of the integration process in viral
replication. S-1360 was also selective against ST with IC50 value of 20 nM and it became
the first IN inhibitor to enter Phase I/II clinical trials.125 Its progression was however
halted due to rapid metabolism of its ȕ-diketo acid functionality and subsequent
formation of inactive metabolites. The SAR studies of the diketo acid derivatives
revealed that the aromatic moiety is important for potency and ST selectivity. Several
diketo acid derivatives were then synthesized with various aromatic systems containing
different substitutions. Examples include MA-DKA which had an azido group on the aryl
moiety designed for cross linking studies.126 One of the common aryl ring system present
in potent IN inhibitors such as L-731,988 and S-1360 was a para-fluorobenzyl group,
which was later identified as an important feature of potent ST selective inhibitors.
Subsequent modifications were made to incorporate the diketo acid chelating heteroatom
into a ring system also leading to potent sub micromolar and nanomolar inhibitory
activities.
Naphthyridine Carboxamide
To circumvent the metabolic issues of a free ȕ-diketo acid functionality, the
diketoacid motif was embedded into a naphthyridine carboxamide core such that the
carboxylic acid was replaced with a lone pair donor atom containing heterocycle.
Examples of metabolically stable naphthyridine carboxamides include L-870,810 (28), L870,812 (29), and GSK-364735 (30) (Figure 1-19). L-870,810 and L-870,812 were
found to be selective for ST inhibition and inhibited ST activity in vitro with potent IC50s
of 8-15 nM and 40 nM, respectively. L-870,812 inhibited HIV replication with 95 %
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L-708,906 (27)
Figure 1-18. Structures of diketo acid HIV-1 integrase inhibitors
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Figure 1-19. Structures of naphthyridine carboxamide HIV-1 integrase inhibitors
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inhibition concentration (IC95) of 250 nM and suppressed viral load in rhesus macaques
infected with SHIV 89.6P recombinant strain.127 L-870,810 became the second candidate
to enter clinical trials; its progression was however halted because of long-term
hepatotoxicity observed in dogs.128 Furthermore, it also suffered from low bioavailability
due to high serum protein binding. L-870,812 also entered clinical trials but its data were
not made public and was discontinued probably because of similar in vivo profile as L870,810. Although integrase ST inhibitors were validated for the treatment of HIV, viral
resistance against them soon emerged. Mutations T66I and F121Y selectively conferred
resistance to diketo acids and naphthyridine carboxamides, respectively. Mutation
N155H/S resulted in viral resistance to diketo acids and also showed cross resistance to
naphthyridine carboxamides.129 GSK-364735 showed potent inhibition of ST activity
(IC50 value of 8.0 nM) of recombinant integrase in enzymatic assay.130 It also inhibited
HIV replication in nanomolar concentrations (1.2 ± 0.4 nM in peripheral blood
mononuclear cells and 5 ± 1.0 nM in MT-4 cells). It entered in Phase I clinical trials but
its development was halted due to long-term toxicity issues.130
Dihydroxypyridopyrazine-1,6-diones
The 1,6- naphthyridine carboxamide core was used to design
dihydroxypyridopyrazine-1,6-diones (Figure 1-20) as a new class of IN inhibitors such
that the diketo functionality was embedded in a pyridinone scaffold.131 Compound (31)
showed ST IC50 value of 0.10 μM and inhibited HIV replication with EC50 value of 0.31
μM. A series of analogs synthesized demonstrated in vitro potency, but they did not
however offer improved anti-HIV activities.
Pyrazolopyrazinone
A bicyclic system having pyrazolopyrazinone scaffold (Figure 1-21) was
designed to enforce coplanarity of the metal-chelating atoms.132 Compound (32) had
potent ST inhibitory activity value of < 10 nM and inhibited HIV-1 replication with EC50
(10% FBS) value of 0.63 μM in cells.
8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-ones
The pyridinone ring was substituted with a pyrrole ring (Figure 1-22) to design
this new class of IN inhibitors.133 Several halogen substitutions were made on the benzyl
group to confer ST selectivity and improve anti-HIV activity. Compound (33) had an ST
IC50 value of 0.04 μM and an anti-HIV CIC50 value of 3.23 μM in cells. Another
compound of the series, (34), showed a potent ST IC50 value of 0.01 μM and also
inhibited HIV replication in cells with a CIC50 value of 0.31 μM. However, it was not
metabolically stable and was readily eliminated with a short half-life of 0.5 h. To improve
metabolic stability, the ester was replaced by an amide functionality in compound (35).
Compound 35 inhibited ST activity with similar potency (IC50 value of 0.08 μM), but
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Figure 1-20. Structure of dihydroxypyridopyrazine-1,6-diones HIV-1 integrase
inhibitors

Figure 1-21. Structure of pyrazolopyrazinone HIV-1 integrase inhibitors

Figure 1-22. Structures of HIV-1 integrase inhibitors pyrrolopyrazine
carboxamides
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showed a marked decrease in the antiviral activity in cell culture (CIC50 value of 10 μM).
Further modifications of the naphthyridine carboxamide core led to the development of
dihydroxy pyrimidine carboxamides (Figure 1-23) as a new class of HIV-1 IN inhibitors
showing potent nanomolar activity in the ST enzymatic assay.134,135 The most potent
compound (36) of this class exhibited an IC50 of 80 nM against ST. However, the
antiviral activity was lost in the presence of serum (EC50 value of 5.0 μM and 59 μM in
the presence of 10% and 50% FBS, respectively). The dihydroxy pyrimidine group was
optimized to a pyrimidinone scaffold having coplanar chelating atoms, which were meant
for coordination with the active site metals. Extensive SAR studies established the parafluoro benzyl as an important group on the carboxamide moiety and the gem-dimethyl
and oxadiazole substituents were identified as optimal groups in the 2ƍ position. These
efforts lead to the discovery of raltegravir as the first HIV-1 IN inhibitor to be approved
for clinical use in AIDS patients.51 Recently reported 3D structures showed raltegravir in
complex with the foamy virus IN and viral DNA. Raltegravir is developed by Merck
Research Laboratories and is marketed as Isentress, a twice daily 400 mg oral tablet, and
used in combination with other retroviral drugs. Raltegravir showed potent in vitro
enzymatic inhibition with an IC50 of 15 nM in cell based assays in the presence of 50%
human serum. Raltegravir is highly selective for IN and did not inhibit other Mg2+
dependant enzymes like HCV polymerases, RNaseH, and human Į, ȕ, and Ȗ polymerases.
Pharmacokinetic studies showed good oral bioavailability in animals (37%-45%).136
Raltegravir is mainly eliminated through bile and urine via O-glucuronidation of the 5hydroxyl group of the pyrimidinone ring, and is neither a substrate nor an inhibitor of
cytochrome P450. In a 48-week study with 198-naive patients, raltegravir in a
combination therapy showed effective reduction of viral load.137 Although raltegravir is
active against several multidrug resistant HIV strains, resistant IN has however
emerged.138,139 The most common mutations include T66I, N155H, Q148H /R, and
G140S. N155H and Q148H/R are the two main mutations resulting in 10 and 25 folds of
in vivo resistance, respectively. Double mutations like Q148H/R/G140S and
N155H/E92Q resulted in about 400 and 64 folds decrease in viral susceptibility to
raltegravir, respectively.140 Another pyrimidinone carboxamide that is structurally similar
to raltegravir was developed by researchers at Bristol Meyers Squibb. BMS-707035
showed potent in vitro activity (IC50 of 20 nM). It entered preclinical studies but its
development was halted in Phase II clinical trials.141
Bicyclic Pyrimidone
Researchers at Merck also incorporated the pyrimidone scaffold into a bicyclic
system (Figure 1-24) giving compounds with potent ST and antiviral activity.142
Sulphone and sulfonamide groups were introduced to improve antiviral activity. Some of
the representative compounds include 37 and 38, both of which showed IC50 values of 7
nM in ST assay and also inhibited HIV-1 replication with potent nM EC50 values in cell
culture.
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Figure 1-23. Structure of dihydroxypyrimidine carboxamide HIV-1 IN inhibitors

Figure 1-24. Structures of bicyclic pyrimidone HIV-1 integrase inhibitors
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4-Quinolone-3-carboxylic Acid
Quinolone carboxylic acid IN inhibitor shown in Figure 1-25 include elvitegravir
(GS-9137, compound 39), which possesses a novel pharmacophore containing only two
coplanar metal-chelating groups.143 It has also been co-crystallized with foamy virus INDNA complex and is shown to bind in a similar mode to raltegravir. Elvitegravir has
demonstrated potent inhibitory activity against ST with an IC50 value of 7.0 nM. It has
also shown potent antiviral activity in vivo against HIV-1 mutatants resistant to other
retroviral drugs.143 Elvitegravir is also active against HIV-2 strains, SIV and murine
leukemia viruses. It is developed jointly by Japan Tobacco and Gilead Sciences as the
next promising IN inhibitor. Elvitegravir has entered into Phase III clinical trials in
antiretroviral (ARV) treatment-experienced patients and is also undergoing a Phase II
study in subjects never exposed to ARV therapy. It has been found to effectively reduce
viral loads and also demonstrated good safety and pharmacokinetic profiles.144
Elvitegravir has showed good oral bioavailability in rats (34%) and dogs (30%). It is
primarily metabolized by cytochrome P450 (CYP) 3A4 while the minor pathways
include glucorinidation and oxidative metabolism. Combination therapy with ritonavir, a
CYP3A4 inhibitor, has shown to boost elvitegravir concentrations and thus enhancing its
efficacy (a 20 fold increase in oral bioavailability) to allow for a once-daily dosing. In
vitro and clinical data suggests overlapping resistance profile with raltegravir.145,146 T66I,
Q148H/R/K and E92Q mutations conferred resistance to both drugs while S153Y
mutation resulted in greater resistance to elvitegravir. T66I and E92Q contributed the
most to resistance, with 37 and 36 folds reduced susceptibility, respectively. A
comparative study of the enzymatic activity of IN mutant using the dual ST and 3ƍ-P
assay showed that the 3ƍ-P step was not significantly affected. Only Q148K mutation was
found to severely impair 3ƍ-P, while ST was defective for most of the viral mutants.
Tricyclic IN Inhibitors
Conformational constraints were applied to incorporate the exocyclic
carboxamide functionality of raltegravir into a ring system. Thus the
pyrazinopyrrolopyridazine class was designed as a coplanar tricyclic core for HIV-1 IN
inhibitors. Examples include MK-2048 (40) (Figure 1-26), which is a promising inhibitor
active against both ST and HIV-1 replication at nanomolar concentrations. It is being
developed by Merck as a second generation inhibitor to circumvent resistance associated
with raltegravir and elvitegravir. Although MK-2048 retained activity against viruses
resistant to raltegravir and elvitegravir, a recent study has shown that mutants G118R and
G118R, E138K have decreased susceptibility to MK-2048 by two and eight folds,
respectively.147
Another promising IN inhibitor which is currently undergoing Phase II clinical
trials is S/GSK1349572 (dolutegravir, compound 41) developed by Shionogi and
GlaxoSmithKline. Its structure is shown in Figure 1-27. It has potent ST IC50 of 2.7 nM.
Dolutegravir has demonstrated encouraging results in clinical studies. It is being studied
as an unboosted inhibitor with a once-daily dosage regimen.148 GS-9160 (42), a

33

Figure 1-25. Structure of Elvitegravir (GS-9137)

Figure 1-26. Structure of MK-2048

Figure 1-27. Structure of Dolutegravir (S/GSK-1349572)
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tricyclic pyrroloquinolone shown in Figure 1-28, is a selective ST inhibitor also
developed by GlaxoSmithKline. GS-9160 showed an IC50 value of 28 nM in ST assay
and potent antiviral activity, with EC50 in the range 0.7 to 2.0 nM.148 Its development was
halted because of an unfavorable pharmacokinetic profile and failure to achieve effective
antiviral activity.149
Miscellaneous Classes
Pyrrolinone derivatives (Figure 1-29) having coplanar chelating atoms have been
reported as HIV-1 integrase inhibitors.150 Some representative examples of this series
include compounds 43, 44 and 45, which had ST IC50 values of 0.03, 0.037, and 0.08
μM, respectively. Their corresponding antiviral activities (EC50) were 0.18, 0.17, and
0.24 μM, respectively.
Coumarin scaffold containing N-benzylcarboxamide derivatives (Figure 1-30)
were reported as HIV-1 IN inhibitors.151 Examples include compound 46 which showed
moderate ST IC50 values of 7.0 μM.
Phenanthrene and anthracene ȕ-diketo acids (Figure 1-31) have been reported as
potent HIV-1 IN inhibitors by our laboratory.152 Compounds 47 and 48 exhibited ST
inhibitory activities of 0.38 and 0.53 μM, respectively.
Hydrazides (Figure 1-32) have been reported to inhibit both 3ƍ-P and ST activities
at micromolar levels.153 Examples include compound 49 which inhibited 3ƍ-P and ST
with corresponding IC50s of 6.9 and 1.6 μM.
Tetracyclines derivatives (Figure 1-33) have been synthesized as HIV-1 integrase
inhibitors.154 This class of compounds has displayed moderate potencies in micromolar
concentrations against ST and against HIV-1 replication in cell cultures. Examples
include compounds 50 and 51.
Quinolinoyl diketo acids (Figure 1-34) combine the diketo acid pharmacophore
with the quinolone system.155 They were reported as selective inhibitors of the ST
catalytic step. A representative compound of the series (compound 52) had a ST IC50
value of 0.18 μM and antiviral activity EC50 of 0.17 μM.
Benzylindole scaffold (Figure 1-35) was attached to a diketo acid in compound
(53).156 It inhibited ST with an IC50 of 0.03 μM but it showed reduced activity against
HIV-1 replication with an EC50 value of 2.13 μM.
Aryl sulfonamides (Figure 1-36) have been reported as HIV-IN inhibitors.157,158
Examples include 2-mercaptobenzene sulfonamides (54) and their cyclic analogue (55),
which inhibit ST activity at μM concentrations.
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Figure 1-28. Structure of GS-9160

Figure 1-29. Structures of pyrrolinone HIV-1 integrase inhibitors

Figure 1-30. Structure of coumarin carboxamide HIV-1 integrase inhibitors
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Figure 1-31. Structures of polycyclic ȕ-diketo acid HIV-1 integrase inhibitors

Figure 1-32. Structures of hydrazides HIV-1 integrase inhibitors
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Figure 1-33. Structures of tetracyclines HIV-1 integrase inhibitors

Figure 1-34. Structures of quinolinoyl diketo acids HIV-1 integrase inhibitors
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Figure 1-35. Structure of benzylindole HIV-1 integrase inhibitors

Figure 1-36. Structures of aryl sulfonamides HIV-1 integrase inhibitors
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Recently Reported HIV-1 IN Inhibitors
N-1 aryl or benzyl substituted 5-hydroxyquinolone-3-carboxylic acids have been
reported as a new series of HIV-1 IN inhibitors.159 The most active compound (56,
Figure 1-37) inhibited wild type HIV-1 with an EC50 value of 3.1 μM in C8166 cells.
On the basis of the C-2 symmetry present in the naphthyridinone core, a new
series of related IN inhibitors have been designed and synthesized.160 Combining the A/B
naphthyridinone type analogs into a single compound inhibited ST in low nM
concentrations and significantly improved their antiviral activities. One of the most active
compounds (Figure 1-38) of the series (57) inhibited ST with an IC50 of 8 nM and also
showed potent antiviral activity, inhibiting HIV-1 replication with an EC50 of 3.0 nM.
Ethyl malonate amides functionality has been discovered to inhibit HIV-1 IN.161
One of the most active compounds of the series (58) shown in Figure 1-39 was active
against ST with an IC50 of 2.0 μM.
Bicyclic pyrimidinones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones classes
of IN inhibitors were combined to design tricyclic hydroxy-1H-pyrrolopyridine-trione as
a novel class of HIV-1 IN inhibitors.162 The most active compound (59) of the series
shown in Figure 1-40 selectively inhibited ST with an IC50 of 9.1 μM. Compound 59 was
also shown to be less susceptible to the resistance producing effects of G140S/Q148H,
N155H and Y143R mutations than raltegravir.
In another study, a series of caffeoyl-anilides have been reported as dual
inhibitors of HIV-1 IN and CCR5 co-receptors.163 Compound (60, Figure 1-41) showed
ST IC50 of 44.6 μM and antiviral EC50 value of 0.90 μM in cell culture.
2-hydroxyisoquinoline-1,3(2H,4H)-diones (Figure 1-42) were reported as
inhibitors of HIV-1 RT ribonuclease (RNase) H domain and HIV-1 IN.164 Compound 61
inhibited ST with an IC50 of 4.77 μM and was also active against HIV-1 RNase H with an
IC50 of 61 nM. In another related publication165 compound 62 showed IC50s of 1.3 μM
and 33.6 μM against ST and RT RNase H, respectively.
N-Hydroxydihydronaphthyridinones has been designed and synthesized as potent
orally available tricyclic HIV-1 IN inhibitors.166 Compound 63 shown in Figure 1-43
inhibited ST with an IC50 of 2.9 nM, displayed potent antiviral activity with an EC50 of
1.0 nM and, also showed good pharmacokinetic properties.
6-substituted quinolonyl diketo acid HIV-1 IN inhibitors have been reported.167
Compound 64 shown in Figure 1-44 was active against ST with an IC50 of 50 nM and
inhibited HIV-1 replication with EC50 of 1.0 μM in TZM-bl cells.
3-Hydroxypyrimidine-2,4-diones were reported as inhibitors of HIV-1 IN and
RT.168 Compound 65 shown in Figure 1-45 exhibited IC50 of 3.5 μM against ST and
inhibited HIV-1 replication with EC50 of 24 nM. Raltegravir resistant mutants
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Figure 1-37. Structure of 5-hydroxylquinolone-3-carboxylic acids HIV-1 integrase
inhibitors

Figure 1-38. Structure of naphthyridinone HIV-1 integrase inhibitors

Figure 1-39. Structure of ethyl malonate amide HIV-1 integrase inhibitors
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Figure 1-40. Structure of hydroxy-1H-pyrrolopyridine-trione HIV-1 integrase
inhibitors

Figure 1-41. Structure of caffeoyl-anilides HIV-1 integrase inhibitors

Figure 1-42. Structure of 2-hydroxyisoquinoline-1,3(2H,4H)-diones HIV-1
integrase inhibitors
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Figure 1-43. Structure of N-hydroxy-dihydronaphthyridinones HIV-1 integrase
inhibitors

Figure 1-44. Structure of 6-substituted quinolonyl diketo acids HIV-1 integrase
inhibitors

O
HO
N

N

O

O

F

65

Figure 1-45. Structure of 3-hydroxypyrimidine-2,4-diones HIV-1 integrase
inhibitors
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showed lower resistance to compound 65 probably because of its anti-reverse
transcriptase activity.
Substituted benzyl indole diketo acids have been designed and synthesized as
HIV-1 IN inhibitors.169 One representative compound of the series (66) shown in Figure
1-46 had potent IC50 of 6 nM against ST step and moderate antiviral activity inhibiting
HIV-1 replication with an EC50 of 8.5 μM.
A new series of naphthyridinone and quinolone carboxylic acid HIV-1 integrase
inhibitors were synthesized to improve their microsomal stability.170 Compound 67
(Figure 1-47) had an EC50 of 9.9 nM and microsomal stability (% remaining) of 97%.
2-Pyrrolinones were discovered from a pharmacophore model and synthesized as
HIV-1 IN inhibitors.171 Compound 68 shown in Figure 1-48 inhibited both ST (IC50 = 40
μM) in assays and HIV-1 replication (EC50 = 0.31 μM) in TZM-bl cells.
Azaindole N-methyl hydroxamic acids have been reported as potent HIV-1 IN
inhibitors.172 Compound 69 shown in Figure 1-49 demonstrated an IC50 of 382 nM
against ST and inhibited HIV-1 replication with an EC50 of 29 nM in CEM-SS cells.
Pyrazolone was discovered as a novel scaffold for IN inhibition inhibiting ST
with low μM concentrations.173 The most active compound (70) of the series shown in
Figure 1-50 inhibited ST with an IC50 of 3.0 μM.
A series of bicyclic inhibitors possessing the azoles, thiazole, and imidazole as
metal chelating moieties (Figure 1-51) were synthesized as HIV-1 IN inhibitors. The
most promising compound (71) had an EC50 of 6 nM.174
2-Pyrrolidinyl-N-methyl pyrimidones (Figure 1-52) were explored and developed
as orally bioavailable potent HIV-1 IN inhibitors.175 Compound 72 was highly active
against viral replication (CIC95 = 5 nM) and also showed a good pharmacokinetic profile.
2-Arylnaphthalenediols and polyhydroxylated compounds were reported as HIV1 IN inhibitors.176 One of the most promising compounds (73) shown in Figure 1-53 had
an IC50 of 0.85 μM against ST and an EC50 of 3.0 μM in MT-4 cells.
Structure-activity relationships studies on benzylindolediketo acids were
developed by investigation of the hydrophobic region.177 One of the most active
compounds of the series (74) shown in Figure 1-54 had an IC50 of 30 nM against ST and
an EC50 of 0.43 μM against HIV-1 in MT-4 cells.
A series of 2,3-dihydroxybenzamide (Figure 1-55) containing compound (75)
was reported to inhibit ST and LEDGF with IC50s of 19 μM and 8 μM, respectively.178
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Figure 1-46. Structure of indole diketo acids HIV-1 integrase inhibitors

Figure 1-47. Structure of quinolone carboxylic acid HIV-1 integrase inhibitors
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Figure 1-48. Structure of 2-pyrrolinones HIV-1 integrase inhibitors

Figure 1-49. Structure of azaindole N-methyl hydroxamic acids HIV-1 integrase
inhibitors
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Figure 1-50. Structure of pyrazolone HIV-1 integrase inhibitors

Figure 1-51. Structure of bicyclic pyrazole containing HIV-1 integrase inhibitors
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Figure 1-52. Structure of 2-pyrrolidinyl-N-methyl pyrimidones HIV-1 integrase
inhibitors

Figure 1-53. Structure of 2-arylnaphthalenediols HIV-1 integrase inhibitors
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Figure 1-54. Structure of benzylindole diketo acids HIV-1 integrase inhibitors

Figure 1-55. Structure of 2,3-dihydroxybenzamide HIV-1 integrase inhibitors
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CHAPTER 2.

RESEARCH OBJECTIVE

Synthesis of HIV-1 Integrase Inhibitors
The emergence of multi-drug resistance and failure of HAART therapy, which
targets primarily the RT and PR, to eliminate HIV from patient demand inhibition of
other steps essential for viral survival and replication. In this regard, HIV-1 IN, which is
crucial enzyme for viral replication, has emerged as a promising target for the
development of anti-retroviral drugs.
Although highly promising IN inhibitors have been developed, raltegravir is the
only IN inhibitor approved by the FDA. Emergence of resistance against raltegravir and
the clinically advanced drug candidate, elvitegravir necessitates the development of novel
scaffolds targeting IN. In this study, covered in Chapter 3, a novel series of 3-keto
salicylic acid chalcones with diverse structural features were synthesized and biologically
evaluated as promising integrase inhibitors. Few analogs of the series showed good
activities against ST in in vitro enzymatic assay and were also equally potent against
HIV-1 replication in cell cultures.
In Chapter 4, the chalcone scaffold was modified to a structurally related amide to
synthesize a new series of compounds. A vast majority of potent IN inhibitors, including
raltegravir, have an amide functionality which gives a conformationally favorable
orientation to the halo benzyl group present in these compounds. In this study, 10 new
amide analogs were synthesized and evaluated as HIV-1 integrase inhibitors. A couple of
amide derivatives showed good in vitro potencies against ST step and displayed moderate
anti-viral activities in cell cultures. These compounds hold promise for further
optimization to obtain more potent HIV-1 IN inhibitors. In the search of novel scaffolds
for integrase inhibition, some structurally diverse compounds containing metal chelating
atoms were also synthesized and tested for IN inhibitory activity.
ȕ-Diketo acid analogs were the first representative compounds that entered
clinical trials. Previously, our laboratory has reported 5(H)-phenanthridin-6-one diketo
acid as a new class of HIV-1 integrase inhibitors. In Chapter 5, 10 analogs of this series
having electron withdrawing groups on the phenanthrene ring were synthesized and
tested as HIV-1 integrase inhibitors. Most of the analogs showed good in vitro ST and
3ƍ-P activities and selected compounds when tested for their antiviral activity, showed
moderate inhibition of HIV-1 replication. Modeling studies, described in Chapter 6,
suggest that these compounds could be investigated against viral mutants resistant to
currently available IN inhibitors.
Computational Studies on HIV-1 Integrase Inhibitors
Despite two decades of tremendous effort leading to promising IN inhibitors their
binding modes, until recently, remained elusive. The absence of a complete DNA-bound
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crystal structure has presented significant challenge to the structure-based design of IN
inhibitors. Although X-ray structures of individual human HIV domains and their
combinations have been reported, the absence of a 3D structure of HIV-1 IN and viral
DNA along with the two-divalent metals in the active site make the structural information
hitherto available limited and far from reality. To address this limitation, a homology
model of HIV-1 integrase in complex with the viral DNA was constructed, by our
collaborators at the Oak Ridge National Laboratory. The homology model was built
based on the recently reported crystal structure of the foamy virus IN-DNA complex
(PDB 3L2T and 3L2U).
In Chapter 6, a detailed computational study was undertaken to elucidate the
binding modes of approved IN inhibitor raltegravir, elvitegravir, and our synthesized IN
inhibitors. To determine the stereo-electronic features important for ligand binding, in the
absence of a crystal structure of a full-length HIV-1 IN-DNA complex, a ligand-based
approach was first employed. A PHASE pharmacophore model of the synthesized
chalcone and amide derivatives was developed to determine their bio-active
conformations which were then used for deriving 3D-QSAR CoMFA and CoMSIA
models. The resulting QSAR models had limited predictive ability probably because of
the narrow range of activities of compounds in the dataset. Next, with the goal of
developing a statistically significant and predictive model capable of estimating potent
compounds, a comprehensive 3D-QSAR CoMFA and CoMSIA study was undertaken. A
data set of 103 compounds including our synthesized chalcone and structurally related
amide IN inhibitors, raltegravir and elvitegravir and their analogs reported in literature
were used for the 3D-QSAR study. Atom-fit alignments and MM-GBSA validated
docking-based conformations were used for the 3D-QSAR modeling. This study has
yielded statistically significant models that could be further optimized to predict the
activities of novel related HIV-1 IN inhibitors. Binding free energies of the inhibitors
were also derived using the Linear Interaction Approximation (LIA) calculations, and the
energy parameters were then used for building a LIA QSAR model. The resulting energy
contributions were also studied to gain insights into the binding modes of raltegravir and
elvitegravir and to validate the binding conformations of our synthesized IN inhibitors.
Another objective of the computational studies was to use structure-based design to
rationally guide the synthesis of potential 3-ketosalicylic acid amides IN inhibitors.
RACHEL, a drug optimization module was used to design compounds with an aim of
having desired interaction with the enzyme. Finally, to determine the binding modes of
our synthesized phenanthrene derivatives, docking studies were performed and their
poses evaluated.
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CHAPTER 3. SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-KETO
SALICYLIC ACID CHALCONES AS NOVEL HIV-1 INTEGRASE
INHIBITORS*
Introduction
ȕ-Diketo acid derivatives and bioisosteres as represented by S-1360 constitute the
first integrase inhibitor class to have entered clinical trials. Naphthyridine carboxamides
such as L-870,810 have also advanced to clinical trials as have novel quinolone
carboxylic acids such as GS-9137 (elvitegravir) which is currently undergoing Phase III
clinical trials. Inspite of over two decades of extensive research leading to promising IN
inhibitors, hitherto only one IN inhibitor, raltegravir, a pyrimidinone carboxamide, has
been approved for clinical use. Moreover, emergence of resistance against raltegravir due
to viral mutations usually T66I, N155H, Q148H/R and E92Q, demands exploration of
novel scaffolds for IN inhibition in the treatment of HIV infection.138,139
In this chapter, is reported the synthesis and biological evaluation of chalcone
derivatives having 3-keto salicylic acid moieties as a new class of IN inhibitors. We have
undertaken substantial analog synthesis and carried out systematic exploration of the
structure activity relationship. It is established that potent IN inhibitors have two common
structural features viz., a hydrophobic benzyl group and a chelating motif capable of
binding two Mg2+ ions. With a 3-keto salicylic acid as chelating pharmacophoric moiety,
diverse structural modifications of the hydrophobic aromatic feature were made to
synthesize 52 novel chalcone derivatives.
Chemistry
In the present study, a novel series of IN inhibitors was discovered based on
modification of the diketo acid pharmacophoric group as represented by structure III
(Figure 3-1). The 2-position OH and 3-postion keto groups together mimic the keto-enol
tautomer of the ȕ-diketo group. Attachment of the carboxylic acid at the 1-position gave
the 3-keto salicylic acid moiety of III, intended to interact with IN similar to the ȕ-diketo
acids. A styryl group was attached to the 3-position keto group to create chalcones (IV)
(Figure 3-1), the type of which have not yet been investigated as HIV IN inhibitors to
our knowledge. The chalcone moiety was also reduced to give an ethylene linker.
The synthesis of target chalcones was performed according to reaction (Scheme
3-1). 5-substituted salicylic acid (X = COOH) starting materials 76 a-e were first
acetylated with acetic anhydride and concentrated sulfuric acid. The acetylated
* Adapted with permission. Sharma, H.; Patil, S.; Sanchez, T. W.; Neamati, N.;
Schinazi, R. F.; Buolamwini, J. K. Synthesis, biological evaluation and 3D-QSAR studies
of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.
Bioorg. Med. Chem. 2011, 19, 2030-2045.179
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Figure 3-1.

Design of 3-keto salicylic acid chalcone as HIV-1 integrase inhibitors

Scheme 3-1. Synthesis of compounds 61-108

Reagents and conditions: (a) Ac2O, H2SO4, 20 min; yield 75-88%(b) AlCl3, 160 °C, 3 h;
yield 26-34% (c) ArCHO, NaOH, EtOH, rt, 1-5 days; yields 15-74%.
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intermediates 77 a-e were then subjected to Fries rearrangement reaction using
anhydrous aluminum chloride and heating at 160 °C to transfer the acetyl group from the
2-position oxygen to the 3-position to yield 3-acetyl salicylic acid intermediates 78 a-e.
The next step involved a Claisen-Schmidt condensation reaction of intermediate 78 with
various aryl aldehydes at room temperature using NaOH to obtain the target chalcones
81-128.180 The synthesis of compounds 129 and 130 was achieved following Scheme 3-2
by using appropriate aromatic aldehydes and commercially available 1-(5-bromo-2hydroxy-3-nitro-phenyl)ethanone starting material. To determine the importance of the
Į,ȕ-unsaturated bond (chalcone scaffold) to IN inhibitory activity, the synthesis of
compound 131 and 132 was undertaken by reduction of compounds 81 and 107,
respectively, by Pd/C-catalyzed hydrogenation (Scheme 3-3).
Results and Discussions
Structure-Activity Relationships
After synthesis, target compounds were tested for integrase inhibitory activity to
assess their potency and study the SAR. In general, the compounds behaved as typical
diketo acid IN inhibitors, being selective against the ST step (Table 3-1) compared to
3ƍ-P. The selected potent compounds of the series were then tested for their ability to
inhibit HIV replication in cell culture. All the biological studies were performed by
collaborators.
Substitution on aromatic ring A. Compound 131, 2-hydroxy-3-(3-phenylpropyl)-benzoic acid, in which salicylic acid is connected to an unsubstituted phenyl ring
B by a propylene linker exhibited only weak inhibitory activity with IC50 of >100 μM for
3ƍ-P and 91 μM for ST. Modification to an Į,ȕ-unsaturated linker along with substitution
with Br at R1 (compound 81 used as reference) demonstrated a significant increase in
both activity and ST selectivity (IC50 25 μM for ST vs. IC50 75 μM for 3ƍ-P). With the
presence of bromine substituent at R1 on aromatic ring A being shown to be important for
activity, chlorine and fluorine substituents were also investigated. Compounds with a Br
substituent were the most active followed by F which was a little better than Cl. To
determine the effect of hydrophobic interactions, a methyl group was substituted for the
halogens at R1 (see compound 128). Compound 128 was found to be 13 times less active
than the corresponding Br-substituted compound 96. Since Br and a methyl group are
similar in steric terms, this implies that it is not the hydrophobic effect of the halogen, but
possibly the electronegativity and/or polarizability that might be the dominant effect. The
3-keto salicylic acid pharmacophore was designed to coordinate with Mg2+. To test this
hypothesis, the carboxylic acid was replaced with a NO2 functionality (129, 130) and this
modification diminished HIV inhibitory activity. Replacement of the carboxyl group with
another polar group but with weaker coordination ability, CN (compound 127) also
resulted in reduced inhibitory activity. This probably indicates that the formal negative
charge of the free ionizable acidic moiety, that would chelate better with the metal ion, is
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Scheme 3-2. Synthesis of compounds 129 and 130

Reagents and conditions: (a) ArCHO, NaOH, EtOH, rt; yields 58-65%.

Scheme 3-3. Synthesis of compounds 131 and 132

Reagents and conditions: (a) H2, Pd/C (10 mol%), methanol 10 h (b) H2, Pd/C (10
mol%), methanol 2 h; yields 43-72%.
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Table 3-1.
synthesized

Structure and HIV-1 integrase inhibitory activities of chalcones

Cpd.

Ar

X

R1

81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110

Ph
2-Cl-Ph
2-F-Ph
3-Cl-Ph
4-Cl-Ph
4-Br-Ph
4-I-Ph
2,4-di-Cl-Ph
2,3-di-Cl-Ph
2,3-di-MeO-Ph
2,3,4-tri-MeO-Ph
2,5-di-Cl-Ph
2,6-di-Cl-Ph
3,4-di-Cl-Ph
2,3,5-tri-Cl-Ph
2,3,6-tri-Cl-Ph
4-Cl-Ph
2,4-di-Cl-Ph
2,3-di-Cl-Ph
2,5-di-Cl-Ph
2,3,5-tri-Cl-Ph
2,3,6-tri-Cl-Ph
3,4-di-Cl-Ph
4-Cl-Ph
2,4-di-Cl-Ph
2,3-di-Cl-Ph
2,5-di-Cl-Ph
2,3,5-tri-Cl-Ph
2,3,6-tri-Cl-Ph
3,5-di-Me-Ph

COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH

Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Cl
Cl
Cl
Cl
Cl
Cl
Cl
F
F
F
F
F
F
Br
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Activity IC50 (μM)
3ƍ-Pa
STb
75 ± 14
25 ± 5
52 ± 13
14 ± 4
74 ± 25
32 ± 3
45 ± 10
9±3
81 ± 28
12 ± 1
11 ± 4
5±2
69
35
28 ± 12
7±4
58 ± 13
19 ± 11
62 ± 14
34 ± 6
85 ± 20
51 ± 16
47 ± 14
18 ± 4
52 ± 12
16 ± 8
27 ± 11
14 ± 4
20 ± 12
13 ± 5
23 ± 12
<3.7
85 ± 13
53 ± 21
>100
>100
100
92 ± 14
75
25
55 ± 40
17 ± 3
77 ± 20
30 ± 5
87 ± 13
41 ± 9
36 ± 13
17 ±3
52 ± 13
24 ± 9
55 ± 18
30 ± 9
50
29 ± 6
33 ± 14
15 ± 4
82 ± 16
39 ± 6
>100
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Table 3-1.
Cpd.

(Continued)
Ar

2-Cl-3,4-di-MeO-Ph
6-F-3,4-di-MeO-Ph
2-BzO-Ph
3-(4-Cl-PhO)-Ph
4-(4-Cl-PhO)-Ph
3-thienyl
3-(cyclopentyloxy)-Ph
3-(2-OEt-naphthyl)
5-MeO-naphthyl
5-benzothiophene
2-furan-2-yl-Ph
3-Cl-4,5methylenedioxy-Ph
3-OCF3-Ph
123
3-NO2-Ph
124
3-Br-Ph
125
3-F-Ph
126
2,3,6-tri-Cl-Ph
127
2,3,6-tri-Cl-Ph
128
2,3,5-tri-Cl-Ph
129
2,3,6-tri-Cl-Ph
130
N/Ac
131
N/A
132
S-1360 N/A
111
112
113
114
115
116
117
118
119
120
121
122

a

X

R1

COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH

Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br
Br

Activity IC50 (μM)
3ƍ-Pa
STb
>100
76
>100
76
21
9
25
18
22
16
30 ± 12 18 ± 1
100
55
92
46
54
54 ± 25
23 ± 3
11 ± 1
>100
16 ± 2
79
63

COOH
COOH
COOH
COOH
CN
COOH
NO2
NO2
N/A
N/A
N/A

Br
Br
Br
Br
Br
CH3
Br
Br
N/A
N/A
N/A

>100
49 ± 8
19 ± 4
71 ± 1
>100
>100
>333
36 ± 4
>100
>100
11 ± 2

52
32 ± 6
18 ± 1
59 ± 2
44 ± 2
50 ± 9
68 ± 5
21 ± 3
91
57 ± 5
0.6 ± 0.1

3ƍ-P represents 3ƍ-procesing; b ST represents strand transfer; c N/A means not applicable.
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required for potent activity, supporting the hypothesis. Of course a chelation study will
have to be done to confirm this.
Substitution on aromatic ring B. Various groups were substituted on aromatic B
to further explore the SAR. The presence of halogens on phenyl ring B produced
noticeable improvements in potency based on the type, number and position on the
aromatic ring. Fluorine substitution in the ortho and meta positions (compounds 83 and
126) diminished activity, as did iodine substitution at the para position (compound 87).
However, substitution with Cl enhanced activity specifically for ST in all the three
positions (compounds 82, 84 and 85). Interestingly, compounds 125 and 86 with m-Br
and p-Br substituent, respectively, were potent against both catalytic steps (compound 84
showed IC50 of 5 μM against ST activity and 11 μM against 3ƍ-P). The 2,3,6-trichlorosubstituted compound (96) was the most active, with IC50 of about ~ 4 μM against the ST
reaction. This suggests a binding site pocket with high affinity for halogenated phenyl
rings. This might be the site that binds the fluorobenzyl group common in potent IN
inhibitors like the clinically used drug raltegravir (Figure 1-8). We next turned our
attention to examining the following.
(1) The effect of a bulky aryl B groups: benzyloxy and chloro substituted phenoxy
in ortho, meta and para positions of phenyl ring B enhanced activity for both 3ƍ-P and ST
steps; whereas an ortho-furan substituent (compound 121) increased the inhibitory
potency against ST but decreased potency against 3ƍ-P; the increase in activity was most
pronounced for the o-benzyloxy substituent (compound 123), with the 3ƍ-P and ST IC50
values lowered to 21 and 9 μM, respectively, compared to corresponding values of 75
and 25 μM for the parent phenyl compound 81.
(2) The effects of electron donating or withdrawing groups: introduction of
electron donating groups such as methoxy, methyl and cyclopentoxy (compounds 90, 110
and 117) decreased integrase inhibitory activity; and, increasing the number of electron
donating groups resulted in further decrease in activity (compare compounds 90 and 91).
Introduction of strong electron withdrawing groups such as trifluoromethyl and nitro also
diminished activity as shown by compounds 123 and 124, respectively.
(3) Boisosteric replacement of phenyl ring B with polycyclic and heteroaromatic
rings: replacement of phenyl with thiophene or benzothiophene, compounds 116 and 120,
respectively, improved activity. Naphthalene derivatives on the other hand decreased
activity (compounds 118 and 119). It thus appears that heteroaromatic B rings may
improve integrase inhibitory activity.
Reduction of the Į,ȕ-unsaturated double bond of the chalcones. To explore
the importance of the Į,ȕ-unsaturated bond of the chalcones on inhibitory activity, we
reduced it to a single bond. Our first attempt at this was with compound 96, but reduction
also led to a loss of the Br substituent. However, reduction (Scheme 3-3) of analog 107,
having a fluorine substituent, which is not as good a leaving group as Br, was successful
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in achieving our objective. The reduction product, compound 132, was less active (ST
IC50 of 57 μM) than the unsaturated analog, showing that the reduction of the double
bond in the chalcone template is detrimental to activity.
Inhibition of HIV Replication in Cell Culture
To evaluate the potential of these new IN inhibitors as antiviral agents, five potent
analogs were tested for the ability to inhibit HIV-1 replication in primary human
peripheral blood mononuclear cells (PBMCs) infected with the virus. The toxicity of the
compounds was also tested against PBMC and human CEM lymphoblastic leukemia
cells. All four compounds tested inhibited HIV replication (Table 3-2). The most potent
compounds, 96 and 86 showed comparable EC50 values of 7.3 and 8.3 μM, respectively.
Compound 120 (integrase ST IC50 = 11 μM) exhibited an EC50 of 10 μM, while analog
88 (integrase ST IC50 = 7.0 μM) displayed an EC50 of 13.9 μM. Thus, in general the cellbased activity correlated well with the IN inhibitory potency. Moreover, the two most
potent IN inhibitory compounds of the set tested, 86 and 96, were also found to have the
highest activity against HIV replication, suggesting that IN might indeed be their antiviral
target. These results demonstrate moderate anti-viral activity, which is not very different
from early members of the diketo acid IN inhibitors, which served as important lead
compounds such as L-706,908 which had an EC50 of 5.7 ± 4.7 μM for inhibition of HIV
replication.181 The compounds showed cytotoxicity, with selectivity index up to 4-fold
for compound 120. It may be noteworthy that compound 120 is the only compound
among the antiviral test set that had a 5-benzothiophene for ring B; this may offer clues
for improving selectivity index. These results demonstrate reasonable anti-viral activity
when compared to the anti-viral activity of reported diketo acid inhibitors like L-706,908
which has an EC50 of 5.7 ± 4.7 μM for inhibition of HIV replication. To put data in
perspective with regard to AZT’s activity, in the same assay, AZT had an EC50 of 0.001
μM.181
Experimental Section
Chemistry
All the reagents and solvents were purchased from the Aldrich Chemical
Company and used without further purification. Progress of reactions was monitored by
TLC on silica gel GHLF-250 micron plates (Analtech, Inc.). Fisher scientific Da visil
grade 1740 (170–400 mesh) silica gel was used for flash column chromatography. 1H
NMR spectra were recorded on Brucker AR, 300 or 500-MHz spectrometer: chemical
shifts are expressed in į values (ppm) and coupling constants (J) in Hertz (Hz). Mass
spectral data were determined on a Brucker-HP Esquire-LC spectrometer (ESI-MS).
Melting points were determined using a Fisher-Johns melting point apparatus and are
reported uncorrected. HPLC analysis of final compounds was carried out using a reverse
phase SUPELCOSIL 5 μm C-18 column of dimensions 25 cm x 4.6 cm. Area % purity
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Table 3-2.

Anti-HIV activities of selected chalcone derivatives

Anti-HIV-1 activity in PBMCsa
EC50(μM)b
EC90(μM)b
8.7
21.0
86
13.9
26.0
88
7.3
20.3
96
10.1
24.3
120
0.0025
0.01
AZT
c
N/A
L-706,908 5.7 ± 4.7
Cpd.

a

Cytotoxicity (IC50 μM)
PBMCs CEM
24.4
27.5
22.1
23.8
22.7
19.0
39.1
20.7
>100
56.1
N/A
N/A

PBMCs represents Human Peripheral blood mononuclear cells; b EC50 and EC90 are the
effective concentrations inhibiting 50% and 90% HIV replication, respectively; c in the
assay on human leukemic T-cell line MOLT-4, the EC50 of AZT was 0.001 μM.
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was detected at 254 nm. An initial isocratic method comprising 40% water (solvent A)
and 60% methanol (solvent B) for 20 min at a flow rate of 1.2 mL/min was optimized to
a linear gradient elution with water (A) and methanol (B) at a flow-rate of 1.7 mL/min.
Gradient elution of the mobile phase was either (a) 80% A to 35% A from 0-5 min, 35%
A, 65% B for 5-12 min, and 35% A to 80% A from 12-15 min or (b) 60% A to 20% A
from 0-4 min, 20% A and 80% B for 4-12 min and 20% A to 60% A from 12-15 min.
The purity of all, but two, compounds was found to be  95%.
General procedure for the synthesis of intermediates 76a-76e. 5-Halogenated
salicylic acids (46 mmol) were stirred with acetic anhydride (20 mL), and 80 μL of conc.
H2SO4 was then added. After a few (20) min, the reaction mixture solidified and was
poured into cold water. The solid so obtained was filtered and extracted with ethyl
acetate, washed with brine and dried over Na2SO4. The solvent was evaporated under
reduced pressure to obtain a crude solid, which was recrystallized from ethyl
acetate/hexane to afford white crystals (76a-76e).
2-acetoxy-5-bromo-benzoic acid (76a). Yield 88%; mp 155-157 °C; 1H NMR (300
MHz, DMSO-d6): į 13.44 (br s, 1H, COOH), 8.0 (d, 1H, J = 2.4 Hz, ArH), 7.85 (dd, 1H,
J1 = 8.7 Hz, J2 = 2.7 Hz, ArH), 7.20 (d, 1H, J = 8.7 Hz, ArH), 2.2 (s, 3H, OCOCH3); MS
(ESI): m/z 216.6 [MíCOCH3]í.
2-acetoxy-5-fluoro-benzoic acid (76b). Yield 85%; mp 133-134 °C; 1H NMR (300
MHz, DMSO-d6): į 13.42 (br s, 1H, COOH), 7.67 (dd, 1H, J1 = 9.0 Hz, J2 = 3.3 Hz,
ArH), 7.51 (ddd, 1H, J1 = 8.7 Hz, J2 = 8.1 Hz, J3 = 3.3 Hz, ArH), 7.26 (dd, 1H, J1 = 4.8
Hz, J2 = 8.7 Hz, ArH), 2.24 (s, 3H, OCOCH3); MS (ESI): m/z 154.7 [MíCOCH3]í .
2-acetoxy-5-chloro-benzoic acid (76c). Yield 85%; mp 150-152 °C; 1H NMR (300
MHz, DMSO-d6): į 7.88 (d, 1H, J = 2.7 Hz, ArH), 7.72 (dd, 1H, J1 = 9.0 Hz, J2 = 2.7 Hz,
ArH), 7.27 (d, 1H, J = 8.4 Hz, ArH), 2.24 (s, 3H, OCOCH3); MS (ESI): m/z 170.7
[MíCOCH3]í.
Acetic acid-4-bromo-2-cyano-phenyl ester (76d). Yield 76%; mp 60-61°C; 1H NMR
(300 MHz, DMSO-d6) : į 8.26 (d, 1H, J = 2.7 Hz, ArH), 8.0 (dd, 1H, J1 = 8.7 Hz, J2 = 2.4
Hz, ArH), 7.44 (d, 1H, J = 8.7 Hz, ArH), 2.29 (s, 3H, OCOCH3); MS (ESI): m/z 197.5
[MíCOCH3]í.
2-acetoxy-5-methyl-benzoic acid (76e). Yield 75%; mp 158-160 °C; 1H NMR (300
MHz, DMSO-d6) : į 8.01 (d, 1H, J = 1.5 Hz, ArH), 7.50 (dd, 1H, J1 = 8.4 Hz, J2 = 1.8 Hz,
ArH), 7.12 (d, 1H, J = 8.1 Hz, ArH), 2.43 (s, 3H, OCOCH3), 2.27 (s, 3H, CH3); MS
(ESI): m/z 150.7 [MíCOCH3]í.
General procedure for the synthesis of intermediates 77a-77e. The Oacetylated intermediates (38.61 mmol) and AlCl3 (120 mmol) were mixed in a threenecked flask and heated to 160 °C under mechanical stirring. After 3 h, the reaction
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mixture was cooled to rt and poured into ice containing 20 mL concentrated HCl. The
slurry was extracted with ethyl acetate, acidified with 1M HCl, washed with brine and
dried over Na2SO4. The solvent was evaporated to give the crude product, which was
washed with dichloromethane for removal of impurities, filtered and dried to give 3acetyl salicylic acids (77a-77e) as pale brown powders.
2-acetoxy-3-acetyl-5-bromo-benzoic acid (77a). Yield 34%; mp 182-185 °C; 1H NMR
(300 MHz, DMSO-d6): į 8.06 (d, 1H, J = 2.7 Hz, ArH), 7.97 (d, 1H, J = 2.7 Hz, ArH),
2.60 (s, 3H, COCH3); MS (ESI): m/z 258.7 [MíH]í.
2-acetoxy-3-acetyl-5-fluoro-benzoic acid (77b). Yield 31%; mp 135-136 °C; 1H NMR
(300 MHz, DMSO-d6): į 7.78 (dd, 1H, J1 = 8.1 Hz, J2 = 3.3 Hz, ArH), 7.72 (dd, 1H, J1 =
8.7 Hz, J2 = 3.3 Hz, ArH), 2.62 (s, 3H, COCH3); MS (ESI): m/z 196.7 [MíH]í.
2-acetoxy-3-acetyl-5-chloro-benzoic acid (77c). Yield 32%; mp 160-163 °C; 1H NMR
(300 MHz, DMSO-d6): į 7.95 (d, 1H, J = 3.0 Hz, ArH), 7.85 (d, 1H J = 2.7 Hz, ArH),
2.61 (s, 3H, COCH3); MS (ESI): m/z 212.7 [MíH]í.
3-acetyl-5-bromo-2-hydroxy-benzonitrile (77d). Yield 26%; mp 75-77 °C; 1H NMR
(300 MHz, DMSO-d6): į 13.17 (s, 1H, OH), 8.41 (d, 1H, J = 2.4 Hz, ArH), 8.32 (d, 1H,
J = 2.4 Hz, ArH), 2.68 (s, 3H, COCH3); MS (ESI): m/z 239.6 [MíH]í.
3-acetyl-2-hydroxy-5-methyl-benzoic acid (77e). Yield 28%; mp >180 °C (dec); 1H
NMR (300 MHz, DMSO-d6): į 7.80 (s, 1H, ArH), 7.64 (s, 1H, ArH), 2.59 (s, 3H,
COCH3), 2.24 (s, 3H, CH3); MS (ESI): m/z 192.7 [MíH]í.
General procedure for the synthesis of chalcones (81-128). Equimolar amounts
of aromatic aldehydes and intermediates 77a-77e were dissolved in 10 mL of ethanol,
and 5 mL of 25% aq NaOH was added. More solvent was added to help stirring in cases
of excessive precipitation. The reaction mixture was stirred at rt for 1-5 days or until
completion of reaction (6 h for compound 127). The mixture was then poured into ice and
acidified with 3M HCl to pH 4. The yellow precipitate formed was filtered and washed
with water. The crude solid was purified by column chromatography (10-25% ethyl
acetate/hexane) and/or recrystallized with ethanol or THF/water to yield pure chalcones.
5-bromo-2-hydroxy-3-(3-phenyl-acryloyl)-benzoic acid (81). Yellow solid, yield 58%;
mp 210-212 °C; 1H NMR (300 MHz, MeOH-d4): į 8.08 (d, 1H, J = 2.4 Hz, ArH), 8.04
(d, 1H, J = 2.7 Hz, ArH), 7.81 (dd, 2H, J1 = 7.5 Hz, J2 = 2.1 Hz, ArH), 7.68 (s, 2H, H-Į
and H-ȕ), 7.42-7.44 (m, 3H, ArH); MS (ESI): m/z 346.6 [MíH]í ; HPLC: tR 7.71 min,
purity 99.10%.
5-bromo-3-[3-(2-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (82). Yellow solid,
yield 60%; mp 211-214 °C; 1H NMR (300 MHz, DMSO-d6): į 8.08 (d, 1H, J = 2.7 Hz,
ArH), 8.03 (d, 1H, J = 2.7 Hz, ArH), 8.01 (dd, 1H, J1 = 5.5 Hz, J2 = 1.5 Hz, ArH), 7.94
(d, 1H, J = 15.9 Hz, H-ȕ), 7.78 (d, 1H, J = 15.9 Hz, H-Į), 7.59 (dd, 1H, J1 = 8.4 Hz, J2 =
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1.8 Hz, ArH), 7.46 (ddd, 2H, J1 = 7.5 Hz, J2 = 7.2 Hz, J3 = 1.8Hz, ArH); MS (ESI): m/z
380.6 [MíH]í; HPLC: tR 8.05 min, purity 98.82%.
5-bromo-3-[3-(2-fluoro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (83). Yellow solid,
yield 47%; mp 185-187 °C; 1H NMR (300 MHz, DMSO-d6): į 8.05 (d, 1H, J = 2.1 Hz,
ArH), 8.0 (s, 1H, H-ȕ), 7.93 (t, 1H, J = 7.2 Hz, ArH), 7.74 (s, 1H, H-Į), 7.73 (d, 1H, J =
2.7 Hz, ArH), 7.51 (d, 1H, J = 6.9 Hz, ArH), 7.31 (dd, 1H, J1 = 8.7 Hz, J2 = 7.2 Hz,
ArH), 7.29 (t, 1H, J = 7.2, ArH); MS (ESI): m/z 364.7 [MíH]í; HPLC: tR 7.24 min,
purity 99.39%.
5-bromo-3-[3-(3-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (84). Yellow solid,
yield 56%; mp 234-236 °C; 1H NMR (300 MHz, DMSO-d6): į 8.06 (d, 1H, J = 2.7 Hz,
ArH), 8.01 (d, 1H, J = 2.7 Hz, ArH), 7.92 (s, 1H, ArH), 7.76 (d, 1H, J = 15.9 Hz, H-ȕ),
7.75 (t, 1H, J = 7.8 Hz ArH), 7.63 (d, 1H, J = 15.9 Hz, H-Į), 7.50 (dd, 2H, J1 = 8.7 Hz,
J2 = 1.5 Hz, ArH); MS (ESI): m/z 380.6 [MíH]í; HPLC: tR 7.67 min, purity 99.30%.
5-bromo-3-[3-(4-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (85). Yellow solid,
yield 62%; mp 238-241 °C; 1H NMR (300 MHz, DMSO-d6): į 8.04 (d, 1H, J = 15.3 Hz,
H-ȕ), 7.91 (d, 1H, J = 2.4 Hz, ArH), 7.74 (d, 2H, J = 8.4 Hz, ArH), 7.71 (d, 1H, J = 3.0
Hz, ArH), 7.58 (d, 1H, J = 15.3 Hz, H-Į), 7.50 (d, 2H, J = 8.4 Hz, ArH); MS (ESI): m/z
380.6 [MíH]í; HPLC: tR 8.1 min, purity 99.10%.
5-bromo-3-[3-(4-bromo-phenyl)-acryloyl]-2-hydroxy-benzoic acid (86). Yellow solid,
yield 34%; mp 236-238 °C; 1H NMR (300 MHz, DMSO-d6): į 8.06 (d, 1H, J = 2.7 Hz,
ArH), 8.02 (d, 1H, J = 2.7 Hz, ArH), 7.74 (d, 2H, J = 8.7 Hz, ArH), 7.69 (s, 1H, H-ȕ),
7.67 (d, 2H, J = 8.7 Hz, ArH), 7.65 (s, 1H, H-Į); MS (ESI): m/z 424.6 [MíH]í; HPLC: tR
6.05 min, purity: 99.02%.
5-bromo-2-hydroxy-3-[3-(4-iodo-phenyl)-acryloyl]-benzoic acid (87). Yellow solid,
yield 48%; mp 237-239 °C; 1H NMR (300 MHz, DMSO-d6): į 8.06 (d, 1H, J = 2.7 Hz,
ArH), 8.01 (d, 1H, J = 2.7 Hz, ArH), 7.83 (d, 1H, J = 8.4 Hz, ArH), 7.73 (d, 1H, J = 15.9
Hz, H-ȕ), 7.69 (d, 1H, J = 8.4 Hz, ArH), 7.60 (d, 1H, J = 15.3 Hz, H-Į), 7.59 (d, 2H J =
8.4 Hz, ArH); MS (ESI): m/z 472.6 [MíH]í; HPLC: tR 6.46 min, purity 94.70%.
5-bromo-3-[3-(2,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (88). Yellow
solid, yield 54%; mp 234-235 °C; 1H NMR (300 MHz, DMSO-d6): į 8.08 (d, 1H, J = 2.7
Hz, ArH), 8.05 (d, 1H, J = 8.4 Hz, ArH), 8.05 (d, 1H, J = 2.7 Hz, ArH), 7.87 (d, 1H, J =
15.9 Hz, H-ȕ), 7.76 (d, 1H, J = 15.9 Hz, H-Į), 7.76 (d, 1H, J = 2.1 Hz, ArH), 7.52 (dd,
1H, J1 = 8.4 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 414.8 [MíH]í; HPLC: tR 10.91 min,
purity 98.23%.
5-bromo-3-[3-(2,3-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (89). Yellow
solid, yield 50%; mp 226-228 °C; 1H NMR (300 MHz, DMSO-d6): į 8.08 (d, 1H, J = 2.7
Hz, ArH), 8.03 (d, 1H, J = 2.4 Hz, ArH), 7.98 (d, 1H, J = 8.1 Hz, ArH), 7.91 (s, 1H, Hȕ), 7.77 (d, 1H, J = 15.6 Hz, H-Į), 7.74 (d, 1H, J = 7.8 Hz, ArH), 7.46 (t, 1H, J = 7.8 Hz,
ArH); MS (ESI): m/z 414.8 [MíH]í; HPLC: tR 6.46 min, purity: 99.08%.
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5-bromo-3-[3-(2,3-dimethoxy-phenyl)-acryloyl]-2-hydroxy-benzoic acid (90). Yellow
solid, yield 51%; mp 195-197 °C; 1H NMR (300 MHz, DMSO-d6): į 8.02 (s, 1H, ArH),
7.92 (s, 1H, ArH), 7.86 (d, 1H, J = 16.2 Hz, H-ȕ), 7.75 (d, 1H, J = 15.9 Hz, H-Į), 7.40
(dd, 1H, J1 = 5.7 Hz, J2 = 3.0 Hz, ArH), 7.13-7.15 (m, 2H, ArH), 3.83 (s, 3H, OCH3),
3.77 (s, 3H, OCH3); MS (ESI): m/z 406.8 [MíH]í; HPLC: tR 7.03 min, purity: 99.7%.
5-bromo-2-hydroxy-3-[3-(2,3,4-trimethoxy-phenyl)-acryloyl]-benzoic acid (91).
Yellow solid, yield 49%; mp 194-195 °C; 1H NMR (300 MHz, DMSO-d6): į 8.05 (d, 1H,
J = 1.8 Hz , ArH), 8.02 (d, 1H, J = 1.8 Hz ArH), 7.80 (d, 1H, J = 15.9 Hz, H-ȕ), 7.63 (d,
1H, J = 8.7 Hz, ArH), 7.10 (d, 1H, J = 15.9 Hz, H-Į), 6.92 (d, 1H, J = 8.7 Hz, ArH), 3.87
(s, 1H, OCH3), 3.84 (s, 1H, OCH3), 3.77 (s, 1H, OCH3); MS (ESI): m/z 436.8 [MíH]í;
HPLC: tR 6.88 min, purity: 99.36%.
5-bromo-3-[3-(2,5-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (92). Yellow
solid, yield 51%; mp 232-234 °C; 1H NMR (300 MHz, DMSO-d6): į 8.16 (d, 1H, J = 2.4
Hz, ArH), 8.11 (d, 1H, J = 2.7 Hz, ArH), 8.0 (d, 1H, J = 2.7 Hz, ArH), 7.87 (s, 2H, H-Į
and H-ȕ), 7.65 (d, 1H, J = 8.4 Hz, ArH), 7.57 (dd, 1H, J1 = 8.4 Hz, J2 = 2.4 Hz, ArH);
MS (ESI): m/z 414.7 [MíH]í; HPLC: tR 8.03 min, purity 97.30%.
5-bromo-3-[3-(2,6-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (93). Yellow
solid, yield 54%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): į 8.08 (d, 1H, J = 2.7
Hz, ArH), 7.96 (d, 1H, J = 2.7 Hz, ArH), 7.79 (d, 1H, J = 16.5 Hz, H-ȕ), 7.67 (d, 1H, J =
16.5 Hz, H-Į), 7.60 (d, 2H, J = 8.1 Hz, ArH), 7.41-7.46 (t, 1H, J = 8.7 Hz, ArH); MS
(ESI): m/z 414.6 [MíH]í; HPLC: tR 7.96 min, purity 96.60%.
5-bromo-3-[3-(3,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (94). Yellow
solid, yield 48%; mp 218-221 °C; 1H NMR (300 MHz, DMSO-d6): į 8.07 (d, 1H, J =
15.9 Hz, H-ȕ), 8.0 (s, 1H, ArH), 7.93 (d, 1H, J = 2.7 Hz, ArH), 7.72 (d, 1H, J = 2.7 Hz,
ArH), 7.70 (d, 2H, J = 7.5 Hz), 7.56 (d, 1H, J = 15.9 Hz, H-Į); MS (ESI): m/z 414.6
[MíH]í; HPLC: tR 7.25 min, purity 97.0%.
5-bromo-2-hydroxy-3-[3-(2,3,5-trichloro-phenyl)-acryloyl]-benzoic acid (95). Yellow
solid, yield 54%; mp 212-214 °C; 1H NMR (300 MHz, DMSO-d6): į 8.10 (d, 1H, J = 2.4
Hz, ArH), 8.08 (d, 1H, J = 2.7 Hz, ArH), 8.05 (d, 1H, J = 2.7 Hz, ArH), 7.96 (d, 1H, J =
2.4 Hz, ArH), 7.84 (br s, 2H, H-Į and H-ȕ); MS (ESI): m/z 448.6 [MíH]í; HPLC: tR 7.41
min, purity 98.21%.
5-bromo-2-hydroxy-3-[3-(2,3,6-trichloro-phenyl)-acryloyl]-benzoic acid (96). Yellow
solid, yield 57%; mp 220-223 °C; 1H NMR (300 MHz, DMSO-d6): į 8.07 (d, 1H, J = 2.7
Hz, ArH), 7.97 (d, 1H, J = 2.4 Hz, ArH), 7.73 (d, 1H, J = 8.7 Hz, ArH), 7.71 (d, 1H, J =
16.2 Hz, H-ȕ), 7.61-7.64 (m, 2H, H-Į and ArH); MS (ESI): m/z 448.6 [MíH]í; HPLC: tR
7.13 min, purity 99.20%.
5-chloro-3-[3-(4-chloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (97). Yellow solid,
yield 43%; mp 213-215 °C; 1H NMR (300 MHz, DMSO-d6): į 7.95 (d, 1H, J = 2.1 Hz,
ArH), 7.93 (d, 1H, J = 2.7 Hz, ArH), 7.84 (dd, 2H, J1 = 6.9 Hz, J2 = 1.5 Hz, ArH), 7.66
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(s, 2H, H-ȕ and H-Į), 7.51 (dd, 2H, J1 = 6.9 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 336.9
[MíH]í; HPLC: tR 6.13 min, purity 99.55%.
5-chloro-3-[3-(2,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (98). Yellow
solid, yield 48%; mp 248-250 °C; 1H NMR (300 MHz, MeOH-d4): į 8.05 (d, 1H, J =
15.9 Hz, H-ȕ), 7.93 (d, 1H, J = 8.7 Hz, ArH), 7.84 (d, 1H, J = 2.4 Hz, ArH), 7.80 (d, 1H,
J = 15.3 Hz, H-Į), 7.73 (d, 1H, J = 2.1 Hz, ArH), 7.65 (d, 1H, J = 2.7 Hz, ArH), 7.52 (dd,
1H, J1 = 8.4 Hz, J2 = 2.1 Hz, ArH); MS (ESI): m/z 370.8 [MíH]í; HPLC: tR 6.76 min,
purity 99.14%.
5-chloro-3-[3-(2,3-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (99). Yellow
solid, yield 41%; mp 250-252 °C; 1H NMR (300 MHz, DMSO-d6): į 8.10 (d, 1H, J =
15.3 Hz, H-ȕ), 7.85-7.89 (m, 3H, H-Į and ArH), 7.70 (d, 1H, J = 7.2 Hz, ArH), 7.62 (s,
1H, ArH), 7.45 (t, 1H, J = 7.5 Hz, ArH); MS (ESI): m/z 370.8 [MíH]í; HPLC: tR 6.06
min, purity 96.61%.
5-chloro-3-[3-(2,5-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (100). Yellow
solid, yield 42%; mp 247-249 °C; 1H NMR (300 MHz, DMSO-d6): į 8.20 (d, 1H, J = 1.2
Hz, ArH), 8.04 (s, 2H, H-ȕ and ArH), 7.90 (s, 2H, H-Į and ArH), 7.67 (d, 1H, J = 8.4 Hz,
ArH), 7.61 (dd, 1H, J1 = 8.4 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 370.7 [MíH]í;
HPLC: tR 8.39 min, purity 99.0%.
5-chloro-2-hydroxy-3-[3-(2,3,5-trichloro-phenyl)-acryloyl]-benzoic acid (101).
Yellow solid, yield 37%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): į 8.05 (d, 1H,
J = 15.9 Hz, H-ȕ), 7.91 (d, 2H, J = 1.2 Hz, ArH), 7.82 (d, 1H, J = 3.0 Hz, ArH), 7.75 (d,
1H, J = 15.6 Hz, H-Į), 7.60 (d, 1H, J = 2.7 Hz, ArH); MS (ESI): m/z 404.6 [MíH]í;
HPLC: tR 7.18 min, purity 98.81%.
5-chloro-2-hydroxy-3-[3-(2,3,6-trichloro-phenyl)-acryloyl]-benzoic acid (102).
Yellow solid, yield 49%; mp 229-231 °C; 1H NMR (300 MHz, DMSO-d6): į 7.99 (d, 1H,
J = 16.2 Hz, H-ȕ), 7.86 (d, 1H, J = 2.1 Hz, ArH), 7.71 (d, 1H, J = 2.7 Hz, ArH), 7.69 (d,
1H, J = 7.8 Hz, ArH), 7.65 (d, 1H, J = 8.4 Hz, ArH), 7.60 (d, 1H, J = 16.2 Hz, H-Į); MS
(ESI): m/z 404.6 [MíH]í; HPLC: tR 6.58 min, purity 95.66%.
5-chloro-3-[3-(3,4-dichloro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (103). Yellow
solid, yield 54%; mp >240 °C (dec); 1H NMR (300 MHz, DMSO-d6): į 8.05 (d, 1H, J =
15.9 Hz, H-ȕ), 7.99 (s, 1H, ArH), 7.80 (d, 1H, J = 3.0 Hz, ArH), 7.71 (d, 2H, J = 6.0 Hz,
ArH), 7.58 (d, 1H, J = 3.0 Hz, ArH), 7.56 (d, 1H, J = 15.9 Hz, H-Į); MS (ESI): m/z
370.8 [MíH]í; HPLC: tR 6.78 min, purity 99.60%.
3-[3-(4-chloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (104). Yellow solid,
yield 56%; mp 198-200 °C; 1H NMR (300 MHz, DMSO-d6): į 7.91 (d, 1H, J = 15.9 Hz,
H-ȕ), 7.60 (d, 1H, J = 15.9 Hz, H-Į), 7.68 (dd, 1H, J1 = 8.4 Hz, J2 = 3.3 Hz, ArH), 7.76
(d, 2H, J = 8.4 Hz, ArH), 7.49 (d, 2H, J = 8.7 Hz, ArH), 7.54 (dd, 1H, J1 = 9.3 Hz, J2 =
3.3 Hz, ArH); MS (ESI): m/z 318.8 [MíH]í; HPLC: tR 7.11 min, purity 99.11%.
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3-[3-(2,4-dichloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (105). Yellow
solid, yield 41%; mp 260-262 °C; 1H NMR (300 MHz, DMSO-d6): į 8.12 (d, 1H, J =
15.6 Hz, H-ȕ), 7.93 (d, 1H, J = 8.4 Hz, ArH), 7.81 (d, 1H, J = 15.9 Hz, H-Į), 7.74 (d, 1H,
J = 2.1 Hz, ArH), 7.65 (dd, 1H, J1 = 8.7 Hz, J2 = 3.3 Hz, ArH), 7.52 (dd, 1H, J1 = 8.4 Hz,
J2 = 2.1 Hz, ArH), 7.43 (dd, 1H, J1 = 9.3 Hz, J2 = 3.3 Hz, ArH); MS (ESI): m/z 352.8
[MíH]í; HPLC: tR 6.51 min, purity 99.5%.
3-[3-(2,3-dichloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (106). Yellow
solid, yield 47%; mp 222-224 °C; 1H NMR (500 MHz, DMSO-d6): į 7.94 (d, 1H, J = 7.8
Hz, ArH), 7.90 (s, 2H, H-Į and H-ȕ), 7.77 (dd, 1H, J1 = 8.5 Hz, J2 = 3.0 Hz, ArH), 7.73
(d, 1H, J = 8.0 Hz, ArH), 7.46 (t, 1H, J = 8.0 Hz, ArH), 7.66 (dd, 1H, J1 = 9.0 Hz, J2 =
2.5 Hz, ArH); MS (ESI): m/z 352.8 [MíH]í; HPLC: tR 5.68 min, purity 97.20%.
3-[3-(2,5-dichloro-phenyl)-acryloyl]-5-fluoro-2-hydroxy-benzoic acid (107). Yellow
solid, yield 59%; mp 238-240 °C; 1H NMR (300 MHz, DMSO-d6): į 8.07 (d, 1H, J =
15.9 Hz, H-ȕ), 7.93 (d, 1H, J = 2.4 Hz, ArH), 7.76 (d, 1H, J = 15.9 Hz, H-Į), 7.66 (dd,
1H, J1 = 8.4 Hz, J2 = 3.6 Hz, ArH), 7.60 (d, 1H, J = 8.7 Hz, ArH), 7.52 (dd, 1H, J1 =8.7
Hz, J2 = 2.4 Hz, ArH), 7.42 (dd, 1H, J1 = 9.3 Hz, J2 = 3.6 Hz, ArH); MS (ESI): m/z
352.8 [MíH]í; HPLC: tR 6.02 min, purity 98.43%.
5-fluoro-2-hydroxy-3-[3-(2,3,5-trichloro-phenyl)-acryloyl]-benzoic acid (108).
Yellow solid, yield 53%; mp 231-233 °C; 1H NMR (300 MHz, DMSO-d6): į 8.02 (d, 1H,
J = 2.4 Hz, ArH), 7.95 (d, 1H, J = 15.9 Hz, H-ȕ), 7.92 (d, 1H, J = 2.4 Hz, ArH), 7.79 (d,
1H, J = 15.6 Hz, H-Į), 7.74 (dd, 1H, J1 = 8.4 Hz, J2 = 3.3 Hz, ArH), 7.64 (dd, 1H, J1 =
9.0 Hz, J2 = 3.3 Hz, ArH); MS (ESI): m/z 388.6 [MíH]í; HPLC: tR 8.11 min, purity
97.86%.
5-fluoro-2-hydroxy-3-[3-(2,3,6-trichloro-phenyl)-acryloyl]-benzoic acid (109).
Yellow solid, yield 46%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): į 8.11 (d, 1H,
J = 16.2 Hz, H-ȕ), 7.70 (d, 1H, J = 8.7 Hz, ArH), 7.62 (d, 1H, J = 8.7 Hz, ArH), 7.58 (d,
1H, J = 16.2 Hz, H-Į), 7.66 (dd, 1H, J1 = 8.4 Hz, J2 = 3.6 Hz, ArH), 7.44 (dd, 1H, J1 =
9.3 Hz, J2 = 3.6 Hz, ArH); MS (ESI): m/z 388.6 [MíH]í; HPLC: tR 7.57 min, purity
97.57%.
5-bromo-3-[3-(3,5-dimethyl-phenyl)-acryloyl]-2-hydroxy-benzoic acid (110). Yellow
solid, yield 51%; mp 223-225 °C; 1H NMR (300 MHz, DMSO-d6): į 8.06 (d, 1H, J = 2.7
Hz, ArH), 7.99 (d, 1H, J = 1.8 Hz, ArH), 7.61 (d, 1H, J = 16.5 Hz, H-ȕ), 7.58 (d, 1H, J =
16.5 Hz, H-Į), 7.40 (s, 2H, Hz, ArH), 7.10 (s, 1H, ArH), 2.32 (s, 6H, CH3); MS (ESI):
m/z 374.9 [MíH]í; HPLC: tR 6.59 min, purity 99.0%.
5-bromo-3-[3-(2-chloro-3,4-dimethoxy-phenyl)-acryloyl]-2-hydroxy-benzoic acid
(111). Yellow solid, yield 21%; mp 217-220 °C; 1H NMR (300 MHz, DMSO-d6): į 8.05
(d, 1H, J = 2.7 Hz, ArH), 8.00 (d, 1H, J = 2.7 Hz, ArH), 7.90 (d, 1H, J = 15.6 Hz, H-ȕ),
7.81 (d, 1H, J = 8.7 Hz, ArH), 7.68 (d, 1H, J = 15.6 Hz, H-Į), 7.16 (d, 1H, J = 8.7 Hz,
ArH), 3.90 (s, 3H, OCH3), 3.77 (s, 3H, OCH3); MS (ESI): m/z 440.8 [MíH]í; HPLC: tR
6.46 min, purity 99.0%.

66

5-bromo-3-[3-(2-fluoro-4,5-dimethoxy-phenyl)-acryloyl]-2-hydroxy-benzoic acid
(112). Yellow solid, yield 32%; mp 193-195 °C; 1H NMR (300 Hz, DMSO-d6): į 8.03 (d,
1H, J = 2.7 Hz, ArH), 7.93 (d, 1H, J = 2.7 Hz, ArH), 7.66 (s, 2H, H-ȕ and H-Į), 7.38 (d,
1H, J = 7.2 Hz, ArH), 7.00 (d, 1H, J = 12.3 Hz, ArH), 3.84 (s, 3H, OCH3), 3.82 (s, 3H,
OCH3); MS (ESI): m/z 424.8 [MíH]í; HPLC: tR 7.19 min, purity 97.51%.
3-[3-(2-benzyloxy-phenyl)-acryloyl]-5-bromo-2-hydroxy-benzoic acid (113). Yellow
solid, yield 26%; mp > 165 °C (dec); 1H NMR (300 MHz, MeOH-d4): į 7.92-7.95 (m,
2H, H-ȕ and ArH), 7.72 (d, 1H, J = 7.5 Hz, ArH), 7.65 (d, 1H, J = 2.7 Hz, ArH), 7.47 (d,
2H, J = 7.2 Hz, ArH), 7.30-7.42 (m, 5H, H-Į, and ArH), 7.20 (d, 1H, J = 8.1 Hz, ArH),
7.0 (t, 1H, J = 7.5 Hz, ArH), 5.22 (s, 2H, CH2); MS (ESI): m/z 452.8 [MíH]í; HPLC: tR
7.83 min, purity 95.65%.
5-bromo-3-{3-[3-(4-chloro-phenoxy)-phenyl]-acryloyl}-2-hydroxy-benzoic acid
(114). Yellow solid, yield 42%; mp 162-165 °C; 1H NMR (300 MHz, DMSO-d6): į 7.94
(s, 2H, ArH), 7.74 (d, 1H, J = 6.9 Hz, ArH), 7.70 (d, 1H, J = 15.9 Hz, H-ȕ), 7.40-7.46 (m,
6H, H- Į and ArH), 7.20 (d, 1H, J = 7.8 Hz, ArH), 7.0 (t, 1H, J = 6.9 Hz, ArH); (ESI):
m/z 472.6 [MíH]í; HPLC: tR 5.86 min, purity 96.8%.
5-bromo-3-{3-[4-(4-chloro-phenoxy)-phenyl]-acryloyl}-2-hydroxy-benzoic acid
(115). Yellow solid, yield 35%; mp 219-220 °C; 1H NMR (300 MHz, DMSO-d6): į 8.06
(d, 1H, J = 2.1 Hz, ArH), 8.02 (d, 1H, J = 2.1 Hz, ArH), 7.84 (d, 2H, J = 8.4 Hz, ArH),
7.67 (d, 1H, J = 15.9 Hz, H-ȕ), 7.59 (d, 1H, J = 15.9 Hz, H-Į), 7.48 (d, 2H, J = 8.7 Hz,
ArH), 7.13 (d, 2H, J = 8.7 Hz, ArH), 7.07 (d, 2H, J = 8.7 Hz, ArH); MS (ESI): m/z 472.6
[MíH]í; HPLC: tR 7.23 min, purity 99.44%.
5-bromo-2-hydroxy-3-(3-thiophen-3-yl-acryloyl)-benzoic acid (116). Yellow solid,
yield 54%; mp 207-210 °C; 1H NMR (300 MHz, DMSO-d6): į 7.97 (s, 2H, ArH), 7.75
(d, 1H, J = 15.9 Hz, H-ȕ), 7.65 (s, 1H, ArH), 7.61 (s, 1H, ArH), 7.58 (d, 1H, J = 15.6 Hz,
H-Į), 7.48 (d, 1H, J = 4.2 Hz, ArH); MS (ESI): m/z 352.6 [MíH]í; HPLC: tR 6.91 min,
purity 99.71%.
5-bromo-3-[3-(3-cyclopentyloxy-4-methoxy-phenyl)-acryloyl]-2-hydroxy-benzoic
acid (117). Yellow solid, yield 31%; mp 233-235 °C; 1H NMR (300 MHz, MeOH-d4): į
7.91 (d, 1H, J = 2.7 Hz, ArH), 7.82 (d, 1H, J = 15.6 Hz, H-ȕ), 7.67 (d, 1H, J = 3.0 Hz,
ArH), 7.59 (d, 1H, J = 15.9 Hz, H-Į), 7.26 (d, 1H, J = 8.7 Hz, ArH), 7.25 (s, 1H, ArH),
6.99 (d, 1H, J = 8.1 Hz, ArH), 4.86 (p, 1H, J = 5.7 Hz, cyclopentyl), 3.79 (s, 3H, CH3)
1.87-1.92 (m, 2H, cyclopentyl), 1.66-1.72 (m, 4H, cyclopentyl), 1.57-1.60 (m, 2H,
cyclopentyl); MS (ESI): m/z 460.8 [MíH]í; HPLC: tR 7.19 min, purity 97.51%.
5-bromo-3-[3-(2-ethoxy-naphthalen-1-yl)-acryloyl]-2-hydroxy-benzoic acid (118).
Yellow solid, yield 23%; mp 216-218 °C; 1H NMR (300 MHz, MeOH-d4): į 8.48 (d, 1H,
J = 15.9 Hz, H-ȕ), 8.30 (d, 1H, J = 8.4 Hz, ArH), 8.19 (d, 1H, J = 2.7 Hz, ArH), 8.17 (d,
1H, J = 15.9 Hz, H-Į), 7.92 (d, 1H, J = 9.0 Hz, ArH), 7.88 (d, 1H, J = 2.7 Hz, ArH), 7.84
(d, 1H, J = 8.4 Hz, ArH), 7.55 (t, 1H, J = 7.2 Hz, ArH), 7.37-7.44 (m, 2H, ArH), 4.33 (q,
2H, J = 6.9 Hz, CH2), 1.55 (t, 3H, J = 6.9 Hz, CH3); MS (ESI): m/z 440.9 [MíH]í;

67

HPLC: tR 8.53 min, purity 95.0%.
5bromo-2-hydroxy-3-[3-(6-methoxy-naphthalen-2-yl)-acryloyl]-benzoic acid (119).
Yellow solid, yield 15%; mp 239-241 °C; 1H NMR (300 Hz, MeOH-d4): į 8.17 (d, 1H,
J = 2.4 Hz, ArH), 8.01 (s, 1H, H-ȕ), 7.86 (d, 1H, J = 7.9 Hz, ArH), 7.84 (d, 2H, J = 8.1
Hz, ArH), 7.83 (d, 1H, J = 2.4 Hz, ArH), 7.80 (s, 2H, H-Į, and ArH), 7.26 (d, 1H, J =
2.4 Hz, ArH), 7.16 (dd, 1H, J1 = 8.7 Hz, J2 = 2.4 Hz, ArH), 3.93 (s, 3H, OCH3); MS
(ESI): m/z 426.8 [MíH]í; HPLC: tR 6.07 min, purity 98.93%.
3-(3benzo[b]thiophen-5-yl-acryloyl)-5-bromo-2-hydroxy-benzoic acid (120). Yellow
solid, yield 21%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): į 8.21 (s, 1H, ArH),
8.1 (d, 1H, J = 15.9 Hz, H-ȕ), 8.0 (s, 1H, ArH), 7.92 (d, 1H, J = 2.7 Hz, ArH), 7.82 (d,
1H, J = 5.4 Hz, ArH), 7.73 (d, 1H, J = 15.9, H-Į), 7.72 (d, 1H, J = 3 Hz, ArH), 7.72 (s,
1H, ArH), 7.53 (d, 1H, J = 5.1 Hz, ArH); MS (ESI): m/z 402.8 [MíH]í; HPLC: tR 5.53
min, purity 98.31%.
5-bromo-3-[3-(2-furan-2-yl-phenyl)-acryloyl]-2-hydroxy-benzoic acid (121). Yellow
solid, yield 36%; mp 208-209 °C; 1H NMR (300 MHz, DMSO-d6): į 7.92 (m, 3H, H-ȕ
and ArH), 7.87 (s, 1H, H-Į), 7.81 (d, 1H, J = 2.7 Hz, ArH), 7.70 (s, 1H, ArH), 7.68 (d,
1H, 9.6 Hz, ArH), 7.48 (t, 2H, J = 7.5 Hz, ArH), 6.66 (s, 1H, ArH), 6.63 (s,1H, ArH); MS
(ESI): m/z 412.8 [MíH]í; HPLC: tR 5.77 min, purity 95.02%.
5-bromo-3-[3-(6-chloro-benzo[1,3]dioxol-5-yl)-acryloyl]-2-hydroxy-benzoic acid
(122). Yellow solid, yield 18%; mp 228-231 °C; 1H NMR (300 MHz, DMSO-d6): į 8.10
(s, 1H, ArH), 8.07 (s, 1H, ArH), 7.90 (d, 1H, J = 15 Hz, H-ȕ), 7.66 (s, 1H, ArH), 7.63 (d,
1H, J = 14.7 Hz, H-Į), 7.21 (s, 1H, ArH), 6.16 (s, 2H, CH2); MS (ESI): m/z 424.6
[MíH]í; HPLC: tR 7.82 min, purity 99.0%.
5-bromo-2-hydroxy-3-[3-(3-trifluoromethoxy-phenyl)-acryloyl]-benzoic acid (123).
Yellow solid, yield 44 %; mp 217-219 °C; 1H NMR (300 MHz, DMSO-d6): į 8.07 (d,
1H, J = 2.7 Hz, ArH), 8.03 (d, 1H, J = 2.7 Hz, ArH), 7.80-7.84 (br s, 2H, H-Į and H-ȕ),
7.72 ( s, 1H, ArH), 7.70 (s, 1H, J = 4.0 Hz, ArH), 7.58 (t, 1H, J = 7.8 Hz, ArH), 7.45 (d,
1H, J = 7.5 Hz, ArH); MS (ESI): m/z 430.8 [MíH]í; HPLC: tR 6.06 min, purity 99.30%.
5-bromo-2-hydroxy-3-[3-(3-nitro-phenyl)-acryloyl]-benzoic acid (124). Yellow solid,
yield 62%; mp 200-202 °C; 1H NMR (500 MHz, DMSO-d6): į 8.62 (s, 1H, ArH), 8.26 (s,
2H, ArH), 8.07 (s, 1H, H-ȕ), 8.02 (s, 1H, H-Į), 7.81 (d, 2H, J = 7.0 Hz, ArH), 7.75 (t, 1H,
J = 7.0 Hz, ArH); MS (ESI): m/z 391.8 [MíH]í; HPLC: tR 11.47 min, purity 95.59%.
5-bromo-3-[3-(3-bromo-phenyl)-acryloyl]-2-hydroxy-benzoic acid (125). Yellow
solid, yield 31%; mp 235-237 °C; 1H NMR (300 MHz, DMSO-d6): į 8.0 (d, 1H, J = 15.9
Hz, H-ȕ), 7.92 (d, 1H, J = 2.7 Hz, ArH), 7.90 (s, 1H, ArH), 7.72 (d, 1H, J = 6.6 Hz,
ArH), 7.70 (d, 1H, J = 2.4 Hz, ArH), 7.59 (d, 1H, J = 8.4 Hz, ArH), 7.55 (d, 1H, J = 15.9
Hz, H-Į), 7.39 (t, 1H, J = 7.8 Hz, ArH); MS (ESI): m/z 424.6 [MíH]í; HPLC: tR 6.14
min, purity 98.81%.
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5-bromo-3-[3-(3-fluoro-phenyl)-acryloyl]-2-hydroxy-benzoic acid (126). Yellow
solid, yield 59%; mp 190-193 °C; 1H NMR (500 MHz, DMSO-d6): į 8.0 (d, 1H, J = 2.0
Hz, ArH), 7.93 (s, 1H, ArH), 7.80 (d, 1H, J = 16.0 Hz, H-ȕ), 7.60-7.77 (m, 3H, H-Į and
ArH), 7.48 (d, 1H, J = 6.5 Hz, ArH), 7.28 (d, 1H, J = 8.0 Hz, ArH); MS (ESI): m/z 364.7
[MíH]í; HPLC: tR 5.39 min, purity 92.5%.
5-bromo-2-hydroxy-3-[3-(2,3,6--trichloro-phenyl)-acryloyl]-benzonitrile (127).
Orange solid, yield 74%; mp 139-141 °C; 1H NMR (300 MHz, DMSO-d6): į 8.34 (d, 1H,
J = 16.2 Hz, H-ȕ), 7.69 (d, 1H, J = 3.0 Hz, ArH), 7.66 (d, 1H, J = 9.0 Hz, ArH), 7.58 (d,
1H, J = 8.7 Hz, ArH), 7.46 (d, 1H, J = 2.4 Hz, ArH), 7.43 (d, 1H, J = 16.2 Hz, H-Į); MS
(ESI): m/z 431.6 [MíH]í; HPLC: tR 6.37 min, purity: 95.69%.
2-hydroxy-5-methyl-3-[3-(2,3,6--trichloro-phenyl)-acryloyl]-benzoic acid (128).
Yellow solid, yield 58.5%; mp 205-208 °C; 1H NMR (300 MHz, DMSO-d6): į 7.87 (s,
1H, ArH), 7.74 (s, 1H, ArH), 7.70 (d, 1H, J = 8.7 Hz, ArH), 7.59-7.64 (m, 3H, H-Į, H-ȕ
and ArH), 2.29 (s, 3H, CH3); MS (ESI): m/z 384.8 [MíH]í; HPLC: tR 6.01 min, purity
97.84%.
General procedure for the synthesis of chalcones (129 -130). A similar
procedure to the one mentioned above for the synthesis of chalcones (81-128) was
followed (Scheme 1-2) with appropriate aromatic aldehydes starting materials 79, 80 and
commercially available 1-(5-bromo-2-hydroxy-3-nitro-phenyl)-ethanone, 78f to
synthesize chalcones 129 and 130.
1-(5-bromo-2-hydroxy-3-nitro-phenyl)-3-(2,3,5-trichloro-phenyl)-propenone (129).
Yellow solid, yield 65%; mp 175-178 °C; 1H NMR (300 MHz, DMSO-d6): į 8.13 (d, 1H,
J = 15.6 Hz, H-ȕ), 7.76 (d, 1H, J = 15.9 Hz, H-Į), 8.05 (d, 1H, J = 2.7 Hz, ArH), 8.0 (d,
2H, J = 2.4 Hz, ArH), 7.92 (d, 1H, J = 2.4 Hz, ArH); MS (ESI): m/z 451.8 [MíH]í;
HPLC: tR 5.46 min, purity 97.30%.
1-(5-bromo-2-hydroxy-3-nitro-phenyl)-3-(2,3,6-trichloro-phenyl)-propenone (130).
Yellow solid, yield 58%; mp 153-154 °C; 1H NMR (500 MHz, DMSO-d6): į 8.32 (s, 1H,
ArH), 8.24 (s, 1H, ArH), 7.77 (d, 1H, J = 16.5 Hz, H-ȕ), 7.75 (d, 1H, J = 9.0 Hz, ArH),
7.65 (d, 1H, J = 15.0 Hz, H-Į), 7.63 (d, 1H, J = 8.0 Hz, ArH); MS (ESI): m/z 451.8
[MíH]í; HPLC: tR 6.53 min, purity 98.0%.
2-hydroxyl-3-(3-phenylpropyl) benzoic acid (131). Compound 81 (0.05 g, 0.195 mmol)
was dissolved in ethanol (10 mL) and Pd/C (10 mol%, 5 mg) was added. The resulting
solution was stirred under hydrogen at atmospheric pressure for 10 h at rt. After the
reaction was complete, the reaction mixture was filtered through celite, and evaporated to
dryness. The resulting crude solid was purified by preparative TLC to give a white solid,
yield 72%; mp 125-127 °C; 1H NMR (300 MHz, DMSO-d6): į 11.66 (s,1H, OH), 7.67
(dd, 1H, J1 = 7.8 Hz, J2 = 1.5 Hz, ArH), 7.39 (dd, 1H, J1 = 7.2 Hz, J2 = 1.5 Hz, ArH),
7.16-7.30 (m, 5H, ArH), 6.85 (t, 1H, J = 7.8 Hz, ArH), 2.62 (t, 4H, J = 7.2 Hz, CH2),
1.81-1.91 (m, 2H, CH2); MS (ESI): m/z 254.8 [MíH]í; HPLC: tR 7.61 min, purity 98 %.
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3-[3-(2,5-dichloro-phenyl)-propionyl]-5-fluoro-2-hydroxy-benzoic acid (132).
Compound 107 (0.2 g, 0.563 mmol) was dissolved in methanol (10 mL) and Pd/C (10
mol %, 20 mg) was added. The resulting solution was stirred under hydrogen at
atmospheric pressure for 2 h at room temperature. After the reaction was complete, the
reaction mixture was filtered through celite, and evaporated to dryness. The resulting
crude solid was recrystallized from ethanol to give a white solid, yield 43%; mp 163164 °C; 1H NMR (300 MHz, DMSO-d6): į 7.79 (d, 1H, J = 8.4 Hz, ArH), 7.74 (d, 1H,
J = 9.0, ArH), 7.49 (s, 1H, ArH), 7.45 (d, 1H, J = 8.7 Hz, ArH), 7.31 (d, 1H, J = 8.1 Hz,
ArH), 3.39 (t, 2H, J = 6.9 Hz, CH2), 3.02 (t, 2H, J = 6.9 Hz, CH2); MS (ESI): m/z 356.9
[MíH]í; HPLC: tR 8.34 min, purity 96.36%.
Biological Assays
Materials, chemicals, and enzymes. All compounds were dissolved in DMSO
and the stock solutions were stored at -20 °C. Ȗ[32P]-ATP was purchased from either
Amersham Biosciences or ICN. The expression systems for wild-type IN were a
generous gift from Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH,
Bethesda, MD. Cell lines were obtained from American Type Culture Collection (ATCC,
Rockville, MD).
Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5ƍGTGTGGAAAATCTCTAGCAGT-3ƍ, and 21bot, 5ƍ-ACTGCTAGAGATTTTCCACAC3ƍ, were purchased from the Norris Cancer Center Microsequencing Core Facility
(University of Southern California) and purified by UV shadowing on polyacrylamide
gel. To analyze the extent of 3ƍ-P and ST using 5ƍ-end labeled substrates, 21top was
5ƍ-end labeled using T4 polynucleotide kinase (Epicentre, Madison, WI) and Ȗ[32P]-ATP
(Amersham Biosciences or ICN). The kinase was heat-inactivated and 21-bot was added
in 1.5M excess. The mixture was heated at 95 °C, allowed to cool slowly to rt, and run
through a G25 mini spin column (USA Scientific) to separate double-stranded
oligonucleotide from unincorporated material.
Integrase assays. To determine the extent of 3ƍ-P and ST, wild-type IN was
preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50
mM NaCl, 1 mM HEPES, pH 7.5, 50 μM EDTA, 50 μM dithiothreitol, 10% glycerol
(w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM 2-mercaptoethanol,
10% dimethylsulfoxide, and 25 mM MOPS, pH 7.2) at 30 °C for 30 min. An aliquot
(5μL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris- borate,
pH 8.3, 2 mM EDTA, 20% acrylamide, and 8M urea). Gels were dried, exposed in a
phosphorImager cassette, and analyzed using a Typhoon 8610 Variable Mode Imager
(Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I)
was calculated using (Equation 3-1);
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(Eq. 3-1)

where C, N, and D are the fractions of 21-mer substrate converted to 19-mer (3ƍ-P
product) or ST products for DNA alone, DNA plus IN, and IN plus compound,
respectively. The IC50 values were determined by plotting the logarithm of compound
concentration versus percent inhibition to obtain the concentration that produced 50%
inhibition.
Anti-HIV-1 activity assay. The testing of the ability of potent compounds to
inhibit HIV replication in cell culture was done according to a previously reported
procedure.182 PBMC (107 cells/T25flask) were stimulated with phytohemagglutinin for 3
days and infected with a wild-type HIV-1 strain (strain LAI) at 100 50% tissue culture
infective doses, as described previously.182 The cultures were kept for 5 days in the
presence of test compounds at serial 1-log dilutions. Subsequently, human PBMC were
removed from the culture supernatant by centrifugation (400g, 10 min, 4 °C). This
clarified supernatant was tested by a reverse transcriptase assay.
Cytotoxicity assays. The cytotoxicity of compounds was evaluated using
uninfected PBMC and CEM leukemia cells according to a previous method.183 PBMC
were obtained from whole blood of healthy individuals, while CEM were obtained from
the ATCC (Rockville, MD). The PBMC and CEM cells were cultured in the presence or
absence of compound for 6 days. After this time period, cells were stained with Trypan
blue dye, and counted for cell proliferation and viability according to the previously
reported procedure.184
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CHAPTER 4. SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-KETO
SALICYLAMIDE AS NOVEL HIV-1 INTEGRASE INHIBITORS*
Introduction
The benzyl carboxamide group was recognized as an important moiety with the
discovery of naphthyridine carboxamides as a new class of HIV-IN inhibitors. Examples
include L-870,810 and L-870,812 (Figure 1-20). Further efforts led to the development
of the pyrimidinone carboxamide class containing the approved drug raltegravir.51 The
carboxamide moiety though not an absolute requirement is believed to give a
conformationally favorable orientation to the halogenated benzyl group present in potent
inhibitors to bind into the cavity formed by protein-DNA interface. In this chapter, the
Į,ȕ-unsaturated moiety of our synthesized chalcone derivatives (described in Chapter 3)
was modified to an amide functionality to synthesize a novel series of compounds,
salicylic acid 3-carboxamides.
Chemistry
The synthesis of target compound 149 is shown in Scheme 4-1. Commercially
available 5-bromo salicylic acid (133a) was first formylated with chloroform at the 2position (ortho) by the Reimer-Tiemann reaction185 to yield the aldehyde intermediate
134. In the next step, intermediate 134 was coupled with 4-fluorobenzyl amine to afford
intermediate 135 which was subsequently subjected to oxidation with KMnO4 to yield
compound 149.186
Low yield of the formylation step (8-10%), and a potential side product (Schiffs
base) in the coupling reaction prompted us to employ an alternate synthetic route
(Scheme 4-2). Thus, for the synthesis of compounds 150-152, 3-formyl salicylaldehyde
(133b) was used as the starting material, which was brominated with N-bromo
succinimide (NBS) in acetonitrile to afford intermediate 134 in higher (90%) yields.187
Next, the sequence of subsequent steps was altered in that the intermediate 134 was first
subjected to KmNO4 oxidation to form a di-acid derivative 136. Intermediate 136 was
then coupled with equimolar amounts of the appropriate amines in the presence of HOBt
and EDCI to form the desired amides 150 and 151.188 For the synthesis of compound 152,
the di-acid intermediate 136 was treated with excess of 4-fluorobenzyl amine (2.2 eq)
under similar conditions.
For the synthesis of amide compounds 153-156, shown in Scheme 4-3,
commercially available acids (137–140) were subjected to HOBt/EDCI coupling with
* Portions of this chapter adapted with permission. Sharma, H.; Patil, S.; Sanchez, T. W.;
Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Synthesis, biological evaluation and 3DQSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1
integrase inhibitors. Bioorg. Med. Chem. 2011, 19, 2030-2045.179

72

Scheme 4-1. Synthesis of compound 149

Reagents and conditions: (a) CHCl3, NaOH, H2O, reflux, 48 h; yield 13% (b) 4-F
benzylamine, EDCI, HOBt, Et3N, rt, overnight; yield 41% (c) KMnO4, H2O/Pyridine,
90 °C, overnight; yield 80%.
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Scheme 4-2. Synthesis of compounds 150-152

Reagent and conditions: (a) NBS, CH3CN, rt, 3 h; yield 90% (b) KMnO4, H2O/Pyridine,
90 °C , overnight; 80% (c) amines (0.90 eq), EDCI, HOBt, Et3N, rt, overnight; yields 3462% (d) 4-F benzylamine (2.2 eq), EDCI, HOBt, Et3N, rt, overnight; yield 48%.
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Scheme 4-3. Synthesis of compounds 153-156

Reagent and conditions: (a) 4-F benzylamine, EDCI, HOBt, Et3N, rt, overnight; yields
53-76%.
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4-fluoro benzyl amine. The synthesis of compound 157 was performed according to
Scheme 4-4. The commercially available 5-acetyl-2-hydroxy-3-methoxybenzoic acid
(141) was first converted to the corresponding amide with standard HOBt/EDCI
coupling. The methoxy substituent in amide intermediate (142) was then demethylated
using BBr3 in DCM at 0 °C.189 The hydroxyl intermediate (143) was then reacted with
benzaldehyde, using aq. sodium hydroxide by Aldol condensation to afford the desired
final Į,ȕ-unsaturated compound 157. The synthesis of compound 158 was achieved using
Scheme 4-5 in which the 3-acetyl-5-bromo-2-hydroxybenzoic acid intermediate (78a),
which was synthesized in Chapter 3, was subjected to routine HOBt/EDCI amide
coupling followed by an Aldol condensation. The synthesis of compound 159, shown in
Scheme 4-6, was achieved according to a method previously reported.190 First, a solution
of peracetic acid was synthesized by stirring a mixture of acetic anhydride and H2O2 at
ice for 4 h. N-hydroxylation of the starting material, 6-hydroxy picolinic acid was
achieved by peracetic acid in a mixture of trifluoroacetic acid and glacial acetic acid and
heating at 80 °C for 10 h. In the next step, the N-hydroxyl group of intermediate 146 was
protected using benzyl chloride and K2CO3 in methanol to obtain benzyl-protected
intermediate 147. The acid moiety in intermediate 147 was then converted to acid
chloride using oxalyl chloride in the presence of a catalytic amount of DMF in toluene
and heating at 80 °C for 4 h. The acid chloride formed was then subsequently reacted
with 4-fluorobenzyl amine in THF by stirring at 60 °C for overnight to afford
intermediate 148. In the last step, the benzyl group was deprotected with acid to give
final compound 159.
Results and Discussions
Structure Activity Relationship (SAR)
The chalcone functionality contained in compounds synthesized in Chapter 3 was
modified to a structurally related amide to synthesize a new series of HIV-IN inhibitors.
Compound 149 having an acid functionality at the X position (Table 4-1) showed low
μM ST inhibitory activity (IC50 value of 15 μM) suggesting that the Į,ȕ-unsaturated
moiety of chalcones could be replaced with an amide functionality with retention of
comparative inhibitory activity but with an increase in ST selectivity. Intermediate 135
having an aldehyde group at the X position was also tested for SAR purposes and was
found to be more active than the corresponding acid containing compound 149. The
synthesis of compounds 153 and 154 was undertaken to determine the ability of twochelating atoms in inhibiting HIV-IN activity. The discovery of elvitegravir has showed
that the presence of even two coplanar chelating moieties, represented by the ȕ-ketone
and a carboxylic acid is sufficient for potent clinically relevant IN inhibition. Compound
153 (X= CH3 R1 = H) was found to be inactive with ST IC50 > 100 μM. In order to
further ascertain if the loss in activity of compound 153 was due to the lack of a chelating
atom at the X position, compound 154 (X= CH3 R1 = Br) was synthesized. Compound
154 also showed ST IC50 > 100 μM indicating the importance of a metal-chelating group
at the X position. Next, an OH substituted compound 155 was synthesized and was found
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Scheme 4-4. Synthesis of compound 157

Reagent and conditions: (a) 4-F benzylamine, EDCI, HOBt, Et3N, rt, overnight; yield
74% (b) BBr3, DCM, 0 °C to rt, overnight; (c) C6H5CHO, NaOH, ethanol, rt, overnight;
overall (steps b and c) yield 36%.
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Scheme 4-5. Synthesis of compound 158

Reagent and conditions: (a) Ac2O, H2SO4, 20 min; yield 88% (b) AlCl3, 160 °C, 3 h;
yield 34% (c) 4-F benzylamine, EDCI, HOBt, Et3N, rt, overnight; yield 41% (d) ArCHO,
NaOH, EtOH, rt, 24 h; yield 51%.
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Scheme 4-6. Synthesis of compound 159

Reagent and conditions: (a) H2O2, Ac2O, 4 h; (b) TFA, GAA, 80 °C, 6 h; overall (steps
a and b) yield 60% (c) BnCl, K2CO3, MeOH, 16 h, reflux; yield 41% (d) (COCl)2,
toluene, DMF, 60 °C, 4 h; (e) 4-F benzylamine, Et3N, THF, 60 °C,12 h; overall (steps d
and e) yield 41% (f) HOAc /Conc. HCl, rt, 2 days; yield 67%.
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Table 4-1.
Structures and activities of 3-keto salicylic acid amides HIV-1
integrase inhibitors

135
144
149
150

CHO
COCH3
COOH
COOH

Br
Br
Br
Br

4-F
4-F
4-F
4-Br

151
152

COOH
CONHCH24-F-Ph
H
CH3
OH
OH
COCHCH-2,3,6tri-Cl-Ph
N/A
N/A

Br
Br

2,4-di-F-3-Cl
4-F

Activity IC50 (μM)
3ƍ-Pa
STb
>100
>100
8±1
>100
>100
>100
15 ± 3
>100
69 ±13
>100
4±1

Br
H
Br
COCHCH-Ph
Br

4-F
4-F
4-F
4-F
4-F

>100
>100
53 ± 2
64 ± 6
>100

6±2
>100
>100
13 ± 6
21 ± 6

N/A
N/A

N/A
N/A

>100
>333

100
255 ± 6

Cpd. X

153
154
155
157
158
156
159
a

R1

R2

3ƍ-P = 3ƍ-procesing; b ST = strand transfer.
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to be marginally better (ST IC50 = 13 μM) than the acid containing compound suggesting
that a catechol substituent is well tolerated. This is in agreement with literature as
polyhydroxylated compounds have been reported as HIV-IN inhibitors.112 The chalcone
series of IN inhibitors have demonstrated that substitution at the R1 position resulted in
notable changes in ST activities. For further development of this series of compounds
structure-based design, described in Chapter 6, was attempted using the RACHEL lead
optimization software (Tripos Inc). Thus, compound 157 was designed and synthesized
based on the binding interactions of raltegravir. It has an extended side chain with an
aromatic ring to serve as an oxadiazole mimic for obtaining ʌ-stacking interactions with
Tyr143 in the IN active site. The phenyl ring was thus connected to the core 3-keto
salicylamide ring with an Į,ȕ-unsaturated linker. Unfortunately, this modification
resulted in a loss of activity (ST IC50 = 21 μM) relative to its reference compound (13
μM). Further modifications with various linkers and heterocyclic ring system need to be
explored to determine the SAR at this position. The diamide compound 152 was designed
with the objective of increasing contacts with the protein. This modification resulted in
improvement in ST activity with IC50 of 6.0 μM opening the possibilities of further
modifications. Compounds 150 and 151 were synthesized to determine the effects of
other halogens on the phenyl ring of their benzyl carboxamide moieties. Compound 150
with a p-bromo substituent at the R2 position was four times less active than compound
149. Moreover, compound 151 resulted in 4-folds improvement in inhibitory activity
with IC50 of 4.0 μM in ST assay with respect to compound 149 and fifteen-folds more
active than compound 150 indicating that further modifications, possibly with different
halogens, could improve the ST activities of this series of compounds.
With an aim of discovering new pharmacophores for inhibiting HIV-1 IN,
synthesis of compounds 156 and 159 was undertaken. Compound 159 is a 3-hydroxy-2pyridinone which has been reported to have strong metal (Fe3+) chelating191,192 properties.
This compound was inactive against IN suggesting that this system may not chelate Mg2+
with similar potencies.
Inhibition of HIV Replication in Cell Culture
To evaluate the potential of the amide derivatives as antiviral agents, three active
analogs were tested for the ability to inhibit HIV-1 replication in primary human
peripheral blood mononuclear cells (PBMCs) infected with the virus. The toxicity of the
compounds was also tested against PBMC and human CEM lymphoblastic leukemia
cells. In general, the compounds showed reduced anti-viral activities. Compounds 135
and 152 showed moderate activities while compound 151 was inactive in inhibiting HIV
replication (Table 4-2). The low antiviral activities may have to do with solubility,
absorption, binding to serum proteins in cell culture media and/or cellular distribution
factors.
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Table 4-2.
Cpd.
135
151
152
AZT
L-706,908

Anti-HIV activity of selected amide derivatives
Anti-HIV-1 activity in PBMCsa
EC50(μM)b EC90(μM)b
30.8
52.7
>100
>100
49.6 ± 4.2
>100
0.0025
0.01
c
5.7 ± 4.7
N/Ad

a

Cytotoxicity (IC50 μM)
PBMCs CEM
44.0
40.2
26.4
26.4
18.0
14.3
>100
56.1
N/A
N/A

PBMCs represents Human Peripheral blood mononuclear cells; b EC50 and EC90 are the
effective concentrations inhibiting 50% and 90% HIV replication, respectively; c in the
assay on human leukemic T-cell line MOLT-4, the EC50 of AZT was 0.001 μM; d N/A
represents not available.
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Experimental Section
Chemistry
All the reagents and solvents were purchased from the Aldrich Chemical
Company and used without further purification. Progress of reactions was monitored by
TLC on silica gel GHLF-250 micron plates (Analtech, Inc.). Fisher scientific Da visil
grade 1740 (170-400 mesh) silica gel was used for flash column chromatography. 1H
NMR spectra were recorded on Brucker AR, 300 or 500-MHz spectrometer: chemical
shifts are expressed in į values (ppm) and coupling constants (J) in Hertz (Hz). Mass
spectral data were determined on a Brucker-HP Esquire-LC spectrometer (ESI-MS).
Melting points of solids were determined using a Fisher-Johns melting point apparatus
and are reported uncorrected. HPLC analysis of final compounds was carried out using a
reverse phase SUPELCOSIL 5 μm C-18 column of dimensions 25 cm x 4.6 cm. Area %
purity was detected at 254 nm. An initial isocratic method comprising 40% water
(solvent A) and 60% methanol (solvent B) for 20 min at a flow rate of 1.2 mL/min was
optimized to a linear gradient elution with water (A) and methanol (B) at a flow-rate of
1.7 mL/min. Gradient elution of the mobile phase was either 80% A to 35% A from 0-5
min, 35% A and 65% B for 5-12 min and 35% A to 80% A from 12-15 min or 80% A to
20% A from 0-4 min, 20% A and 80% B for 4-17 min and 20% A to 80% A from 17-20
min.
5-bromo-3-formyl-2-hydroxy-benzoic acid (134). Method (a): NaOH (5.53 g, 0.138
mol) was added to a solution of 5-bromosalicylic acid (5 g, 23.0 mmol) in DCM (45 mL)
and water (1 mL, 55.55 mmol) at rt. The reaction mixture was refluxed for 48 h, diluted
with water and acidified with 6M HCl to pH 1.0. The resulting solution was extracted
with ethyl acetate washed with brine and dried over Na2SO4. The organic layer was
evaporated to yield a crude product which was purified by column chromatography (2535% MeOHl/DCM) to give a white solid, yield 13%; mp 172-174 °C; 1H NMR (300
MHz, DMSO-d6): į 10.27 (s, 1H, CHO), 8.12 (d, 1H, J = 2.7, ArH), 7.93 (d, 1H, J = 2.7
ArH); MS (ESI): m/z 244.7 [MíH]í.
5-bromo-N-(4-fluoro-benzyl)-3-formyl-2-hydroxy-benzamide (135). To a solution of
intermediate (0.4 g, 1.63 mmol), HOBt (0.441 g, 3.26 mmol) and Et3N (0.45 mL, 3.26
mmol) in DCM (20 mL) was added EDCI (0.344 g, 1.8 mmol) at 0 °C. 4fluorobenzylamine (0.20 mL, 1.8 mmol) was then added and the reaction mixture stirred
overnight at rt. The reaction mixture was extracted with ethyl acetate, washed with dilute
hydrochloric acid and sodium bicarbonate solution. The organic layer was further washed
with brine and dried over sodium sulfate. The crude was purified by recrystalization with
ethyl acetate/hexane to give a yellow solid. yield 41%; mp 135-137 °C; 1H NMR (300
MHz, DMSO-d6): į 10.27 (s,1H, CHO), 9.90 (s, 1H, NH), 8.41 (s, 1H, ArH), 7.87 (s, 1H,
ArH), 7.40 (d, 2H, J = 8.1 Hz, ArH), 7.18 (t, 2H, J = 8.1 Hz, ArH), 4.52 (s, 2H, CH2);
MS (ESI): m/z 351.9 [MíH]í.
5-bromo-N-(4-fluoro-benzyl)-2-hydroxy-isopthalamic acid (149). Intermediate 135
(0.20 g, 0.568 mmol) was added to a mixture of water (2.5 mL) and pyridine (2.5 mL).
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the reaction mixture was heated to 90 °C, KMnO4 (0.18 g, 1.13 mmol) was added to the
hot solution was and the heating continued overnight at 90 °C. After completion, the
mixture was filtered through celite and evaporated to dryness. The resulting residue was
purified by recrystalization from ethyl acetate/hexane. White solid; yield 80 %; mp 208210 °C; 1H NMR (300 MHz, DMSO-d6): į 10.20 (s, 1H, NH), 7.98 (s, 1H, ArH), 7.85 (s,
1H, ArH), 7.13-7.34 (m, 4H, ArH), 4.50 (s, 2H, CH2); MS (ESI): m/z 367.9 [MíH]í;
HPLC: tR 4.21 min, purity 97.7%.
5-bromo-3-formyl-2-hydroxy-benzoic acid (134). Method (b): 3-formyl salicylic acid
hydrate starting material (1.0 g, 6.0 mmol) was dissolved in dry acetonitrile (20 mL). Nbromo succinimide (1.02 g, 5.73 mmol) was added and the reaction mixture stirred at rt
for 3 h. The white crystals formed were filtered and washed with water. The filtrate was
extracted with ethyl acetate, and washed with brine. The organic layer was dried over
Na2SO4 and evaporated to dryness. The two fractions were combined to give intermediate
as white crystals, yield 90%; mp 172-174 °C; 1H NMR (300 MHz, DMSO-d6): į 10.27
(s, 1H, CHO), 8.12 (d, 1H, J = 2.7, ArH), 7.93 (d, 1H, J = 2.7 ArH); MS (ESI): m/z 244.7
[MíH]í.
5-bromo-2-hydroxyisophthalic acid (136). Intermediate 134 (0.30 g, 1.22 mmol) was
added to a mixture of water (3.5 mL) and pyridine (3.5 mL). The reaction mixture was
heated to 90 °C, KMnO4 (0.387g, 2.45 mmol) was added to the hot solution was and the
heating continued overnight at 90 °C. After completion, the mixture was filtered through
celite and evaporated to dryness. The resulting residue was washed with ethyl acetate and
purified by recrystalization from ethanol. Yield 68%; mp >220 °C; 1H NMR (300 MHz,
DMSO-d6): į 10.25 (s, 1H, OH), 7.60 (s, 1H, ArH), 7.92 (s, 1H, ArH); MS (ESI): m/z
260.7 [MíH]í.
General procedure for the synthesis of compounds 150 and 151. Intermediate
136 (0.50 g, 1.91 mmol), HOBt (0.517g, 3.83 mmol) and triethyl amine (0.534 mL, 3.83
mmol) were added to a mixture of DCM (10 mL) and DMF (10 mL) at 0 °C. EDCI
(0.404 g, 2.10 mmol) was added to the above solution followed by 4-bromo-benzylamine
(0.22 mL, 1.82 mmol) or 3-chloro-2,4-difluorobenzylamine (0.323 gm, 1.82 mmol) for
compounds 150 and 151, respectively. The reaction mixture was then stirred overnight at
rt. After the reaction, the reaction mixture was evaporated and poured into excess water,
and extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric
acid and sodium bicarbonate solution and then with brine and dried over sodium sulfate.
The resulting crude solid was washed with hexane and recrystalization with ethyl acetate.
5-bromo-3-((4-bromobenzyl)carbamoyl)-2-hydroxybenzoic acid (150).White solid,
yield 34%; mp >220 °C dec; 1H NMR (500 MHz, DMSO-d6): į 9.28 (s, 1H, NH), 8.07
(d, 1H, J = 2.0 Hz, ArH), 7.96 (d, 1H, J = 2.0 Hz, ArH), 7.52 (d, 1H, J = 8.0 Hz, ArH),
7.27 (d, 1H, J = 8.0 Hz, ArH), 4.47 (d, 2H, J = 6.0 Hz, CH2); MS (ESI): m/z [MíH]í;
HPLC: tR 6.41 min, purity 99.7%.
5-bromo-N-(3-chloro-2,4-difluorobenzyl)-2,3-dihydroxybenzamide (151). Yellow
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solid, yield 62%; mp 140-142 °C; 1H NMR (300 MHz, DMSO-d6): į 9.73 (s, 1H, NH),
8.02 (s, 1H, ArH), 7.92 (s, 1H, ArH), 7.45 (d, 1H, J = 7.8 Hz, ArH), 7.27 (d, 1H, J = 9.0
Hz, ArH), 4.56 (d, 2H, J = 5.1 Hz, CH2); MS (ESI): m/z 419.8 [MíH]í; HPLC: tR 4.43
min, purity 97.7%.
5-bromo-N1,N3-bis(4-fluorobenzyl)-2-hydroxyisophthalamide (152). Intermediate 136
(0.20 g, 0.766 mmol), HOBt (0.415 g, 3.06 mmol) and Et3N (0.22 mL, 1.53 mmol) was
added in a mixture of DCM (20 mL) and DMF (5 mL) at 0 °C. EDCI (0.323 g, 1.69
mmol) was added to the above solution followed by 4-fluorobenzylamine (0.20 mL, 1.69
mmol) after which the reaction mixture was kept at 0 °C for 1 h and stirred overnight at
rt. The reaction mixture was then evaporated and poured into excess water, and extracted
with ethyl acetate. The organic layer was washed with dilute hydrochloric acid and
sodium bicarbonate solution and then with brine and dried over sodium sulfate. The crude
was washed with hexane and purified by column chromatography with 5-10% of
MeOH/DCM to give pure compound 152. Yellow solid; yield 48%; mp 235-237 °C; 1H
NMR (300 MHz, DMSO-d6): į 9.23 (bs, 2H, NH), 8.09 (d, 1H, J = 2.7 Hz, ArH), 7.98 (d,
1H, J = 2.7 Hz, ArH), 7.29-7.39 (m, 4H, ArH), 4.48 (d, 1H, J = 4.2 Hz, CH2); MS (ESI):
m/z 474.8 [MíH]í.
General procedure for the synthesis of compounds 153-156. Similar procedure
for amide coupling described above for compound 149 was used such that appropriate
commercially available acids (0.25 g, 0.98 mmol), HOBt (0.29 g, 2.1 mmol) and Et3N
(0.15 mL, 0.98 mmol) were added to either DCM or THF (15 mL) at 0 °C. EDCI (0.22 g,
1.07 mmol) was added to the above solution followed by 4-fluorobenzylamine (0.12 mL,
0.98 mmol) after which the reaction mixture was kept at ice for 1 h and then allowed to
come to rt and stirred overnight for 14 h. The reaction mixture was then evaporated and
extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric acid
and sodium bicarbonate solution and then with brine and dried over sodium sulfate. The
resulting crude was washed with hexane and purified by column chromatography (1020% ethyl acetate/ hexane or recrystallized with ethyl acetate/hexane.
N-(4-fluoro-benzyl)-2-hydroxy-3-methyl-benzamide (153). White solid; yield 76%;
mp 165-166 °C; 1H NMR (300 MHz, DMSO-d6): į 13.10 (s, 1H, OH), 9.43 (t, 1H, J =
6.0 Hz, NH), 7.72 (d, 1H, J = 7.2 Hz, ArH), 7.37 (d, 1H, J = 8.7 Hz, ArH), 7.35 (d, 1H,
J = 8.4 Hz, ArH), 7.31 (d, 1H, J = 7.2 Hz, ArH), 7.15 (t, 2H, J = 9.0 Hz, ArH), 6.78 (t,
1H, J = 7.5 Hz, ArH), 4.48 (d, 1H, J = 6.0 Hz, CH2), 2.15 (s, 3H, CH3); MS (ESI): m/z
257.9 [MíH]í; HPLC: tR 8.63 min, purity 99.11%.
5-bromo-N-(4-fluoro-benzyl)-2-hydroxy-benzamide (154). White solid; yield 62%; mp
83-84 °C; 1H NMR (300 MHz, DMSO-d6): į 12.47 (s,1H, OH), 9.37 (t, 1H, J = 5.7 Hz,
NH), 8.07 (d, 1H, J = 2.4 Hz, ArH), 7.55 (dd, 1H, J1 = 8.7 Hz, J2 = 2.4 Hz, ArH), 7.36
(dd, 2H, J1 = 8.1 Hz, J2 =5.7 Hz, ArH), 7.15 (t, 2H, J = 9.0, ArH), 6.89 (d, 1H, J = 8.7
Hz, ArH), 4.47 (d, 2H, J = 5.7 Hz, CH2); MS (ESI): m/z 323.8 [MíH]í; HPLC: tR 9.7
min, purity 98.66%.
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5-bromo-N-(4-fluorobenzyl)-2,3-dihydroxybenzamide (155). Yellow solid; yield
61 %; mp 215-217 °C; 1H NMR (300 MHz, DMSO-d6): į 9.42 (t, 1H, J = 5.4 Hz, NH),
7.56 (d, 1H, J = 2.4 Hz, ArH), 7.36 (dd, 2H, J1 = 8.1 Hz, J2 = 2.4 Hz, ArH), 7.16 (t, 2H,
J = 8.7 Hz, ArH), 7.05 (d, 1H, J = 2.4 Hz, ArH), 4.47 (d, 2H, J = 5.4 Hz, CH2); MS
(ESI): m/z 339.8 [MíH]í.
N-(4-fluorobenzyl)-4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxamide (156). White
solid; yield 53%; 1H NMR (500 MHz, DMSO-d6): į 8.83 (s, 1H, NH), 8.61 (d, 1H, J =
6.5 Hz, NH), 8.30 (d, 1H, J = 9.0 Hz, ArH), 8.08 (d, 1H, J = 9.0 Hz, ArH), 7.85 (d, 1H,
J = 8.5 Hz, ArH), 7.75-7.77 (m, 2H, ArH), 7.42 (dd, 3H, J1 = 9.0 Hz, J2 = 1.5 Hz), 7.06
(t, 3H, J = 9.0 Hz, ArH); MS (ESI): m/z 344.9 [MíH]í.
5-acetyl-N-(4-fluorobenzyl)-2-hydroxy-3-methoxybenzamide (142). 5-acetyl-2hydroxy-3-methoxybenzoic acid starting material (1.0 g, 4.76 mmol), HOBt (1.28 g, 9.51
mmol) and Et3N (0.66 mL, 4.76 mmol) was added in a THF (20 mL) at 0 °C. EDCI (1.0
g, 5.23 mmol) was added to the above solution followed by 4-fluorobenzylamine (0.54
mL, 4.76 mmol) after which the reaction mixture was kept at 0 °C for 1 h and stirred
overnight at rt. After the reaction, the reaction mixture was evaporated to a small volume
and extracted with ethyl acetate. The organic layer was washed with dilute hydrochloric
acid and sodium bicarbonate solution and then with brine and dried over sodium sulfate.
The resulting crude was washed with hexane and recrystallized with ethyl acetate/hexane
to give pure intermediate 142. White solid, mp 165-167 °C; yield 74%; 1H NMR (500
MHz, DMSO-d6): į 9.67(s, 1H, NH), 8.20 (d, 1H, J = 1.0 Hz, ArH), 7.55 (d, 1H, J = 1.0
Hz, ArH), 7.39 (dd, 2H, J1 = 8.5 Hz, J2 = 6.0 Hz, ArH), 7.17 (t, 2H, J = 8.5 Hz, ArH),
4.53 (d, 2H, J = 6.0 Hz, CH2), 3.85 (s, 3H, 3.85, OCH3), 2.55 (s, 3H, 2.55, COCH3); MS
(ESI): m/z 316.0 [MíH]í.
5-cinnamoyl-N-(4-fluorobenzyl)-2,3-dihydroxybenzamide (157). To a solution of
intermediate 142 (1.0 g, 3.15 mmol) in DCM (20 mL) was added BBr3 (6.30 mL of 1M
solution in DCM) at 0 °C. The reaction mixture was allowed to come to room
temperature and stirred for 16 h. After the reaction, the mixture was quenched with ice
cold water and extracted with DCM. The organic layer was evaporated and dried in
vacuo to give the demethoxy intermediate 143, which was used for the next step without
further purification (MS (ESI): m/z 301.9 [MíH]í). Intermediate 143 (0.80 gm, 2.64
mmol) and benzaldehyde (0.26 mL, 2.64 mmol), were dissolved in 10 mL of ethanol, and
5 mL of 25% aq NaOH was added. The reaction mixture was stirred at room temperature
for 24 h. The mixture was then poured into ice and acidified with 3 M HCl to pH 4. The
yellow precipitate formed was filtered and washed with water. The crude solid was
purified by preparative chromatography (DCM: ethyl acetate, 8:2) to afford pure
compound 157. Brown solid; overall yield 36%; mp 170-173 °C; 1H NMR (300 MHz,
DMSO-d6): į 13.56 (s, 1H, OH), 9.73 (s, 1H, NH), 9.66 (s, 1H, OH), 8.26 (s, 1H, ArH),
7.75-7.93 (m, 4H, ArH, HĮ, Hȕ), 7.67 (s, 1H, ArH), 7.37-7.54 (m, 5H, ArH), 7.18 (m,
2H, ArH), 4.57 (s, 2H, CH2); MS (ESI): m/z 390.0 [MíH]í.
3-acetyl-5-bromo-N-(4-fluorobenzyl)-2-hydroxybenzamide (144). Intermediate 78a
(1.0 g, 3.86 mmol), which was synthesized as an intermediate in the Chapter 3, HOBt
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(1.04 g, 7.72 mmol) and triethylamine (0.53 mL, 3.86 mmol) were added in DCM (20
mL) at 0 °C. EDCI (0.81 g, 4.24 mmol) was added to the above solution followed by 4fluorobenzylamine (0.44 mL, 3.86 mmol) after which the reaction mixture was kept at ice
for 1 h and stirred overnight at rt. After the reaction, the reaction mixture was evaporated
to a small volume and extracted with ethyl acetate. The organic layer was washed with
dilute hydrochloric acid and sodium bicarbonate solution and then with brine and dried
over sodium sulfate. The resulting crude was washed with hexane and purified by column
chromatography (10-20% ethyl acetate/hexane). White solid; mp 125-126 °C; yield
41%; mp 125-126 °C; 1H NMR (500 MHz, DMSO-d6): į 9.43 (t, 1H, J = 6.0 Hz, NH),
8.26 (s, 1H, ArH), 7.98 (s, 1H, ArH), 7.38-7.42 (m, 2H, ArH), 7.16 (t, 2H, J = 8.5 Hz,
ArH), 2.63 (s, 3H, COCH3); MS (ESI): m/z 365.9 [MíH]í.
(E)-5-bromo-N-(4-fluorobenzyl)-2-hydroxy-3-(3-(2,3,6-trichlorophenyl) acryloyl)
benzamide (158). Intermediate 144 (0.53 g, 1.44 mmol) and 2,3,6-trichlorobenzaldehyde
(0.33 g, 1.44 mmol) were dissolved in 10 mL of ethanol, and 5 mL of 25% aq NaOH was
added. The reaction mixture was stirred at rt for 24 h. The mixture was then poured into
ice and acidified with 3M HCl to pH 4. The yellow precipitate formed was filtered and
washed with water. The crude was purified using preparative TLC to give pure
compound 158. Yellow solid; yield 51%; mp 108-110 °C; 1H NMR (500 MHz, DMSOd6): į 9.43 (t, 1H, J = 5.0 Hz, NH), 8.16 (s, 1H, ArH), 7.81-7.97 (m, 2H, ArH, H-ȕ), 7.68
(d, 1H, J = 8.5 Hz, ArH), 7.59 (d, 1H, J = 8.5 Hz, ArH), 7.50 (d, 1H, J = 16.0 Hz, H-Į),
7.34 (dd, 2H, J1 = 8.0 Hz, J2 = 5.5 Hz), 7.13 (t, 2H, J = 8.5 Hz), 4.47 (d, 2H, J = 5.0 Hz,
CH2); MS (ESI): m/z 555.8 [MíH]í.
1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylic acid (146). A mixture of acetic
anhydride (4 mL) and 30% H2O2 (1 mL) was stirred in ice bath for 4 h to form a
homogenous peracetic acid solution. The peracetic acid formed was then added drop-wise
to a stirring solution of 6-hydroxypicolinic acid (0.25 gm, 1.79 mmol) in a mixture of
trifluoro acetic acid (3 mL) and glacial acetic acid (3 mL). The reaction mixture was
stirred at rt for 1h and then heated gradually to 80 °C and kept at 80 °C for 10 h. After the
reaction, the reaction mixture was evaporated and 10% KOH solution was added to the
residue and the solution stirred at 80 °C for another 6 h after which the product was
precipitated with conc. HCl. The crude was purified using column chromatography (1025% MeOH: DCM) to afford pure 146. White solid; yield 60%; 1H NMR (300 MHz,
DMSO-d6): į 7.45 (dd, 1H, J1 = 9.0 Hz, J2 = 7.2 Hz, ArH), 6.73 (dd, 1H, J1 = 9.0 Hz, J2 =
1.8 Hz, ArH), 6.65 (dd, 1H, J1 = 6.9 Hz, J2 = 1.5 Hz, ArH); MS (ESI): m/z 153.7
[MíH]í.
1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid (147). Benzyl chloride
(3.09 mmol, 0.357 mL) was added to a solution of intermediate 146 (0.40 gm, 2.58
mmol) and anhydrous K2CO3 (5.16 mmol) in methanol (20 mL). The reaction was then
refluxed for 16 h. After the reaction, the reaction mixture was filtered and evaporated to
dryness. The residue was dissolved in water and acidified with 6M HCl to a pH 2.0. The
white precipitate formed was filtered, washed with cold water and dried to give a pure
product. White solid; mp 178-180 °C; yield 41%; 1H NMR (300 MHz, DMSO-d6): į
7.40-7.52 (m, 6H, ArH), 6.74 (dd, 1H, J1 = 9.1 Hz, J2 = 1.8 Hz, ArH), 6.56 (dd, 1H, J1 =
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6.6 Hz, J2 = 1.5 Hz, ArH), 5.28 (s, 2H, CH2); MS (ESI): m/z 243.8 [MíH]í.
1-(benzyloxy)-N-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (148).
Excess oxalyl chloride was added to a suspension of intermediate 147 (0.475 gm, 1.93
mmol) in toluene (10 mL). DMF (1 drop) as catalyst was added after which the mixture
became clear. The resulting solution was stirred at 60 °C for 4 h and the solvent
evaporated to dryness. The resulting residue (acid chloride) was directly used for the next
reaction. The crude acid chloride (0.45 g, 1.71 mmol) was dissolved in dry THF and Et3N
(0.24 mL) was added. 4-fluoro benzyl amine (0.19 mL, 1.71 mmol) was then added to the
above solution and reaction mixture stirred overnight at 60 °C. After the reaction was
complete, the solvent was evaporated and extracted with DCM. The organic layer was
washed with 1M NaOH and 1M HCl and evaporated to get the crude product. The crude
was purified using column chromatography (10-20% ethyl acetate/hexane) to get pure
intermediate 148. White solid; mp 183-185 °C; overall yield 41%; 1H NMR (300 MHz,
DMSO-d6): į 9.41 (t, 1H, J = 5.5 Hz, NH), 7.50 (dd, 1H, J1 = 8.5 Hz, J2 = 6.5 Hz, ArH),
7.36-7.40 (m, 5H, ArH), 7.32 (dd, 2H, J1 = 8.0 Hz, J2 = 6.0 Hz, ArH), 7.04 (t, 2H, J = 8.5
Hz, ArH), 6.66 (d, 1H, J = 9.0 Hz, ArH), 6.35 (d, 1H, J = 6.5 Hz, ArH), 5.23 (s, 2H,
CH2), 4.41 (d, 2H, J = 5.5 Hz, CH2); MS (ESI): m/z 375.1 [M+23].
N-(4-fluorobenzyl)-1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxamide (159). The
intermediate 148 (0.27 gm, 0.766 mol) was deprotected using a 1:1 mixture of HCl and
glacial acetic acid and stirring at rt for 48 h. the reaction mixture was then evaporated,
dissolved in minimum amount of water, filtered and dried. The crude was crystallized
with ethyl acetate. White solid; yield 67%; mp 138-140 °C; 1H NMR (300 MHz, DMSOd6): į 9.31(t, 1H, J = 5.5 Hz, NH), 7.36-7.42 (m, 3H, ArH), 7.16 (t, 2H, J = 9.0 Hz, 6.58
(d, 1H, J = 9.5 Hz, ArH), 6.33 (d, 1H, J = 7.0 Hz), 4.41 (d, 2H, J = 5.5 Hz); MS (ESI):
m/z 285.0 [M+23].
Biological Assays
Materials, chemicals, and enzymes. All compounds were dissolved in DMSO
and the stock solutions were stored at -20 °C. Ȗ[32P]-ATP was purchased from either
Amersham Biosciences or ICN. The expression systems for wild-type IN were a
generous gift from Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH,
Bethesda, MD. Cell lines were obtained from American Type Culture Collection (ATCC,
Rockville, MD).
Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5ƍGTGTGGAAAATCTCTAGCAGT-3ƍ, and 21bot, 5ƍ-ACTGCTAGAGATTTTCCACAC3ƍ, were purchased from the Norris Cancer Center Microsequencing Core Facility
(University of Southern California) and purified by UV shadowing on polyacrylamide
gel. To analyze the extent of 3ƍ-P and ST using 5ƍ-end labeled substrates, 21top was 5ƍend labeled using T4 polynucleotide kinase (Epicentre, Madison, WI) and Ȗ[32P]-ATP
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(Amersham Biosciences or ICN). The kinase was heat-inactivated and 21-bot was added
in 1.5M excess. The mixture was heated at 95 °C, allowed to cool slowly to rt, and run
through a G25 mini spin column (USA Scientific) to separate double-stranded
oligonucleotide from unincorporated material.
Integrase assays. To determine the extent of 3ƍ-P and ST, wild-type IN was
preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50
mM NaCl, 1 mM HEPES, pH 7.5, 50 μM EDTA, 50 μM dithiothreitol, 10% glycerol
(w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM 2-mercaptoethanol,
10% dimethylsulfoxide, and 25 mM MOPS, pH 7.2) at 30 °C for 30 min. An aliquot
(5μL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris-borate,
pH 8.3, 2 mM EDTA, 20% acrylamide, and 8M urea). Gels were dried, exposed in a
PhosphorImager cassette, and analyzed using a Typhoon 8610 Variable Mode Imager
(Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I)
was calculated using (Equation 3-1). The IC50 values were determined by plotting the
logarithm of compound concentration versus percent inhibition to obtain the
concentration that produced 50% inhibition.
Anti-HIV-1 activity assay. The testing of the ability of potent compounds to
inhibit HIV replication in cell culture was done according to a previously reported
procedure.182 PBMC (107 cells/T25flask) were stimulated with phytohemagglutinin for 3
days and infected with a wild-type HIV-1 strain (strain LAI) at 100 50% tissue culture
infective doses, as described previously.182 The cultures were kept for 5 days in the
presence of test compounds at serial 1-log dilutions. Subsequently, human PBMC were
removed from the culture supernatant by centrifugation (400g, 10 min, 4 °C). This
clarified supernatant was tested by a reverse transcriptase assay.
Cytotoxicity assays. The cytotoxicity of compounds was evaluated using
uninfected PBMC and CEM leukemia cells according to a previous method.183 PBMC
were obtained from whole blood of healthy individuals, while CEM were obtained from
the ATCC (Rockville, MD). The PBMC and CEM cells were cultured in the presence or
absence of compound for 6 days. After this time period, cells were stained with Trypan
blue dye, and counted for cell proliferation and viability according to the previously
reported procedure.184
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CHAPTER 5. SYNTHESIS AND BIOLOGICAL STUDIES OF
PHENANTHRENE DIKETO ACIDS AS HIV-1 INTEGRASE INHIBITORS
Introduction
Raltegravir is currently the only IN inhibitor approved by the FDA.51
Unfortunately, clinical studies have reported viral mutants particularly T66I, G148H,
N155H, and double mutant G148H G140S, that are resistant to both raltegravir and
elvitegravir.138,139 Thus, it is highly imperative to design new chemical classes as second
generation HIV-1 IN inhibitors that not only have potent inhibitory activities, but also
have the potential to circumvent the eminent failure resulting from the emergence of viral
resistance to current IN inhibitors.
Previously, our laboratory has reported 5(H)-phenanthridin-6-one diketo acids
and related compounds as a novel class of HIV-1 IN inhibitors.152 In this chapter, I have
synthesized a series of substituted phenanthrene ȕ-diketo acids having potent in vitro IN
inhibitory activities. Selected compounds were also tested for their abilities to inhibit
HIV-1 replication in cell culture.
Chemistry
The synthesis of target phenanthrenes ȕ-diketo acids was accomplished by first
synthesizing the acetyl phenanthrene intermediates 168a-168h using Scheme 5-1. On the
basis of commercial availability, two different sets of starting materials were used to
perform the Suzuki coupling reaction. Thus, either the acetyl boronic acid derivatives
(160a-160d) were reacted with the aldehyde containing halogen partners (161a-161d) to
synthesize intermediates 164a-164d or alternatively, the formyl boronic acid derivatives
(162e-162h) were coupled with iodo acetyl starting materials (163e-163h) to synthesize
intermediates 164e-164h. For the coupling reaction, our first attempt with Pd (PPh3)4 in
toluene did not yield the desired product. The reaction was then successfully optimized
by using a polymer bound Pd (PPh3)4 with triethyl amine as a base in a dioxane-ethanol
solvent under inert atmosphere.193,194 Conditions varied from ice-cold (0 °C) to reflux and
the reaction was stirred from 6 h to 48 h depending upon the starting materials used. The
aldehyde intermediates were converted to the corresponding alkynes by Seyferth-Gilbert
homologation under which, a mixture of intermediates 164a-164h, dimethyl-(1-diazo-2oxopropyl) phosphonate, and K2CO3 was stirred in methanol at 0 °C for 17 h.195 The
alkyne intermediates 165a-165h were then subjected to a 6-endo dig cyclization with
PtCl2 by refluxing in toluene for 24 h under inert conditions to yield desired
phenanthrenes 168a-168h.196 An alternative efficient microwave synthesis reported by
Kim et al.197 was also used to synthesize the acetyl phenanthrene derivatives 168i and
168j (Scheme 5-2). This one-pot synthesis of 9ƍ-acetyl phenanthrenes was accomplished
by a step-wise Suzuki-Miyaura coupling reaction followed by an intramolecular Aldol
condensation. Therefore, 166a and 166b phenyl propanone starting materials were
coupled with (2-formyl-4-methoxyphenyl) boronic acid (167) using Pd (PPh3)4 with
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Scheme 5-1. Synthesis of intermediates 168a-168h

Reagent and conditions: (a) Polymer bound Pd (PPh3)4 (1mol%), Et3N, dioxane, EtOH
ice/reflux , 6 h-2 days; yields 34-78% (b) dimethyl-(1-diazo-2-oxopropyl) phosphonate,
K2CO3, MeOH, ice, 17 h; yields 35-64% (c) PtCl2, toluene, reflux, 24 h; yields 43-60%.

Scheme 5-2. Synthesis of intermediates 168i-168j

R2

HO

OH
B

O

CHO

+

R2

a
MeO

X

166a, 166b
166a. R2 = F ; X = Cl
166b. R2 = H ; X = Br

O
OMe

168i-168j

167

168i. R2 = F
168j. R2 = H

Reagent and conditions: (a) Microwave: 10 min, 150 °C, Pd (PPh3)4 (4 mol%), S-Phos
(6 mol%), Cs2CO3, toluene-EtOH (2:1); yields 48-51%.
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cesium carbonate as a base and S-Phos as catalyst. The reaction was performed in
toluene/ethanol (2:1) mixture and irradiated at 60-80 W power and 150 °C for 10 min.
All the acetyl phenanthrene intermediates 168i-168j were then subjected to oxalylation
reaction. Our initial attempt with diethyl oxalate did not yield the desired product.
Literature reports198 suggest terbutyl methyl oxalate as an oxalylating agent for halogensubstituted acetophenones. The use of terbutyl methyl oxalate (170), which was prepared
according to literature199 by the reaction of methyl chlorooxo acetate, t-butanol and
pyridine in anhydrous ether, successfully resulted in the formation (Scheme 5-3) of the
corresponding diketo esters 171i-171j. The ester derivatives were taken to the next step
directly without further purification and hydrolyzed with aq. NaOH to their
corresponding desired diketo acid final products 172-181.
Biological Results and Discussion
The synthesized target compounds (Table 5-1) were then tested for their ability to
inhibit strand transfer (ST) and 3ƍ-processing (3ƍ-P). The structure activity relationship
around these halogen-substituted phenanthrene derivatives suggests that the ȕ-diketo acid
functionality is well tolerated at R1 and R2 positions. For e.g., compare analogs 176, 177,
and 179 all of which have potent and similar ST IC50s of 1.4, 1.3, and 1.2 μM,
respectively. However, comparison of compounds 179 vs. 178 and 172 vs. 173 indicates
that the ȕ-diketo acid functionality is slightly more favorable at R2 position. In particular,
compound 159 was about four times more active than compound 178 against ST reaction.
Our laboratory has previously reported unsubstituted phenanthrene derivative 182 with
diketo acid at the R2 position had ST IC50 value of 2.7 μM.152 With respect to compound
182, while substitution of chlorine moiety at R6 position (compound 179) improved
activity, a fluoro substituent at this position (compound 172) resulted in a slight loss of
potency; also implying that the Cl substituent did better than the fluoro counterpart
(compare compounds 179 and 172) at this position. That fluorine may not be an optimal
substituent at R6 position is also evident when one considers that compound 181 (ST IC50
of 3 μM) was two-folds more active than compound 180 (ST IC50 of 6 μM). Chlorine
was also found to improve activity at R4 and R5 positions. Compounds 177 and 176 were
about four times more potent than their unsubstituted counterparts (2,4-dioxo-4(phenanthren-2-yl) butanoic acid, ST IC50 of 4.8 μM), synthesized previously.152
Chlorine substitution at R5 in compound 176 also improved selectivity (nine-folds) for
the ST step. Compound 177 showed potent activities against both 3ƍ-P and ST reactions
with IC50s of 5.0 μM and 1.3 μM, respectively. The reason for the dramatic loss of
potency for both ST and 3ƍ-P with compound 174 is not very apparent. It might be due to
ineffective metal chelation by the ȕ-diketo acid functionality considering, the electron
withdrawing effect of the adjacent fluorine substituent. The improvement of activity of
compound 175 (ST IC50 of 8.0 μM) implies a favorable effect of the fluorine substituent
at the R5 position. This may be one of the reasons why compound 176, having a more
hydrophobic Cl at the R5 position, has improved activity over compound 175; also
implying that hydrophobic interaction at this position may be an important contributor to
activity. Compound 181, with an electron donating methoxy group at the R1 position, and
the diketo acid moiety at R7 showed an IC50 of 3 μM against ST. This is a significant loss
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Scheme 5-3. Synthesis of compounds 172-181

Reagent and conditions: (a) t-butanol, pyridine, ether, rt, 2 h; (b) NaOMe, MeOH,
60 °C, 4 h; (c) aq. NaOH, MeOH-THF(1:1), 6 h; overall (steps b and c) yield 78-93%.
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Table 5-1.
acids

Cpd. R1
172
173
174
175
176
177
178
179
180
181
182d

H
DKA
H
H
DKA
DKA
DKA
H
OCH3
OCH3
H

Structure and HIV-1 IN inhibitory activities of phenanthrene ȕ-diketo

R2

R3

R4

R5

R6

R7

DKAc
H
DKA
DKA
H
H
H
DKA
H
H
DKA

H
H
F
F
H
H
H
H
H
H
H

H
H
H
H
H
Cl
H
H
H
H
H

H
H
H
F
Cl
H
H
H
H
H
H

F
F
H
H
H
H
Cl
Cl
F
H
H

H
H
H
H
H
H
H
H
DKA
DKA
H

a

Activity (IC50 μM)
3ƍ-Pa
STb
11 ± 2
3±2
35 ± 13 4 ± 1
83 ± 15 63 ± 16
63 ± 12 8 ± 2
12 ± 3
1.4
5±3
1.3 ± 0.1
19 ± 2
4±1
11 ± 4
1.2 ± 0.3
44 ± 10 6 ± 2
32 ± 12 3 ± 2
25 ± 7
2.7 ± 2

3ƍ-P = 3ƍ-procesing; b ST = Strand Transfer; c DKA = diketo acid; d compound
previously reported.152
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of activity when compared to its parent unsubstituted diketo acid analog, 2,4-dioxo-4(phenanthren-9-yl)butanoic acid (ST IC50 of 0.38 μM) that our laboratory has earlier
reported.152 This suggests that the R1 position is sensitive to modifications and could be
further exploited to determine the structure activity relationship around this novel class of
IN inhibitors.
Next, to determine their potential as anti-HIV agents, two potent analogs
(compounds 176 and 177) were tested for their ability to inhibit HIV-1 replication in
primary human peripheral blood mononuclear cells (PBMC). Both compounds showed
moderate inhibition of HIV replication with IC50s of 20.7 and 27.5 μM, respectively,
(Table 5-2). The reduced antiviral potency might be because of poor solubility, binding
to serum proteins and/or cellular distribution factors. The cytotoxicity assays showed that
the selected compounds, 176 and 177, have toxicities when tested against PBMC, human
CEM lymphoblastic leukemia cells and African green monkey Vero cells. However, a
phenanthrene analog (183) which our lab has previously reported possessed potent antiHIV activity (EC50 of 8.0 μM) and had selectivity index of 10 for inhibition of HIV
replication in cell culture. This indicates that this series could be further developed with
optimization efforts directed at reducing their cell-based toxicities and simultaneously
enhancing their anti-viral activities.
Experimental Section
Chemistry
All the reagents and solvents were purchased from the Aldrich Chemical
Company and used without further purification. Progress of reactions was monitored by
TLC on silica gel GHLF-250 micron plates (Analtech, Inc.). Fisher scientific Da visil
grade 1740 (170–400 mesh) silica gel was used for flash column chromatography. 1H
NMR spectra were recorded on Brucker AR, 300 or 500-MHz spectrometer: chemical
shifts are expressed in į values (ppm) and coupling constants (J) in Hertz (Hz). Mass
spectral data were determined on a Brucker-HP Esquire-LC spectrometer (ESI-MS). Infra
red (IR) spectra of alkyne derivatives were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer. HPLC analysis of final compounds was carried out using a reverse
phase SUPELCOSIL 5 μm C-18 column of dimensions 25 cm x 4.6 cm. Area % purity
was detected at 254 nm. A linear gradient elution with water (A) and methanol (B) at a
flow-rate of 1.5 mL/min was used. Gradient elution of the mobile phase was 80% A to
20% A from 0-3 min, 20% A and 80% B for 3-17 min and 20% A to 80% A from 17-20
min. Melting points of solids were determined using a Fisher-Johns melting point
apparatus and are reported uncorrected.
General procedure for the synthesis of intermediates 164a-164h. Acetyl
phenyl boronic acid derivatives (3.78 g, 20.77 mmol) were reacted with halogen
containing aldehyde partners (4 g, 16 mmol) or alternatively, aldehyde phenyl
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Table 5-2.

Anti-HIV activities of selected phenanthrene compounds

Comp. R1
176
177

DKA
DKA

R4

R5

EC50 (μM)

H
Cl

Cl
H

20.9 ± 15.8
27.5 ± 10.2

Cytotoxicity (IC50 μM)
PBMCa
CEMb VEROc
14.1
12.1
7.2
4.0
13.1
4.5

a

Human Peripheral blood mononuclear cells; b CEM lymphoblastic leukemia cells; c
African green monkey Vero cells.
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boronic acid starting materials (3.9 g, 21.13 mmol) were reacted with halogen substituted
acetophenones (4.0 g, 16.25 mmol) for the Suzuki coupling reaction. Thus, aryl halide
and polymer bound Pd (PPh3)4 (0.25 g, 1.35 mol%) were added to a dioxane-ethanol (30
mL, 4:1) mixture. This was followed by the addition of triethylamine (1.17 mL, 32
mmol) and the boronic acid derivative. The resultant solution was degassed several times
with argon and stirred in ice or refluxed for 6-48 h depending upon the starting materials
used. After the reaction, the mixture was filtered through celite and evaporated to
dryness. The crude material was purified by column chromatography (10-20% ethyl
acetate/ hexane) to obtain pure intermediates 164a-164h.
3'-acetyl-3-fluoro-[1,1'-biphenyl]-2-carbaldehyde (164a). Yellow solid; mp 73-75 °C;
yield 42%; 1H NMR (300 MHz, DMSO-d6): į 9.94 (s, 1H, CHO), 8.04 (d, 1H, J = 7.2
Hz, ArH), 7.95 (s, 1H, ArH), 7.77 (dd, 1H, J1 = 9.0 Hz, J2 = 3.0 Hz, ArH), 7.65 (d, 2H,
J = 7.2 Hz, ArH), 7.45 (t, 1H, J = 7.8 Hz, ArH), 7.35 (d, 1H, J = 7.8 Hz, ArH), 2.62 (s,
3H, COCH3); MS (ESI): m/z 265.0 [M+Na]+.
4'-acetyl-3-fluoro-[1,1'-biphenyl]-2-carbaldehyde (164b). Yellow solid; mp
106-108 °C; yield 63%; 1H NMR (300 MHz, DMSO-d6): į 9.94 (s, 1H, CHO), 8.05 (d,
2H, J = 8.4 Hz, ArH), 7.74-7.82 (m, 1H, ArH), 7.55 (d, 2H, J = 8.1 Hz, ArH), 7.46 (t, 1H,
J = 8.4 Hz, ArH), 7.35 (d, 1H, J = 7.5 Hz, ArH), 2.64 (s, 3H, COCH3); MS (ESI): m/z
265.0 [M+Na]+.
3'-acetyl-2'-fluoro-[1,1'-biphenyl]-2-carbaldehyde (164c). White solid; mp 74-76 °C;
yield 45%; 1H NMR (300 MHz, DMSO-d6): į 9.89 (d, 1H, J = 2.1 Hz, CHO), 8.0 (d, 1H,
J = 7.8 Hz, ArH), 7.87-7.93 (m, 1H, ArH), 7.79-7.84 (m, 1H, ArH), 7.66-7.72 (m, 2H,
ArH), 7.52 (d, 1H, J = 7.5 Hz, ArH), 7.42-7.48 (m, 1H, ArH), 2.58 (d, 3H, J = 4.2 Hz,
COCH3); MS (ESI): m/z 265.0 [M+Na]+.
3'-acetyl-2',5-difluoro-[1,1'-biphenyl]-2-carbaldehyde (164d). Light yellow solid; mp
48-50 °C; yield 34 %; 1H NMR (300 MHz, DMSO-d6): į 9.82 (d, 1H, J = 2.4 Hz, CHO),
8.09 (dd, 1H, J1 = 8.4 Hz, J2 = 6.0 Hz, ArH), 7.92 (dt, 1H, J1 = 7.5 Hz, J2 = 1.8 Hz, ArH),
7.73 (dt, 1H, J1 = 7.8 Hz, J2 = 1.8 Hz, ArH), 7.55 (dt, 1H, J1 = 8.7 Hz, J2 = 2.7 Hz, ArH),
7.43-7.50 (m, 2H, ArH), 2.60 (d, 3H, J = 4.2 Hz, COCH3); MS (ESI): m/z 283.0
[M+Na]+.
4'-acetyl-4-chloro-[1,1'-biphenyl]-2-carbaldehyde (164e). White solid; mp
138-140 °C; yield 71%; 1H NMR (300 MHz, DMSO-d6): į 9.83 (s, 1H, CHO), 8.08 (d,
2H, J = 8.1 Hz, ArH), 7.92 (d, 1H, J = 2.1 Hz, ArH), 7.85 (dd, 1H, J1 = 8.4 Hz, J2 = 2.4
Hz, ArH), 7.62 (d, 2H, J = 8.4 Hz, ArH), 7.60 (d, 1H, J = 8.4 Hz, ArH), 2.64 (s, 3H,
COCH3); m/z 281.0 [M+Na]+.
4'-acetyl-5-chloro-[1,1'-biphenyl]-2-carbaldehyde (164f). White solid; mp 100-102 °C;
yield 71%; 1H NMR (300 MHz, DMSO-d6): į 9.83 (s, 1H, CHO), 8.07 (d, 2H, J = 8.4
Hz, ArH), 7.97 (d, 1H, J = 8.4 Hz, ArH), 7.71 (d, 1H, J = 8.4 Hz, ArH), 7.66 (d, 2H, J =
7.5 Hz, ArH), 7.63 (s, 1H, ArH), 2.65 (s, 3H, COCH3); MS (ESI): m/z 281.0 [M+Na]+.
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4'-acetyl-3-chloro-[1,1'-biphenyl]-2-carbaldehyde (164g). Light yellow solid; mp 9597 °C; yield 78%; 1H NMR (300 MHz, DMSO-d6): į 10.13 (s, 1H, CHO), 8.02 (dd, 2H,
J1 = 8.11 Hz, J2 = 1.5 Hz, ArH), 7.66-7.73 (m, 2H, ArH), 7.50 (dd, 2H, J1 = 8.1 Hz, J2 =
1.2 Hz, ArH), 7.43-7.46 (m, 1H, ArH), 2.63 (d, 3H, J = 1.5 Hz, COCH3); MS (ESI): m/z
281.0 [M+Na]+.
3'-acetyl-3-chloro-[1,1'-biphenyl]-2-carbaldehyde (164h). White solid; mp 86-88 °C;
yield 58%; 1H NMR (300 MHz, DMSO-d6): į 10.15 (s, 1H, CHO), 7.99-8.02 (m, 1H,
ArH), 7.91 (s, 1H, ArH), 7.58-7.73 (m, 4H, ArH), 7.47 (dd, 1H, J1 = 6.6 Hz, J2 = 1.8 Hz,
ArH), 2.61 (s, 1H, COCH3); MS (ESI): m/z 281.0 [M+Na]+.
General procedure for the synthesis of intermediates 165a-165h. Dimethyl-(1diazo-2-oxopropyl) phosphonate (4.46 g, 23.21 mmol) was added drop wise to a mixture
of K2CO3 (4.0 g, 28.94 mmol) in methanol (30 mL) at 0 °C. The solution was stirred for
10 min during which the color turned yellow. Aldehyde intermediates 164a-164h (3.0 g,
11.62 mmol) were then added to the above solution and the reaction stirred in ice for 17
h. After completion of reaction, the reaction mixture was evaporated. Saturated NaHCO3
solution was added to the residue and extracted with ethyl acetate. The ethyl acetate layer
was evaporated to dryness and the crude was purified by column chromatography (5-15%
ethyl acetate/hexane) to afford pure intermediates 165a-165h.
1-(2'-ethynyl-3'-fluoro-[1,1'-biphenyl]-3-yl)ethanone (165a). Brown flakes; mp
56-58 °C; yield 59%; IR neat 3288 cm-1 (alkyne C-H), 2107 cm-1 (alkyne C-C); 1H NMR
(300 MHz, DMSO-d6): į 8.15 (s, 1H, ArH), 8.06 (d, 1H, J = 7.5 Hz, ArH), 7.83 (d, 1H,
J = 7.2 Hz, ArH), 7.52-7.65 (m, 2H, ArH), 7.36 (t, 2H, J = 7.8 Hz, ArH), 4.48 (s, 1H,
alkyne CH), 2.62 (s, 3H, COCH3); MS (ESI): m/z 261.0 [M+Na]+.
1-(2'-ethynyl-3'-fluoro-[1,1'-biphenyl]-4-yl)ethanone (165b). Off-white solid; mp 100102 °C; yield 63 %; IR neat 3282 cm-1 (alkyne C-H), 2116 cm-1 (alkyne C-C); 1H NMR
(300 MHz, DMSO-d6): į 8.05 (d, 2H, J = 8.1 Hz, ArH), 7.72 (d, 2H, J = 8.4 Hz, ArH),
7.56 (dd, 1H, J1 = 7.8 Hz, J2 = 7.5 Hz, ArH), 7.39 (t, 1H, J = 8.7 Hz, ArH), 7.34 (d, 1H,
J = 7.5 Hz, ArH), 4.5 (s, 1H, alkyne CH), 2.64 (s, 3H, COCH3); MS (ESI): m/z 261.0
[M+Na]+.
1-(2'-ethynyl-2-fluoro-[1,1'-biphenyl]-3-yl)ethanone (165c). Violet liquid; yield 57%;
H NMR (300 MHz, DMSO-d6): į 7.84 (t, 1H, J = 7.5 Hz, ArH), 7.64 (d, 2H, J = 6.9 Hz,
ArH), 7.37-7.56 (m, 4H, ArH), 4.11 (s, 1H, alkyne CH), 2.60 (d, 1H, J = 4.2 Hz,
COCH3); MS (ESI): m/z 261.0 [M+Na]+.
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1-(2'-ethynyl-2,5'-difluoro-[1,1'-biphenyl]-3-yl)ethanone (165d). Violet solid; mp 5153 °C; yield 35%; IR neat 3312 cm-1 (alkyne C-H); 1H NMR (300 MHz, DMSO-d6): į
7.83-7.90 (m, 1H, ArH), 7.66-7.73 (m, 2H, ArH), 7.32-7.44 (m, 3H, ArH), 4.10 (s, 1H,
alkyne CH), 2.64 (dd, 3H, J1 = 1.8 Hz, J2 = 1.5 Hz, COCH3); MS (ESI): m/z 279.0
[M+Na]+.
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1-(4'-chloro-2'-ethynyl-[1,1'-biphenyl]-4-yl)ethanone (165e). White solid; mp
138-140 °C; yield 61%; IR neat 3230 cm-1 (alkyne C-H ), 2097 cm-1 (alkyne C-C); 1H
NMR (300 MHz, DMSO-d6): į 8.04 (d, 2H, J = 7.8 Hz, ArH), 7.71 (s, 1H, ArH), 7.70 (d,
2H, J = 8.1 Hz, ArH), 7.61 (d, 1H, J = 8.1 Hz, ArH), 7.50 (d, 1H, J = 8.4 Hz, ArH), 4.25
(s, 1H, alkyne CH), 2.63 (s, 3H, COCH3); m/z 277.0 [M+Na]+.
1-(5'-chloro-2'-ethynyl-[1,1'-biphenyl]-4-yl)ethanone (165f). White solid; mp
102-104 °C; yield 64%; IR neat 3224 cm-1 (alkyne C-H ), 2106 cm-1 (alkyne C-C); 1H
NMR (300 MHz, DMSO-d6): į 8.02 (d, 2H, J = 8.1 Hz, ArH), 7.71 (d, 2H, J = 7.8 Hz,
ArH), 7.65 (d, 1H, J = 8.1 Hz, ArH), 7.54 (d, 1H, J = 1.5 Hz, ArH), 7.49-7.52 (m, 1H,
ArH), 4.26 (s, 1H, alkyne CH), 2.64 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+.
1-(3'-chloro-2'-ethynyl-[1,1'-biphenyl]-4-yl)ethanone (165g). Light yellow solid; mp
123-125 °C; yield 50%; IR neat 3266 cm-1 (alkyne C-H ), 2109 cm-1 (alkyne C-C); 1H
NMR (300 MHz, DMSO-d6): į 8.05 (dd, 2H, J1 = 8.1 Hz, J2 = 1.5 Hz, ArH), 7.70 (dd,
2H, J1 = 8.1 Hz, J2 = 1.5 Hz, ArH), 7.63 (d, 1H, J = 8.7 Hz, ArH), 7.52 (dt, 1H, J1 = 7.8
Hz, J2 = 1.8 Hz, ArH), 7.42 (d, 1H, J = 7.8 Hz, ArH), 4.96 (s, 1H, alkyne CH), 2.63 (d,
3H, J = 1.8 Hz, COCH3); MS (ESI): m/z 277.0 [M+Na]+.
1-(3'-chloro-2'-ethynyl-[1,1'-biphenyl]-3-yl)ethanone (165h). White solid; mp
97-99 °C; yield 46%; IR neat 3293 cm-1 (alkyne C-H ), 2104 cm-1 (alkyne C-C); 1H NMR
(300 MHz, DMSO-d6): į 8.13 (s, 1H, ArH), 8.00 (d, 1H, J = 7.2 Hz, ArH), 7.81 (d, 1H,
J = 7.2 Hz, ArH), 7.61-7.65 (m, 2H, ArH), 7.53 (t, 1H, J = 7.8 Hz, ArH), 7.45 (d, 1H, J =
7.8 Hz, ArH), 4.53 (s, 1H, alkyne CH); MS (ESI): m/z 277.0 [M+Na]+.
General procedure for the synthesis of intermediates 168a-168h. A solution of
alkyne intermediates 165a-165h (1.0 g, 4.19 mmol) and PtCl2 (0.55 g, 5 mol%) in
toluene (20 mL) was stirred at 80 °C in argon for 24 h. After the reaction, the solution
was filtered through celite and evaporated to dryness. The crudes were then purified by
column chromatography (5-15% ethyl acetate/hexane) to give pure intermediates 168a168h.
1-(8-fluorophenanthren-3-yl)ethanone (168a). White solid; mp 80-82 °C; yield 60%;
1
H NMR (300 MHz, DMSO-d6): į 9.36 (s, 1H, ArH), 8.83 (d, 1H, J = 7.8 Hz, ArH),
8.09-8.16 (m, 3H, ArH), 7.99 (d, 1H, J = 9.0 Hz, ArH), 7.77 (d, 1H, J = 7.8 Hz, ArH),
7.55 (d, 1H, J = 7.8 Hz, ArH), 2.81 (s, 3H, COCH3); MS (ESI): m/z 261.0 [M+Na]+.
1-(8-fluorophenanthren-2-yl)ethanone (168b). Light yellow solid; mp 128-130 °C;
yield 51%; 1H NMR (300 MHz, DMSO-d6): į 8.95 (d, 1H, J = 8.7 Hz, ArH), 8.75 (d, 1H,
J = 8.4 Hz, ArH), 8.73 (s, 1H, ArH), 8.21 (dd, 1H, J1 = 8.7 Hz, J2 = 1.5 Hz, ArH), 8.12
(d, 1H, J = 9.0 Hz, ArH), 8.07 (d, 1H, J = 9.0 Hz, ArH), 7.72-7.79 (m, 1H, ArH), 7.58 (t,
1H, J = 7.8 Hz, ArH), 2.75 (s, 3H, COCH3); MS (ESI): m/z 261.0 [M+Na]+.
1-(4-fluorophenanthren-3-yl)ethanone (168c). Off-white solid; mp 80-82 °C; yield
57%; 1H NMR (300 MHz, DMSO-d6): į 9.03 (d, 1H, J = 7.8 Hz, ArH), 8.11 (d, 1H, J =
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7.5 Hz, ArH), 8.07 (d, 1H, J = 9.0 Hz, ArH), 7.92-8.01 (m, 3H, ArH), 7.74-7.84 (m, 2H,
ArH), 2.78 (d, 3H, J = 4.5 Hz, COCH3); MS (ESI): m/z 261.0 [M+Na]+.
1-(4,6-difluorophenanthren-3-yl)ethanone (168d). White solid; mp 128-130 °C; yield
53%; 1H NMR (300 MHz, DMSO-d6): 8.60 (d, 1H, J = 12.6 Hz, ArH), 8.18 (t, 1H, J =
7.8 Hz, ArH), 8.06 (d, 1H, J = 8.7 Hz, ArH), 7.87-8.01 (m, 3H, ArH), 7.66 (t, 1H, J = 8.4
Hz, ArH), 2.76 (d, 3H, J = 4.5 Hz, COCH3); MS (ESI): m/z 279.0 [M+Na]+.
1-(7-chlorophenanthren-2-yl)ethanone (168e). Light yellow solid; mp 122-124 °C;
yield 43%;1H NMR (300 MHz, DMSO-d6): į 8.92 (dd, 2H, J1 = 8.7 Hz, J2 = 2.1 Hz,
ArH), 8.69 (s, 1H, ArH), 8.20 (d, 1H, J = 9.3 Hz, ArH), 8.18 (s, 1H, ArH), 8.08 (d, 1H,
J = 9.0 Hz, ArH), 7.93 (d, 1H, J = 9.0 Hz, ArH), 7.76 (dd, 1H, J1 = 8.7 Hz, J2 = 2.1 Hz,
ArH), 2.74 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+.
1-(6-chlorophenanthren-2-yl)ethanone (168f). Yellow solid; mp 103-105 °C; yield
53%;1H NMR (300 MHz, DMSO-d6): į 8.99 (d, 1H, J = 8.7 Hz, ArH), 8.96 (s, 1H, ArH),
8.68 (d, 1H, J = 1.5 Hz, ArH), 8.17 (dd, 1H, J1 = 8.7 Hz, J2 = 1.8 Hz, ArH), 8.08 (d, 1H,
J = 8.4 Hz, ArH), 8.04 (d, 1H, J = 9.0 Hz, ArH), 7.96 (d, 1H, J = 9.0 Hz, ArH), 7.75 (dd,
1H, J1 = 8.4 Hz, J2 = 1.8 Hz, ArH), 2.75 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+.
1-(8-chlorophenanthren-2-yl)ethanone (168g). White solid; mp 108-110 °C; yield
54%; 1H NMR (300 MHz, DMSO-d6): į 8.98 (d, 1H, J = 8.7 Hz, ArH), 8.75 (s, 1H,
ArH), 8.24 (d, 1H, J = 8.1 Hz, ArH), 8.04 (d, 1H, J = 6.9 Hz, ArH), 7.91 (d, 1H, J = 7.5
Hz, ArH), 7.70 (d, 1H, J = 6.9 Hz, ArH), 7.52 (t, 1H, J = 7.8 Hz, ArH), 7.41 (d, 1H, J =
7.5 Hz, ArH), 2.63 (s, 3H, COCH3); MS (ESI): m/z 277.0 [M+Na]+.
1-(8-chlorophenanthren-1-yl)ethanone and 1-(8-chlorophenanthren-3-yl)ethanone
isomer (168h). White solid; mp 110-112 °C yield 60%; 1H NMR (300 MHz, DMSO-d6):
į 9.13 (d, 1H, J = 8.4 Hz, ArH), 8.94 (d, 1H, J = 8.4 Hz, ArH), 8.58 (d, 1H, J = 9.6 Hz,
ArH), 8.16-8.23 (m, 3H, ArH), 8.13 (s, 1H, ArH), 7.99 (d, 1H, J = 7.8 Hz, ArH), 7.87 (d,
2H, J = 8.1 Hz, ArH), 7.82 (d, 1H, J = 7.8 Hz, ArH), 7.75 (t, 2H, J = 7.5 Hz, ArH), 7.627.70 (m, 1H, ArH), 7.40-7.60 (m, 2H, ArH), 2.78 (s, 3H, COCH3), 2.63 (s, 3H, COCH3);
MS (ESI): m/z 277.0 [M+Na]+.
General procedure for the synthesis of intermediates 168i and 168j. To a
thick-well borosilicate glass vial (10 mL) was added phenyl propanone starting materials
(0.20 g, 0.94 mmol), 4-methoxy-2-formyl boronic acid (0.20 g, 1.12 mmol), Pd (PPh3)4
(0.043 g, 4mol %), Cs2CO3 ( 0.91 g, 2.82 mmol) and S-Phos (0.022 g, 6 mol%)
sequentially in a toluene: ethanol (4 mL:2 mL) mixture. The reaction vial was then sealed
and placed in a microwave reactor and irradiated with 60-80 W power at 150 °C for 10
min. The reaction mixture was then cooled to room temperature and diluted with excess
ethyl acetate. The resulting solution was filtered through celite and concentrated in vacuo.
The crude solid was purified by column chromatography (10-15% ethyl acetate/hexane).
1-(8-fluoro-2-methoxyphenanthren-9-yl)ethanone (168i). Yellow solid; mp
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110-112 °C; yield 48%; 1H NMR (300 MHz, DMSO-d6): į 8.76 (dd, 1H, J1 = 9.0 Hz,
J2 = 2.4 Hz, ArH), 8.65 (dd, 1H, J1 = 8.4 Hz, J2 = 2.7 Hz, ArH), 7.88 (d, 1H, J = 2.7 Hz,
ArH), 7.68-7.74 (m, 1H, ArH), 7.56 (bs, 1H, ArH), 7.39-7.48 (2H, m, ArH), 3.94 (d, 3H,
J = 2.7 Hz, OCH3), 2.61(t, 3H, J = 2.4 Hz, COCH3); MS (ESI): m/z 291.0 [M+Na]+.
1-(2-methoxyphenanthren-9-yl)ethanone (168j). Yellow solid; mp 97-99 °C; yield
51%; 1H NMR (300 MHz, DMSO-d6): į 8.78 (d, 1H, J = 7.5 Hz, ArH), 8.76 (d, 1H, J =
8.4 Hz, ArH), 8.58 (d, 1H, J = 8.7 Hz, ArH), 8.50 (s, 1H, ArH), 7.64 (s, 1H, ArH), 7.597.72 (m, 2H, ArH), 7.43 (d, 1H, J = 8.7 Hz, ArH), 3.95 (s, 3H, OCH3), 2.80 (s, 3H,
COCH3); MS (ESI): m/z 273.0 [M+Na]+.
Synthesis of reagent tert-butyl methyl oxalate (170). Methyl oxalyl chloride (4.08
mmol, 0.376 mL) was added drop wise to a mixture of anhydrous pyridine (4.08 mmol,
194 μL), tert-butanol (2.04 mmol, 0.194 μL) and anhydrous ether (5 mL), and the
resulting solution stirred at room temperature for 2 h. After the reaction, water was added
to the mixture followed by a saturated solution of NaHCO3. The reaction mixture was
thereafter extracted with ethyl acetate and organic layer was concentration to obtain tertbutyl methyl oxalate (170) which was used without further purification. White liquid; MS
(ESI): m/z 183.0 [M+Na]+.
General procedure for the synthesis of final diketo acid compounds 172-181.
To a stirred solution of freshly prepared NaOMe (145 mg Na metal in 2 mL methanol) in
anhydrous THF(15 mL) at rt was added drop wise a mixture of tert-butyl methyl oxalate
(1 mL) and acetyl phenanthrene intermediates (168a-168j) (0.4 g, 1.57 mmol) in DME
(15 mL). The resulting red colored mixture was stirred at room temperature for 4 h. After
the reaction, the mixture was poured into cold water and acidified with dilute HCl. Solid
ester intermediates were precipitated in quantitative yields and were dried in vacuo and
taken to the next step without further purification. Aqueous NaOH (5.87 mL, 1M) was
added to the solution of ester intermediates 171i-171j (0.50 g, 1.47 mmol) in a MeOHTHF (1:1, 20 mL) mixture. The resulting solution was stirred at rt for 6 h. After the
reaction the mixture was poured into cold water and acidified with dilute HCl. The solid
precipitated was dried in vacuo. The crude was recrystallized with ethanol to give pure
final products 172-181.
4-(8-fluorophenanthren-3-yl)-2,4-dioxobutanoic acid (172). Yellow solid; yield 89%;
mp 138-140 °C; 1H NMR (500 MHz, DMSO-d6): į 9.43 (s, 1H, ArH), 8.91 (d, 1H, J =
8.0 Hz, ArH), 8.27 (d, 1H, J = 9.0 Hz, ArH), 8.10-8.30 (m, 3H, ArH, enolic CH), 8.05 (d,
1H, J = 9.0 Hz, ArH), 7.75-7.80 (m, 1H, ArH), 7.56 (t, 1H, J = 9.0 Hz, ArH); MS (ESI):
m/z 308.8 [MíH]í.
4-(8-fluorophenanthren-2-yl)-2,4-dioxobutanoic acid (173). Yellow solid; yield 92%;
mp 205-206 °C; 1H NMR (300 MHz, DMSO-d6): į 9.0 (d, 1H, J = 8.7 Hz, ArH), 8.89 (s,
1H, ArH), 8.76 (d, 1H, J = 8.4 Hz, ArH), 8.30 (d, 1H, J = 8.7 Hz, ArH), 8.18 (d, 1H, J =
8.7 Hz, ArH), 8.10 (d, 1H, J = 9.0 Hz, ArH), 7.57-7.78 (m, 2H, ArH), 7.35 (s, 1H, enolic
CH); MS (ESI): m/z 308.8 [MíH]í.
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4-(4-fluorophenanthren-3-yl)-2,4-dioxobutanoic acid (174). Dark yellow solid; yield
87%; mp 226-227 °C; 1H NMR (300 MHz, DMSO-d6): į 10.03 (d, 1H, J = 7.2 Hz, ArH),
8.12-8.20 (m, 3H, ArH), 7.99-8.07 (m, 2H, ArH), 7.74-7.80 (m, 2H, ArH), 7.10 (s, 1H,
enolic CH); m/z 288.7 [MíHF]í; HPLC: tR 4.11 min, purity 97.5%.
4-(4,6-difluorophenanthren-3-yl)-2,4-dioxobutanoic acid (175). Yellow solid; yield
81%; mp >250 °C dec; 1H NMR (300 MHz, DMSO-d6): į 9.63 (d, 1H, J = 13.8 Hz,
ArH), 8.09-8.17 (m, 3H, ArH), 7.97 (d, 1H, J = 7.8 Hz, ArH), 7.89 (d, 1H, J = 8.7 Hz,
ArH), 7.62 (t, 1H, J = 8.4 Hz, ArH), 7.05 (s, 1H, enolic CH); m/z 306.8 [MíHF]í; HPLC:
tR 4.11 min, purity 98.4%.
4-(7-chlorophenanthren-2-yl)-2,4-dioxobutanoic acid (176). Yellow solid; yield 93%;
mp 220-222 °C; 1H NMR (300 MHz, DMSO-d6): į 8.96 (d, 1H, J = 9.0 Hz, ArH), 8.92
(d, 1H, J = 9.0 Hz, ArH), 8.84 (d, 1H, J = 1.7 Hz, ArH), 8.27 (dd, 1H, J1 = 8.7 Hz, J2 =
1.8 Hz, ArH), 8.18 (d, 1H, J = 2.1 Hz, ArH), 8.15 (d, 1H, J = 9.0 Hz, ArH), 7.95 (d, 1H,
J = 9.0 Hz, ArH), 7.75 (dd, 1H, J1 = 9.0 Hz, J2 = 2.1 Hz, ArH), 7.32 (s, 1H, enolic CH);
m/z 325.0 [MíH]í.
3-(6-chlorophenanthren-2-yl)-3-oxopropanoic acid (177). Yellow solid; yield 78%; mp
213-215 °C; 1H NMR (300 MHz, DMSO-d6): į 9.02 (d, 1H, J = 9.0 Hz, ArH), 8.97 (s,
1H, ArH), 8.82 (s, 1H, ArH), 8.24 (d, 1H, J = 8.7 Hz, ArH), 8.08 (d, 2H, J = 8.4 Hz,
ArH), 7.97 (d, 1H, J = 9.0 Hz, ArH), 7.77 (d, 1H, J = 8.7 Hz, ArH), 7.28 (s, 1H, enolic
CH); m/z 325.0 [MíH]í.
4-(8-chlorophenanthren-2-yl)-2,4-dioxobutanoic acid (178). Yellow solid; yield 86%;
mp 204-206 °C; 1H NMR (300 MHz, DMSO-d6): į 9.0 (d, 1H, J = 8.1 Hz, ArH), 8.92 (d,
1H, J = 7.8 Hz, ArH), 8.87 (s,1H, ArH), 8.28 (d, 1H, J = 8.7 Hz, ArH), 8.23 (d, 2H, J =
1.2 Hz, ArH), 7.90 (d, 1H, J = 6.3 Hz, ArH), 7.74 (t, 1H, J = 7.5 Hz, ArH), 7.31 (s, 1H,
enolic CH); m/z 325.0 [MíH]í.
4-(8-chlorophenanthren-3-yl)-2,4-dioxobutanoic acid (179). Yellow solid; yield 83%;
mp >235 °C dec; 1H NMR (300 MHz, DMSO-d6): į 9.34 (s, 1H, ArH), 9.02 (d, 1H, J =
8.1 Hz, ArH), 8.00-8.26 (m, 5H, ArH, enolic CH), 7.85 (d, 1H, J = 7.5 Hz, ArH), 7.74 (t,
1H, J = 7.8 Hz, ArH); m/z 325.0 [MíH]í.
4-(8-fluoro-2-methoxyphenanthren-9-yl)-2,4-dioxobutanoic acid (180). Yellow solid;
yield 91%; mp 211-213 °C; 1H NMR (300 MHz, DMSO-d6): į 8.80 (d, 1H, J = 9.0 Hz,
ArH), 8.70 (d, 1H, J = 8.1 Hz, ArH), 8.02 (s, 1H, ArH), 7.75 (t, 1H, J = 8.1 Hz), 7.66 (d,
1H, J = 2.1 Hz, ArH), 7.43-7.51 (m, 2H, ArH), 6.58 (s, 1H, enolic CH), 3.95 (s, 3H,
OCH3); MS (ESI): m/z 338.9 [MíH]í.
4-(2-methoxyphenanthren-9-yl)-2,4-dioxobutanoic acid (181). Orange solid; yield
88%; mp 198-200 °C; 1H NMR (300 MHz, DMSO-d6): į 8.82 (d, 1H, J = 9.0 Hz, ArH),
8.79 (d, 1H, J = 9.3 Hz, ArH), 8.50 (d, 1H, J = 8.1 Hz, ArH), 8.41 (s, 1H, ArH), 7.74 (s,
1H, ArH), 7.72 (t, 1H, J = 8.1 Hz, ArH), 7.64 (t, 1H, J = 8.1 Hz, ArH), 7.45 (dd, 1H, J1 =
9.0 Hz, J2 = 2.7 Hz, ArH), 6.98 (s, 1H, enolic CH), 3.94 (s, 3H, ArH); MS (ESI): m/z
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320.9 [MíH]í.
Biological Assays
Materials, chemicals, and enzymes. All compounds were dissolved in DMSO
and the stock solutions were stored at -20 °C. Ȗ[32P]-ATP was purchased from either
Amersham Biosciences or ICN. The expression systems for wild-type IN were a
generous gift from Dr. Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH,
Bethesda, MD. Cell lines were obtained from American Type Culture Collection (ATCC,
Rockville, MD).
Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5ƍGTGTGGAAAATCTCTAGCAGT-3ƍ, and 21bot, 5ƍ-ACTGCTAGAGATTTTCCACAC3ƍ, were purchased from the Norris Cancer Center Microsequencing Core Facility
(University of Southern California) and purified by UV shadowing on polyacrylamide
gel. To analyze the extent of 3ƍ-P and ST using 5ƍ-end labeled substrates, 21top was 5ƍend labeled using T4 polynucleotide kinase (Epicentre, Madison, WI) and Ȗ[32P]-ATP
(Amersham Biosciences or ICN). The kinase was heat-inactivated and 21-bot was added
in 1.5M excess. The mixture was heated at 95 °C, allowed to cool slowly to rt, and run
through a G25 mini spin column (USA Scientific) to separate double-stranded
oligonucleotide from unincorporated material.
Integrase assays. To determine the extent of 3ƍ-P and ST, wild-type IN was
preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50
mM NaCl, 1 mM HEPES, pH 7.5, 50 μM EDTA, 50 μM dithiothreitol, 10% glycerol
(w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM 2-mercaptoethanol,
10% dimethylsulfoxide, and 25 mM MOPS, pH 7.2) at 30 °C for 30 min. An aliquot
(5μL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris-borate,
pH 8.3, 2 mM EDTA, 20% acrylamide, and 8M urea). Gels were dried, exposed in a
PhosphorImager cassette, and analyzed using a Typhoon 8610 Variable Mode Imager
(Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I)
was calculated using (Equation 3-1). The IC50 values were determined by plotting the
logarithm of compound concentration versus percent inhibition to obtain the
concentration that produced 50% inhibition.
Anti-HIV-1 activity assay. The testing of the ability of potent compounds to
inhibit HIV replication in cell culture was done according to a previously reported
procedure.182 PBMC (107 cells/T25flask) were stimulated with phytohemagglutinin for 3
days and infected with a wild-type HIV-1 strain (strain LAI) at 100 50% tissue culture
infective doses, as described previously.182 The cultures were kept for 5 days in the
presence of test compounds at serial 1-log dilutions. Subsequently, human PBMC were
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removed from the culture supernatant by centrifugation (400g, 10 min, 4 °C). This
clarified supernatant was tested by a reverse transcriptase assay.
Cytotoxicity assays. The cytotoxicity of compounds was evaluated using
uninfected PBMC and CEM leukemia cells according to a previous method.183 PBMC
were obtained from whole blood of healthy individuals, while CEM were obtained from
the ATCC (Rockville, MD). The PBMC and CEM cells were cultured in the presence or
absence of compound for 6 days. After this time period, cells were stained with Trypan
blue dye, and counted for cell proliferation and viability according to the previously
reported procedure.184
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CHAPTER 6.

COMPUTATIONAL STUDIES ON HIV-1 INTEGRASE
INHIBITORS*
Introduction

The absence of a complete DNA-bound HIV IN crystal structure has presented a
significant challenge for the structure-based design of potent IN inhibitors. Although Xray structures of individual human HIV domains and their combinations (core domain
and N terminal domain; core domain and C terminal domain; and core domain with an
inhibitor (5-CITEP)) have been reported,62-76 most of these structures have an unresolved
flexible loop. Moreover, there are differences in conformations of the active site residues
in the two structures that show a completely resolved flexible loop (chain B of 1BIS and
chain C of 1BL3).66,67 The absence of a 3D structure of IN and viral DNA along with the
two-divalent metals bound in the active site makes the structural information hitherto
available limited and may be far from reality.
In the first part of this chapter, three dimensional structure-activity relationship
(3D-QSAR) studies were conducted to gain insights into the binding of chalcone IN
inhibitors (described in Chapter 3) at the IN active site. CoMFA and CoMSIA 3D-QSAR
models were derived to study the influence of stereoelectronic, hydrophobic and
hydrogen bonding interactions on activity; and to establish predictive tools for design of
novel inhibitors. In the absence of the complete HIV-DNA crystal structure, ligand-based
pharmacophore alignments were used to develop the 3D-QSAR models. The resulting
models showed moderate statistical significance and limited predictive ability.
With an aim to develop improved QSAR models, in the next part of this chapter, a
homology model of full length IN-DNA-Raltegravir complex developed by our
collaborator at the Oak Ridge National Laboratory, was used to perform the dockingbased QSAR studies. The models developed demonstrated significant improvement in
terms of statistical significance and predictive ability over the previous ligand-based
models. Prospective compounds predicted by the models were synthesized and tested for
HIV-1 IN inhibitory activities.
The third part of this chapter describes docking studies and exploration of binding
modes of the substituted phenanthrene ȕ-diketo acids synthesized in Chapter 5. These
studies have provided insights into designing further modifications to improve their HIV1 IN inhibitory activities.
In last part of this chapter, I have attempted structure-based design to modify our
synthesized amide derivatives as well as performed in silico screening to discover new
* Portions of this chapter adapted with permission. Sharma, H.; Patil, S.; Sanchez, T. W.;
Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Synthesis, biological evaluation and 3DQSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1
integrase inhibitors. Bioorg. Med. Chem. 2011, 19, 2030-2045.179
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hits for inhibition of HIV-1 IN. The 3D-database searches have resulted in the discovery
of a hit, displaying ST inhibitory activity of 9 μM, that could be developed as a novel
class of HIV-1 IN inhibitor.
Ligand-Based Modeling Studies
Generation of a Pharmacophore Model Using the PHASE Program
Knowledge of the structure of target protein inhibitor interations is limited as no
crystal structure of human integrase-ligand-DNA complex is available. Therefore, to
explore the bioactive conformation of these novel IN inhibitors, the PHASE200 (v3.0)
pharmacophore mapping program implemented in Maestro modeling program package
(v8.5; Shrodinger Inc.) was used. The 3D structures of molecules were constructed in and
imported from the SYBYL modeling program (v8.3, Tripos). Conformers of each
molecule were generated using the OPLS_2005 force field in the macromodel
conformational analysis program of PHASE. A set of pharmacophoric sites based on
features defined in PHASE were assigned to the molecules. These included H-bond
acceptor (A), H-bond donor (D), hydrophobic group (H), negatively charged group (N)
and aromatic ring (R). The three most potent compounds of the chalcone series,
compound 86, 88 and 96 were selected as actives for use in identifying a common
pharmacophore hypothesis using a tree-based partitioning technique of PHASE. The
resulting pharmacophores were then scored and ranked. The top twenty pharmacophore
hypotheses were analyzed and validated by partial least square (PLS) regression-based
PHASE 3D-QSAR. Random external test sets were generated automatically to determine
the predictive ability of the models. The hypothesis that afforded the best PLS statistics
(Table 6-1) and the highest predicted ability consisted of six features viz., two H-bond
acceptors, two hydrophobic groups, a negative group and one aromatic ring (Figure 6-1).
Two H-bond acceptor features mapped onto the oxygen of the hydroxyl and the 3-keto
moiety and negative feature mapped onto the carboxylate group of the salicylic acid
pharmacophore. The two hydrophobic features mapped to the halogen substituent of ring
A and the para substituted halogen in aryl ring B. The aromatic pharmacophoric feature
mapped onto aromatic ring A. Residuals of the training and the test set are listed in
Tables 6-2 and 6-3, respectively. The prediction curve for the test set is shown in Figure
6-2. As can be seen, the hypothesis gave a good predictive model with a predictive r2 of
0.57 for an external test set of ten compounds. It was also able to distinguish active and
inactive compounds, with the latter group not aligning well to the features (Figure 6-3
and Figure 6-4).
Ligand-Based 3D-QSAR Analysis
CoMFA and CoMSIA 3D-QSAR models. Statistical analysis by PLS201,202 was
done using CoMFA and CoMSIA descriptors as independent variables and biological
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Table 6-1.
Cpd.
81
82
83
85
86
87
88
89
90
91
92
93
95
96
97
98
99
103
104
105
106
107
108
110
111
112
113
114
115
116
117
118
119
120
124
125
126
127
128
129
130
149
153

Residuals of training set by PHASE 3D-QSAR

Actual ST pIC50
4.60
4.85
4.49
4.92
5.30
4.45
5.15
4.72
4.46
4.29
4.74
4.79
4.88
5.40
4.27
4.00
4.03
4.39
4.76
4.62
4.52
4.54
4.82
4.23
4.12
4.12
5.04
4.74
4.79
4.74
4.26
4.33
4.26
4.96
4.49
4.74
4.23
4.40
4.30
4.16
4.68
4.82
4.00

Predicted ST pIC50
4.85
4.59
4.53
4.84
4.94
4.85
5.02
4.66
4.59
4.29
4.87
4.83
4.82
5.40
4.49
4.21
4.48
4.44
4.63
4.33
4.44
4.63
4.59
4.42
3.94
4.15
4.99
4.79
4.79
4.85
4.32
4.16
4.28
4.86
4.46
4.60
4.32
4.24
4.37
4.10
4.80
4.83
4.26
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Residuals
-0.25
0.26
-0.04
0.08
0.36
-0.40
0.13
0.06
-0.13
0.00
-0.13
-0.04
0.06
0.00
-0.22
-0.21
-0.45
-0.05
0.13
0.29
0.08
-0.09
0.23
-0.19
0.18
-0.03
0.05
-0.05
0.00
-0.11
-0.06
0.17
-0.02
0.10
0.03
0.14
-0.09
0.16
-0.07
0.06
-0.12
-0.01
-0.26

Figure 6-1. The best pharmacophore hypothesis (AAHHNR) mapped on
compound 88

Table 6-2.

PLS statistics of PHASE 3D-QSAR model

PLS statistics
q2
r2
SD
F
PLS factors
Pearson r

Results
0.57
0.74
0.17
28.30
4.00
0.75
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Table 6-3.
Cpd.
84
94
100
101
102
109
121
122
123
154

Residuals of test set by PHASE 3D-QSAR

Actual ST
pIC50
5.04
4.85
4.60
4.77
4.52
4.41
4.80
4.20
4.28
4.00

Figure 6-2.

Predicted
ST pIC50
4.86
4.78
4.71
4.63
4.25
4.28
4.91
4.51
4.46
4.35

Residuals
0.18
0.07
-0.11
0.14
0.27
0.13
-0.11
-0.31
-0.18
-0.35

PHASE 3D-QSAR predictions of the test set
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Figure 6-3.

Alignment of active compounds by PHASE

Figure 6-4.

Alignment of inactive compounds by PHASE
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activity in the form of pIC50 values as dependent variable. The molecular alignment used
for CoMFA and CoMSIA 3D-QSAR modeling was derived from PHASE pharmacophore
mapping (Schrödinger, Inc.). PHASE derived pharmacaphore hypotheses have been
successfully used to derive “bioactive conformations” for 3D-QSAR modeling in
previous work from our laboratory203 and elsewhere (Telvekar et al.).204 Thus, “bioactive
conformations” of all the molecules from PHASE conformational analysis were
superimposed using the MATCH alignment tool in SYBYL (Figure 6-5). Fifty three (53)
synthesized target compounds were used for the 3D-QSAR analyses. The Leave-One-Out
(LOO) method of cross validation was used for initial assessment of the predictive
abilities of the models with the training sets. The optimal number of components used in
the final QSAR models was that which gave the smallest standard error of prediction.
Reliability of the models was tested by prediction of 10 compounds selected as an
external test set using factor analysis. The PLS analysis results from both the CoMFA
and CoMSIA models are summarized in Table 6-4. Cross-validated q2 values of 0.43 and
0.54 were obtained for CoMFA and CoMSIA, respectively. Results of rigorous statistical
testing using group cross-validation (20 groups), bootstrapping and randomization of
activity data demonstrated the robustness of the QSAR models. Both CoMSIA and
CoMFA identified six outliers, which were excluded on the basis of their extreme
residual values (Table 6-5). Out of these, five outliers were common to both CoMFA and
CoMSIA. These were compounds 87, 98, 99, 126 and 128. The reasons for compound
126 being an outlier are not apparent. With compound 87 (iodo substituted) and
compound 128 (X = CH3), their outlier status may stem from structural uniqueness,
whereas the outlier status of compounds 98 and 99 (least active analogs, X = Cl) may
drive from different binding modes. The CoMFA and CoMSIA predictions for the
training and the test sets are shown in Figures 6-6 and 6-7, respectively. The CoMFA
and CoMSIA residual values for the training set are given in Table 6-5 and the
corresponding values for the test set in Table 6-6. In concordance with the higher q2
value, the CoMSIA model performed better than CoMFA model, and predicted all test set
compounds within 0.56 log unit of the actual pIC50 values.
CoMFA and CoMSIA contour maps. Steric CoMFA maps (Figure 6-8) show
green contours around the ortho and para positions on aryl ring B indicating that bulky
groups are favored at these positions. This is validated by the fact that a benzyl group
substitution at the ortho-position resulted in higher activity (compound 113). Compounds
115 and 120, which have a bulky chloro phenoxy and thiophene groups around the green
contour at the para-position also displayed better inhibitory activities. A large yellow
contour surrounds a small green contour at the meta position on aryl ring B suggesting
that only a limited bulk is favorable for activity. This is apparent by the loss of inhibitory
activity observed with compound 117, the bulky cyclopentyl ring of which occupies the
sterically disfavored yellow contour region. There is also a green contour evident at the
R1 position on the aromatic ring A. This may be the reason why among the three
halogens at that position, bromine, which is the bulkiest, afforded the highest activity. At
the aryl ring B, CoMFA electrostatic map reveals a red contour at the 3ƍ-position
suggesting that electronegative groups could increase activity at this position. This is
most exemplified by the 3ƍ-Cl substitution in compound 84 which had an IC50
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Figure 6-5.

Alignment of dataset for 3D-QSAR

Table 6-4.

PLS statistics of CoMFA and CoMSIA 3D-QSAR

PLS statistics
q2
r2
S
F
PLS components
Field contribution
Steric
Electrostatic
Hydrophobic
Donor
Acceptor
Bootstrapping r2 (20 runs)
Randomization r2 (20 runs)
Cross-validation q2 (20 runs)

CoMFA
0.43
0.94
0.09
78.32
6.0

CoMSIA
0.54
0.94
0.09
78.69
6.00

0.474
0.526

0.100
0.428
0.283
0.146
0.044
0.96 ± 0.01
0.96 ±
0.01
0.33
0.39
0.44
0.50
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Table 6-5.
Cpd.
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
104
105
106
107
109
110
111
114
115
117
118
119
120
122
123
126
127
128
129
153
154

Residuals of training set of CoMFA and CoMSIA models

Actual ST pIC50
4.60
4.85
4.49
5.04
4.92
5.30
4.45
5.15
4.72
4.46
4.29
4.74
4.79
4.85
4.88
5.40
4.27
4.00
4.03
4.60
4.77
4.52
4.76
4.62
4.52
4.54
4.41
4.23
4.12
4.74
4.79
4.26
4.33
4.26
4.96
4.20
4.28
4.23
4.35
4.30
4.16
4.00
4.00

CoMFA Res.
-0.13
0.12
-0.18
0.05
-0.15
0.16
-0.62
0.21
0.10
0.06
0.05
0.01
-0.03
-0.13
0.07
-0.05
-0.02
-0.62
-0.79
0.02
0.01
0.03
-0.009
-0.02
-0.03
0.06
-0.001
-0.05
-0.02
-0.07
-0.07
-0.03
0.07
0.002
0.10
0.01
-0.84
-0.41
-0.05
-1.03
-0.01
-0.047
0.07
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CoMSIA Res.
-0.12
0.12
-0.19
0.03
-0.08
0.11
-0.96
0.19
-0.07
-0.04
-0.003
0.04
-0.03
-0.03
0.11
-0.05
0.09
-0.89
-0.74
0.005
0.11
0.06
0.04
-0.13
-0.12
0.04
-0.04
-0.05
-0.02
-0.01
0.56
0.00
0.09
-0.03
0.04
-0.07
-0.09
-0.31
-0.01
-1.03
0.11
-0.05
0.04

Figure 6-6.
by CoMFA

Predictions of ST activities of the training and the test set compounds

Training and the test sets are represented by blue diamonds and red triangles,
respectively.
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Figure 6-7. Predictions of ST activities of the training and the test set compounds
by CoMSIA
Training and the test sets are represented by blue diamonds and red triangles,
respectively.
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Table 6-6.
models
Cpd.
103
108
112
113
116
121
124
125
130
149

Residuals of the test set predictions given by CoMSIA and CoMSIA

Actual ST pIC50
4.39
4.82
4.12
5.04
4.74
4.79
4.49
4.74
4.67
4.82

CoMFA Res.
-0.41
0.35
-1.00
0.25
0.14
0.09
-0.10
0.19
0.11
0.76

116

CoMSIA Res.
-0.28
0.30
-0.32
0.35
0.37
0.09
0.22
0.05
0.56
0.40

Figure 6-8.

CoMFA steric and electrostatic contour plots of ligand-based model

Green and yellow contours illustrate regions where steric bulk has favorable and
unfavorable effects on activity, respectively. Blue and red isopleths indicate regions
where an increase of positive and negative charge is required for activity.
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value of 9 μM. However, for compound 126, a decrease in activity was observed. Red
contours are also present at the 5ƍ- and the 6ƍ-positions. The dichloro-substituted
compounds 92 and 93 having Cl at the 5ƍ- and 6ƍ-positions showed improved activities.
There are also distant blue contours around aryl ring B, which predicts that
electropositive groups should increase activity at these positions. Electronegative oxygen
atom of the methoxy substituents in compounds 91, 111 and 112 points towards the blue
contours and thus may explain the loss of activity observed by the presence of methoxy
groups in these compounds. The red contours around the salicylic acid moiety in aryl ring
A suggest that a negative charge is important for activity in this region, possibly for
chelation with the active site Mg2+ ions. This is in agreement with the proposed
mechanism of action of these compounds as HIV-1 integrase inhibitors. There is a red
contour around the 4ƍ-position and both blue and red contours at the 5ƍ-position (R1). This
suggests that polarizability effect might be important at R1 and could explain the
increased activity conferred by bromine substitution over other halogens and the similarsized hydrophobic methyl group at this position.
The CoMSIA steric contour map shown in Figure 6-9 reveals a large green
contour around aryl ring B. Like in the CoMFA, the electrostatic contours of CoMSIA
also show red contours at the 3ƍ and the 4ƍ-positions on ring B, and at the 5ƍ-position (R1)
on ring A. There is a blue contour located at the position of the hydrogen atom of the
hydroxyl group of the salicylic acid moiety. The hydrophobic, H-bond donor and
acceptor contours are shown in Figure 6-10. There is a white contour located near the R1
substituent position which suggests hydrophophilic groups increase activity at this region.
This might be the reason why compound 128 which has a hydrophobic methyl group was
less active than the fluorine (compound 109) and chlorine substituted analogs (compound
102) at the R1 position. Furthermore, compound 128 resulted in 13 times reduction of
activity when compared to bromine at this position. The improved activity observed with
bromine at R1 position may result because of its polarization effect. White contours are
also evident at the 2ƍ and the 5ƍ-positions on ring B indicating that hydrophilic groups are
favored for activity. This was confirmed with the loss of potency of compounds 90 and
110 which have hydrophobic methoxy and methyl groups at these regions. There is
another white region observed over the 3-keto oxygen again signifying the presence of
hydrophilic groups at this position. There is a yellow contour close to the 4ƍ-positions on
ring B. A hydrophobic group at the 4ƍ-position is expected to increase activity, as
bromine substituent does in compound 86 and chlorine substituent in compound 85. The
3ƍ-keto functionality perfectly fit the magenta contour within their vicinity indicating that
they may act as H-bond acceptors. The cyan contour which appears to have merged into
the magenta contour might result from the hydrogen of the hydroxyl moiety. It indicates
its role as H-bond donor and may involve in H-bonding interactions with the acceptor
residues (acidic catalytic triad) of the receptor active site. The good congruence of
CoMFA and CoMSIA contour maps with the observed biological activity suggests these
models could aid the design of more active compounds.
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Figure 6-9.

CoMSIA steric and electrostatic contour plots of ligand-based model

Green contour illustrates region where steric bulk has favorable effect on activity. Blue
and red isopleths indicate regions where an increase of positive and negative charge is
required for activity.

Figure 6-10. CoMSIA hydrophobic, H-bond donor and H-bond acceptor contour
plots of ligand-based model
White contours indicate regions where hydrophilic groups increase activity, whereas
yellow contours indicate regions where hydrophobic groups increase activity, cyan
indicates region where H-donors increase activity and magenta contour indicate region
where H-bond acceptor groups increase activity.
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Homology Model-Guided Computational Studies on HIV-1 IN Inhibitors
Later, in order to improve the statistical significance and predictive power of our
developed 3D-QSAR models, a structure-based approach was followed. Furthermore, a
different strategy was used to obtain new composite 3D-QSAR models by incorporating
important physico-chemical parameters from potent IN inhibitory compounds to guide
our lead optimization efforts on a novel series of 3-keto salicylic acid IN inhibitors
synthesized in Chapter 4. The approved raltegravir,51 which belongs to the class of Nmethyl-4-hydroxypyrimidinone carboxamides,134,135 diketotriazole S-1360125 and
naphthyridine carboxamide L-870,812127 all have three metal-chelating groups in a
coplanar conformation mimicking the ȕ-diketo acid motif. Promising IN inhibitors were
thus designed as bioisosteres of the diketo acid functionality. However, the advent of
mono-keto quinolone HIV-1 IN inhibitors143,205 showed that the presence of even two
coplanar chelating moieties, represented by the ȕ-ketone and a carboxylic acid in
elvitegravir is sufficient for potent clinically relevant IN inhibition. Although it is
established that potent IN inhibitors have two common structural features viz., a
hydrophobic benzyl group and a chelating motif capable of binding two Mg2+ ions, a
detailed understanding of the structural features essential for HIV-IN inhibitory activity
still evades researchers. Therefore, it is important to develop quantitative structureactivity relationships (QSARs) that combine the most advanced first and secondgeneration inhibitors to arrive at a comprehensive and more unified model for IN
inhibition. Although QSAR studies on IN inhibitors have been reported,206-210 there is
none combining the two classes viz., the N-methyl-4-hydroxypyrimidinone-carboxamide
and 4-quinolone-3-carboxylic acid as represented by the approved raltegravir, the
clinically advanced elvitegravir and their analogs.
The absence of a 3D structure of IN and viral DNA along with the two-divalent
metals bound in the active site makes the structural information hitherto available limited
and may be far from reality. As shown in the Figure 6-11, the inhibitor binding site is
located at the interface between catalytic core domain (CCD) and C-terminal domain
(CTD), and involving contacts with the 3ƍ terminus of the viral DNA. Therefore, the
correct binding mode of drug molecules could not have been predicted based on previous
partial IN structures. It has been shown that the full-length IN-DNA-inhibitor complex
model would be required to gain a better understanding of how the inhibitors act against
IN.
Thus to achieve our objective, we first developed a new homology model of HIV1 IN in complex with DNA and inhibitors, based on the recently published crystal
structure of the foamy virus IN-DNA complex (PDB 3L2T and 3L2U)93 for use in
structure-based 3D-QSAR studies. Although homology models using the foamy virus
IN-DNA complex as template were reported by Tang211 and Krishnan et al.,95 they were
not without shortcomings. The model developed by Tang et al. consisted of only the
CCD-DNA complex and may not be a true representation considering the absence of
CTD and NTD, both of which have been implicated in viral DNA binding. Although, the
model reported by Krishnan et al. involved all the three domains and the viral DNA, no
direct contacts of raltegravir with mutant residues Gln148 and Asn155 that are involved
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Figure 6-11. PFV IN active site
Protein is shown in cartoon representation (green); inhibitor RLT is shown in licorice
representation; DNA is shown in ribbon representation (purple); two magnesium ions are
shown as mauve spheres; the residues within 6 Å of RLT are shown as orange lines. Only
one protein chain is shown for clarity.
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in viral resistance, are observed. Thus, first a homolog model of a full-length HIV-1 INDNA- inhibitor complex was constructed by our collaborator at the Oak Ridge National
Laboratory. The sequence alignment of HIV-1 and foamy IN, which are about 20%
identical, is shown in Figure 6-12. The homology model was then used for docking
simulations to explore binding interactions of inhibitors with the DNA-bound HIV IN. A
data set of 103 compounds including our synthesized IN inhibitors described in Chapters
3 and 4 together with raltegravir and elvitegravir and their analogs reported in the
literature134,135,143,205 were used for docking and 3D-QSAR studies. Because determining
the bioactive conformation is critical to developing a successful QSAR model,
alignments obtained from docking on the homology model were used for the study and
compared with the usual atom-by atom alignments. 3D-QSAR coefficient contour maps
were superimposed over the IN active site to visualize and advance our understanding of
the ligand-receptor interactions.
Homology Model: Analysis of Binding Sites
Interactions of the substituted benzyl group. Binding mode and interactions of
raltegravir are shown in Figure 6-13 and Figure 6-14; and those of elvitegravir in Figure
6-15 and Figure 6-16, respectively. The docking indicated that the para-fluoro benzyl
ring of raltegravir is nicely inserted into the cavity (Figure 6-13) that is formed by
displacement of the 3ƍ-adenosine the when viral DNA associates with integrase in a preintegration complex. This unpairing of the terminal 3ƍ-adenosine of the donor DNA
duplex is essential to unmask the scissile phosphodiester bond for 3ƍ-P and subsequent ST
reactions. Thus, the interactions of viral DNA with the IN and subsequent unpairing of its
3ƍ-adenosine result in a cavity being formed at the DNA-protein interface. The 3-chloro2-fluorobenzyl ring of elvitegravir also occupied the same cavity (Figure 6-15) formed
by the DNA-protein interface as the para-fluoro benzyl ring of raltegravir, but is oriented
slightly upwards at about 45° angle within the cavity relative to raltegravir. The phenyl
rings of both raltegravir and elvitegravir are involved in ʌ-ʌ interaction with the cytosine
base of the viral DNA (see Figure 6-14 and Figure 6-16). While, the phenyl ring of
raltegravir interacts with the adenine and guanine bases, it is the methoxy and metachlorine substituents in elvitegravir that make contacts with the adenine and guanine
bases of the viral DNA, respectively. Furthermore, the para-fluorine substituent in
raltegravir and the ortho-fluorine substituent in elvitegravir engaged in electrostatic
interactions with the 4-amino group of the cytosine of the donor DNA. The phenyl rings
of both compounds interact with Glu152. Gln148 appears within 4Å radius of raltegravir
and elvitegravir, in our homology models. Thus, our homology models suggest physical
contacts between raltegravir and elvitegravir with Gln148, which is in agreement with the
observation that mutation of this residue results in resistance to these drugs. We should
note that in the crystal structure of foamy virus IN–DNA in complex with raltegravir or
elvitegravir, there appeared to be no physical contact between both drugs and the
equivalent residue Ser217.93 The p-fluoro phenyl ring of raltegravir also makes extensive
vdW with the side chain methylenes, and electrostatic contacts with the amino group of
Gln146. In contrast, while the vdW contact with Gln146 is maintained, there is no
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Figure 6-12. Amino acid sequence alignment of PFV and HIV-1 IN
Residues are colored according to the clustal color scheme.
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Figure 6-13. Binding mode of raltegravir within the active site of IN-DNA
homology model
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Figure 6-14. Binding interactions of raltegravir
Mg2+ ions are represented by purple spheres. Active site residues is represented by tubes
and colored by element. Raltegravir is represented in tubes and highlighted with yellow
carbons. Other atoms in ligand are colored as follows: O, red; N, blue; F, bright green.
Hydrogens are omitted for clarity.
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Figure 6-15. Binding mode of elvitegravir within the active site of IN-DNA
homology model

Figure 6-16. Binding interactions of elvitegravir
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes
and colored by element. Elvitegravir is represented in tubes and highlighted with yellow
carbons. Other atoms in the ligand are colored as follows: O, red; N, blue; F, bright
green; Cl, dark green. Hydrogens are omitted for clarity.
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apparent electrostatic interaction with this residue in the case of elvitegravir, which on the
other hand appears to be directed more towards Gln152.
Interactions of metal-chelating motif. The three-metal chelating groups in
raltegravir are involved in coordination with the two metal atoms (Mg2+) in the IN
active site. The pyrimidinone oxo and the acidic hydroxyl oxygen coordinate in a bidentate manner with the Mg2+ between Asp116 and Asp64. Likewise, the keto oxygen of
the carboxamide moiety and the acidic hydroxyl oxygen are chelated with the second
Mg2+ between Asp64 and Glu152. This hydroxyl moiety may also engage in H-bonding
interaction with Gln148, Asp64 and Asp116. The binding pose of elvitegravir shows that
it’s two chelating pharmacophore namely, the 4-keto group and the carboxylate
coordinates the two Mg2+ ions in the integrase active site.
Interactions of side chain. The gem-dimethyl oxadiazole carboxamide moiety in
raltegravir is inserted into the cleft formed by Asp116, Asn117 and loop residues Pro142,
Tyr143, Asn144 and Pro145. One of the methyl groups of the gem-dimethyl moiety
interacts with Pro145. The oxadiazole ring is involved in ʌ-stacking interaction with the
phenyl ring of Tyr143. The methyl on the oxadiazole is engaged in vdW interactions with
the side chain methylene of Asn117. Site 3 binding region in elvitegravir has a
hydroxyalkyl chain which in our model is also directed towards this cleft. One of the two
methyl groups of the isopropyl substituents makes hydrophobic contacts with Tyr143,
while the other makes contact with Pro145. The binding interactions revealed by the
model are in accordance with those seen with the foamy virus crystal structure complex
with these inhibitors, and confirm the importance of this side chain in the binding of
raltegravir and elvitegravir. Tyr143 is a conserved residue among all the classes of
polynucleotidyl transferases212 and is proposed to be important for viral DNA binding.
Another key residue to target is Asn117 which is implicated in binding of the host
DNA213 and may thus be important for potent strand transfer (ST) inhibitory activity. Our
homology model has also revealed Arg263 and Lys264 as important residues close to the
active site that are involved in viral DNA binding.
Docking Studies
For prediction of bioactive conformation and binding modes of our synthesized
chalcone and amide compounds, we conducted docking simulations using the GLIDE
(v5.7) program from Schrödinger Inc. (Portland, Oregon, USA).214 Both standardprecision (SP) and extra-precision (XP) modes of GLIDE were evaluated using a flexible
ligand and rigid receptor routine. Twenty docking poses were obtained for each molecule,
the docking being terminated if two consecutive solutions were within a rmsd of 5 Å.
Overlay of the X-ray derived conformation of raltegravir (Figure 6-17) over the docked
(SP) conformation resulted in a lower rmsd of 0.60 between all heavy atoms as compared
with an rmsd of 0.64 obtained with GLIDE XP. The SP option was therefore selected for
subsequent docking studies, moreover, in addition to slightly better in reproducing the
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Figure 6-17. Overlay of the crystal structure, homology model, and docked
conformations of raltegravir
Crystal structure derived conformation of raltegravir is colored green and represented by
ball and stick; the homology model derived conformation is colored in element and
represented by tubes; and the GLIDE docking (SP) derived pose is colored by orange
carbons and shown in tubes. The homology model is shown in ribbons and Mg2+ is
shown by purple sphere. Hydrogens are omitted for clarity.
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crystal structure conformation it is computationally less expensive. To test the ranking
accuracy of GLIDE (SP), the docked poses of raltegravir and elvitegravir were analyzed,
and it was found that the poses of elvitegravir have better G-scores and E-model energies
and were ranked higher than those of raltegravir. This reflected the enzyme inhibitory
activities of the two compounds, with elvitegravir being more potent than raltegravir. The
best pose of the two most active compounds (86 and 96) selected on the basis of glide
score are shown in Figure 6-18. The topmost pose of compound 86 showed that its parabromobenzyl group is inserted into the cavity formed by the DNA-protein interface
(Figure 6-18). The phenyl ring interacts with the cytosine and adenine bases of the viral
DNA and also makes favorable vdW contacts with Gln146 and Pro145 (Figure 6-19).
Furthermore, the para-bromo substituent interacted with amino group of Gln146. The 3keto and the carboxylate group chelated the two divalent (Mg2+) ions in accordance with
the proposed mechanism of action of ST inhibitors. The hydroxyl group also weakly
coordinated with Mg2+ and makes H-bonding contact with the carboxylate of Asp116.
The docking pose of compound 96 revealed that the 2,3,6-trichloro-substituted phenyl
ring does not dock into the cavity formed by the DNA-protein interface, but was placed
rather on the opposite (180°) side exposed to solvent. In this orientation, the
trichlorophenyl group interacted with Pro142, the methylene of Ser119 and the methine
of Gly118 (Figure 6-20). The salicylic acid motif coordinates with the two Mg2+ ions,
and the hydroxyl group H-bonds to the carboxylate of Asp116. The bromine substituent
on the salicylic acid appears to weakly interact with Tyr143 and Pro145. The docking
poses thus suggest the presence of multiple binding modes for the chalcones. Their
smaller size gives them the flexibility to adopt different poses within the IN active site as
opposed to the relatively bulky elvitegravir and raltegravir which preferentially docked in
their respective ‘bioactive conformations’.
The amide derivative (compound 149) docked into the IN active site as shown in
Figure 6-21 and Figure 6-22. Similar to the p-fluorobenzyl group in raltegravir, the pfluorobenzyl group of compound 149 also fitted well into the cavity formed at the INDNA interface, and make contacts with Pro145 and Glu152. The phenyl ring ʌ-stacks
with the pyrimidinone ring of cytosine, as well as interact with the adenine base of the
viral DNA. The F atom makes vdW contacts with side chain methylenes of Gln146 and
may be involved in H-bonding with the amino group of the cytosine. The 3-keto salicylic
acid motif coordinates with the two metals in the IN active site. Furthermore, the 2hydroxyl group forms H-bond with Glu152. Notably, no interactions with Tyr143 and
Asn117 were observed. These compounds could be optimized to interact extensively with
these residues to improve their inhibitory activities. The models developed could thus
serve as a surrogate platform for structure-based design of potent IN inhibitors.
With a further objective of using the docked conformations to build a dockingbased QSAR model all 103 IN inhibitors of the dataset were docked on the IN active site
and 20 poses for each compound were generated. These include 3-keto salicylic acid
chalcones (Table 3-1) and amide derivatives (Table 4-1), synthesized in previous
chapters. The data set also included reported N-methyl-4-hydroxypyrimidinone
carboxamides (Tables 6-7 to 6-12 ) and 4-quinolone-3-carboxylic acid and analogs
(Tables 6-13 and 6-14). Top-most (based on the glide score) pose of 85 compounds
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Figure 6-18. Comparison of the docked poses of compounds 86 and 96
Compound 86 is colored by yellow carbons and compound 96 colored by orange carbons.
Mg2+ ions are shown by purple spheres.

Figure 6-19. Binding interactions of compound 86 in the IN active site
Compound 86 is colored by yellow carbons. Other atoms in the ligand are colored as
follows: O, red; Br, dark red. Amino acid residues are colored in element; Mg2+ ions are
shown by purple spheres.
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Figure 6-20. Binding interactions of chalcone derivative 96 in the IN active site
Compound 96 is colored by orange carbons. Other atoms in ligand are colored as follows:
O, red; Br, dark red; Cl, dark green. Amino acid residues are colored in element; and
Mg2+ ions are shown by purple spheres.
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Figure 6-21. Binding mode of amide derivative 149 in the IN active site

Figure 6-22. Binding interactions of compound 149 within IN-DNA homology
model
Compound 149 is colored by yellow carbons. Other atoms in the ligand are colored as
follows: O, red; Br, dark red; F, bright green. Mg2+ ions are represented by purple
spheres. IN-DNA complex is colored by element and represented in tubes. Hydrogens are
omitted for clarity.
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Table 6-7.
Structure and HIV-1 IN inhibitory activities of N-methyl-4hydroxypyrimidinone-carboxamides (scaffold 1) used in 3D-QSAR study

R2
H

STa IC50 (ȝM)
0.010

H

0.015

H
CH3

0.004
0.015

187

H

0.020

188

H

0.026

Cpd.
183

R1

184
185
186

a

OH

ST represents strand transfer.

(Table adapted with permission from: Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi,
B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.;
Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.;
Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M.
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor
for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.)134
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Table 6-8.
Structure and HIV-1 IN inhibitory activities of N-methyl-4hydroxypyrimidinone-carboxamides (scaffold 2) used in 3D-QSAR study

Cpd.
189

R
Me

STa IC50 (ȝM)
>5.0
0.021

190

a

191

0.004

192

0.009

ST represents strand transfer.

(Table adapted with permission from: Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi,
B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.;
Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.;
Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M.
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor
for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.)134
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Table 6-9.
Structure and HIV-1 IN inhibitory activities of N-methyl-4hydroxypyrimidinone-carboxamides (scaffold 3) used in 3D-QSAR study

a

Cpd. R
193b

STa IC50 (ȝM)
0.015

194

0.012

195

0.015

ST represents strand transfer; b structure of raltegravir.

(Table adapted with permission from: Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi,
B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.;
Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.;
Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M.
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor
for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.)134
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Table 6-10. Structure and HIV-1 IN inhibitory activities of N-methyl-4hydroxypyrimidinone-carboxamides (scaffold 4) used in 3D-QSAR study

Cpd.
196
197
a

n
1
2

STa IC50 (ȝM)
0.12
0.22

ST represents strand transfer.

(Table adapted with permission from: Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.;
Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; Ferreira Mdel, R.; Scarpelli,
R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Paz, O. G.;
Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda,
D.; Rowley, M.; Summa, V. Discovery and synthesis of HIV integrase inhibitors:
development of potent and orally bioavailable N-methyl pyrimidones. J. Med. Chem.
2007, 50, 4953-4975.)135
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Table 6-11. Structure and HIV-1 IN inhibitory activities of N-methyl-4hydroxypyrimidinone-carboxamides (scaffold 5) used in 3D-QSAR study

Cpd.
198

a

R

STa IC50 (ȝM)
0.062

199

0.69

200

0.14

201

0.10

202

0.20

203

0.25

204

0.13

205

4.00

ST represents strand transfer.

(Table adapted with permission from: Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.;
Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; Ferreira Mdel, R.; Scarpelli,
R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Paz, O. G.;
Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda,
D.; Rowley, M.; Summa, V. Discovery and synthesis of HIV integrase inhibitors:
development of potent and orally bioavailable N-methyl pyrimidones. J. Med. Chem.
2007, 50, 4953-4975.)135
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Table 6-12. Structure and HIV-1 IN inhibitory activities of N-methyl-4hydroxypyrimidinone-carboxamides (scaffold 6) used in 3D-QSAR study

Cpd.
206
207
208
209
210
a

R1
H
2-F
3-Cl
3-Br
3-OMe

R2
H
H
H
H
H

R3
Me
H
H
H
H

n
1
1
1
1
1

STa IC50 (ȝM)
>5
0.175
0.062
0.019
0.140

ST represents strand transfer.

(Table adapted with permission from: Gardelli, C.; Nizi, E.; Muraglia, E.; Crescenzi, B.;
Ferrara, M.; Orvieto, F.; Pace, P.; Pescatore, G.; Poma, M.; Ferreira Mdel, R.; Scarpelli,
R.; Homnick, C. F.; Ikemoto, N.; Alfieri, A.; Verdirame, M.; Bonelli, F.; Paz, O. G.;
Taliani, M.; Monteagudo, E.; Pesci, S.; Laufer, R.; Felock, P.; Stillmock, K. A.; Hazuda,
D.; Rowley, M.; Summa, V. Discovery and synthesis of HIV integrase inhibitors:
development of potent and orally bioavailable N-methyl pyrimidones. J. Med. Chem.
2007, 50, 4953-4975.)135
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Table 6-13. Structure and HIV-1 IN inhibitory activities of 4-quinolone-3carboxylic acid-carboxamides (scaffold 1) used in 3D-QSAR study

a

Cpd. R1
211

R2
H

R3
H

STa IC50 (ȝM)
1.6 ± 0.300

212

H

H

0.043 ± 0.008

213

H

0.024 ± 0.011

214

OCH3

0.009 ± 0.002

215

H

0.008 ± 0.001

216b

OCH3

0.007 ± 0.002

ST represents strand transfer; b structure of elvitegravir.

(Table adapted with permission from: Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.;
Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.;
Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors
derived from quinolone antibiotics. J. Med. Chem. 2006, 49, 1506-1508.)143
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Table 6-14. Structure and HIV-1 IN inhibitory activities of 4-quinolone-3carboxylic acid-carboxamides (scaffold 2) used in 3D-QSAR study

Cpd.
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
a

X
O
S
CH2
CH2
CH2
CH2
CH2
CO
CO
CO
CHCH
CONH
NHCO
NH
NH

R1
F
H
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
H
H
H
H
H

R2
Cl
H
H
H
H
H
H
H
H
H
H
H
H
Cl
Cl

R3
H
H
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
H
H
H
F
F

R4
(CH2)2OH
(CH2)2OH
(CH2)2OH
(CH2)3OH
(CH2)4OH
(CH2)2N(CH3)2
(CH2)2OCH3
(CH2)2OH
(CH2)3OH
(CH2)4OH
(CH2)2OH
(CH2)2OH
(CH2)2OH
(CH2)2OH
CH2CH3

STa IC50 (ȝM)
>100
18.5 ± 3.7
0.2 ± 0.0
1.3 ± 0.1
0.6 ± 0.3
24.1 ± 5.9
16.5 ± 0.7
>100
>100
>100
>100
>100
>100
>100
>100

ST represents strand transfer.

(Table adapted with permission from: Pasquini, S.; Mugnaini, C.; Tintori, C.; Botta, M.;
Trejos, A.; Arvela, R. K.; Larhed, M.; Witvrouw, M.; Michiels, M.; Christ, F.; Debyser,
Z.; Corelli, F. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and
structure-activity relationship of a class of human immunodeficiency virus type 1
integrase inhibitors. J. Med. Chem. 2008, 51, 5125-5129.)205
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found to have identical binding modes. The other poses for the remaining compounds
were then studied and 13 more compounds were identified to share similar binding
modes. Markedly different poses were obtained for compounds 191, 214, 217, 220, and
223. These compounds may have different binding mode or require an induced fit.
Although it is well established that the GLIDE docking is successful in giving the best
ligand poses, it fails to rank-order compounds on the basis of their binding affinities. We
observed that Glide score showed no correlation (r2 = 0.05) with the ST inhibitory
activities for the 98 similar binding compounds. Thus to further validate their “bioactive
conformations” a post-docking MM-GBSA rescoring was performed.
MM-GBSA Results
The docked poses of the pruned dataset were subjected to Molecular
Mechanics/Generalized Born Surface Area (MM-GBSA)215 free energy calculations with
PRIME (v) of the Schrödinger package. The calculated ǻGbind along with vdW
contributions to binding free energy are listed in Table 6-15. Analysis of the MM-GBSA
calculations revealed an improved correlation, with r2 = 0.34, between the binding free
energies (ǻGbind) and the ST inhibitory activities (Figure 6-23). A low, albeit better,
correlation might be a result of a large and diverse set of chemical structures included in
the analysis and a poor estimation of electrostatic binding energies. However, the vdW
contribution to the MM-GBSA binding free energy correlated best with the activities with
an r2 value of 0.57 (Figure 6-24), which went up to 0.62 with the removal of one outlier
(compound 113). A better correlation with the vdW energy term is significant since
hydrophobic interactions are one of the most important contributors to IN inhibitory
activity, and all potent IN inhibitors have a common hydrophobic halogenated benzyl
ring system as a pharmacophoric feature. Another important contribution to the IN
inhibitory activity comes from the electrostatic interactions, notably the coordination of
the metal-chelating heteroatoms in an IN inhibitor with Mg2+ in the IN active site. The
electrostatic contributions to the binding free energy are however not well predicted (data
not shown). Previous studies216, 217 have shown that electrostatic energies are difficult to
estimate particularly when the dataset have both charged and neutral molecules as is the
case with the present study. Moreover, the negatively charged residues, Asp64, Asp116,
Glu152 and the two Mg2+ ions are involved in important interactions with inhibitors in
the IN active site. This system warrants further studies to determine the effects of protein
charge states, electrostatic interactions cut-offs, parameterization of Mg2+ and the effect
of solute dielectric constant in the calculation of polar solvation energies. Although prime
MM-GBSA did not predict accurate binding affinities, it was successful in discriminating
the data set into active and inactive compounds and validated the docking derived
‘bioactive conformations’ for 3D-QSAR studies.
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Table 6-15.

Results of free energy calculations by Prime MM-GBSA

Cpd. STa pIC50
4.60
81
4.85
82
4.49
83
5.04
84
4.92
85
5.30
86
4.45
87
5.13
88
4.72
89
4.46
90
4.29
91
4.74
92
4.79
93
4.85
94
4.88
95
5.43
96
4.27
97
4.00
98
4.03
99
4.60
100
4.76
101
4.52
102
4.38
103
4.76
104
4.61
105
4.52
106
4.53
107
4.82
108
4.40
109
4.23
110
4.11
111
4.11
112
5.04
113
4.74
114
4.79
115
4.74
116
4.25
117
4.33
118
4.25
119
4.95
120
4.79
121
4.20
122
4.28
123

ǻEvdWb
-37.70
-35.39
-39.00
-25.46
-26.84
-28.39
-28.98
-28.63
-39.03
-28.17
-31.13
-35.34
-34.29
-26.66
-28.61
-30.41
-25.25
-28.93
-38.10
-34.37
-27.73
-29.64
-25.87
-23.73
-25.95
-30.02
-27.90
-25.39
-27.36
-29.06
-32.14
-28.81
-55.14
-42.70
-43.87
-25.41
-32.82
-28.20
-35.18
-27.33
-32.29
-28.55
-26.55

ǻGbindc
-6.33
-19.30
-11.52
-11.41
-1.60
-4.79
3.77
-24.25
-20.05
-10.75
-14.47
-15.91
-19.40
-16.78
-23.72
-25.26
-12.55
0.27
-20.39
-15.78
-23.46
-24.89
-16.25
-8.31
-17.72
-19.88
-16.80
-14.12
-20.57
-0.58
0.30
-17.90
-8.66
-8.18
-15.13
-10.32
-12.33
-2.46
7.00
-12.42
-20.32
-19.60
-9.40

Cpd. STa pIC50
4.67
130
4.82
149
4.00
153
4.00
154
4.88
155
8.00
183
7.82
184
8.39
185
7.82
186
7.69
187
7.58
188
5.30
189
7.67
190
8.04
192
7.82
193
7.92
194
7.82
195
6.92
196
6.65
197
7.00
198
6.16
199
6.85
200
7.00
201
6.69
202
6.60
203
6.88
204
5.39
205
5.30
206
6.75
207
7.20
208
7.72
209
6.85
210
5.79
211
7.36
212
7.61
213
8.08
215
8.14
216
4.74
218
6.69
219
6.22
221
4.61
222
4.00
224
4.00
225
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ǻEvdWb
-29.98
-36.94
-34.56
-33.07
-34.30
-49.16
-47.31
-46.12
-49.23
-53.89
-49.50
-39.23
-45.10
-50.90
-53.16
-48.03
-54.68
-38.24
-36.54
-41.86
-42.60
-41.47
-42.29
-42.38
-43.74
-45.00
-44.73
-41.10
-42.57
-43.18
-38.83
-43.05
-36.08
-37.86
-41.43
-46.00
-46.90
-42.09
-29.96
-32.79
-29.89
-29.53
-38.45

ǻGbindc
-13.63
-6.32
-3.41
-0.85
-14.90
-25.99
-23.00
-33.17
-26.32
-14.50
-18.62
-11.15
-17.67
-28.62
-36.04
-17.85
-15.89
-13.52
-11.69
-15.60
-22.80
-17.45
-18.98
-19.51
-26.00
-27.90
-17.11
-17.03
-18.06
-20.70
-19.28
-14.69
-13.24
-18.06
-14.66
-23.88
-26.64
-19.74
-33.75
-21.98
-9.10
-12.84
1.80

Table 6-15.
Cpd.
124
125
126
127
128
129

(Continued)

STa pIC50
4.49
4.74
4.22
4.35
4.30
4.16

ǻEvdWb
-25.68
-25.25
-36.65
-28.73
-28.85
-27.15

ǻGbindc
-9.55
-9.30
-6.59
-4.40
-22.05
-3.69

Cpd.
226
227
228
229
230
231

a

STa pIC50
4.00
4.00
4.00
4.00
4.00
4.00

ǻEvdWb ǻGbindc
-29.02
-4.09
-5.34
-29.57
-4.21
-30.55
-29.68 -10.79
-31.40 -14.31
-4.49
-24.93

ST represents strand transfer; b represents van der Waals energy; c represents binding
free energy.
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Figure 6-23. Correlation between the MM-GBSA ǻGbind and the ST inhibitory
activities (pIC50s)

Figure 6-24. Correlation between the MM-GBSA ǻGvdW energies and the ST
inhibitory activities (pIC50s)
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Homology Model-Guided 3D-QSAR Studies
Molecular data set. A total of 103 compounds were used for the 3D-QSAR
studies. Although the data set represented several different compound classes, they all
share a somewhat similar structural core. These compounds have common mechanism of
action (chelation of the divalent metal and inhibition of ST) and cover a wide range of
IC50 values spanning over 5 log units, thus constitute a suitable set of compounds for
QSAR studies. The dataset was also evenly distributed with regard to activity, comprising
potent IN inhibitors having IC50s of 7-8 nM, moderately active 3-keto salicylic acid
derivatives with IC50s of 4-5 μM and inactive compounds with IC50s of 100 μM. To
evaluate the predictive ability of models, the dataset was divided into a training set of 90
compounds and an external validation test set of 13 compounds. The test set was selected
randomly using factor analysis in the SYBYL package (vX1.1, Tripos Associates Inc. St.
Louis, MO) and contained compounds representing all the four different potency
categories.
Conformation and alignment of the data set. For 3D-QSAR studies we
compared two atom-fit alignment rules (models 1 and 2), with the docking alignment
(model 3). Determination of the “bioactive conformation” is of utmost importance for the
development of a successful 3D-QSAR model of the CoMFA and CoMSIA type. To this
end, the developed raltegravir-IN-DNA homology model was used to extract the
conformation of raltegravir (compound 193). This conformation of raltegravir obtained
from our homology model perfectly superimposed over its reported X-ray conformation
in the PDB 3L2T complex. This conformation of raltegravir was used as a template for
alignment and as a conformational template to build the remaining N-methyl-4hydroxypyrimidinone carboxamides. Similarly, the homology model derived
conformation of elvitegravir (compound 216) was used to build the remaining 4quinolone-3-carboxylic acid analogs. The topmost pose of the amide derivative 149
obtained from the docking simulations was used as a template to build the other amide
derivatives. As discussed in the docking studies, chalcones appear to have multiple
binding modes. The highest-ranked poses of the two most active compounds 86 and 96
were each used as a bioactive conformation template to build the remaining chalcones of
the series. To take into account the conformations of the two most active chalcone
derivatives, two different alignments rules, alignment I (model 1) and alignment II
(model 2), were generated. It was primarily aimed to assess their effect on the overall
unified 3D-QSAR model for IN inhibition. However, the conformations of the N-methyl4-hydroxypyrimidinone carboxamides, 4-quinolone-3-carboxylic acids and 3-keto
salicylic acid amides remained identical in both alignments.
Alignment I. For alignment I, the atom-fit alignment function in SYBYL was
used for a pair-wise alignment of elvitegravir, chalcone and amide derivatives with
raltegravir as a template. The conformations of these compounds were judiciously
aligned over raltegravir template taking into consideration their interactions with the IN
active site, and with atomic coordinates adjusted to provide the maximum overlap of the
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molecules in the dataset. All the compounds were then partially energy minimized by the
Simplex procedure to relieve excessive strain. The bound X-ray and homology modelderived conformations revealed partial overlap of the pyrimidinone and quinolone
moieties of raltegravir and elvitegravir, respectively. The carboxylate of elvitegravir and
the 6-oxo group of raltegravir chelate the same Mg2+ ion (between Asp116 and Asp64).
Therefore, for alignment, the pyridone ring of elvitegravir was superimposed over the
pyrimidinone ring of raltegravir such that the 3ƍ-carbon of the quinolone system was
superimposed over the 6ƍ-carbon of the pyrimidinone ring of raltegravir. In this
orientation, the Cƍ-5 carbon of the quinolone ring in elvitegravir superimposed over the
carbonyl carbon of the carboxamide moiety in raltegravir. This alignment rule resulted in
a good overlap of the six-membered rings and matched the crucial metal-chelating
pharmacophoric groups. Other pharmacophoric features as represented by their
halogenated phenyl rings, which inserted into a cavity as shown in the homology models
aligned well. The docked conformation of the topmost poses of the amide analog 149 and
chalcone derivative 86, revealed that their salicylic acid groups mimicked the
pyrimidinone ring of raltegravir. The docking also suggested that the 3-keto oxygen of
reference compounds 149 and 86, and the carbonyl oxygen of the carboxamide of
raltegravir interacted with the same Mg2+ ion (between Asp64 and Glu152). Likewise, the
carboxylate groups of compounds 149 and 86 and the pyrimidinone oxo of raltegravir
coordinated with the Mg2+ between Asp64 and Asp116. Thus, for alignment of the amide
and chalcone derivatives, the salicylic acid rings of compounds 149 and 86 were aligned
over the pyrimidinone ring of raltegravir such that 1ƍ-carbon atoms of compounds 149
and 86 were superimposed over the 6ƍ-carbon of the pyrimidinone ring of raltegravir.
Furthermore, the carbonyl carbons of compounds 149 and 86 were superimposed over the
carbonyl carbon of the carboxamide moiety of raltegravir. This alignment rightly
positioned their halogenated phenyl rings into the hydrophobic cavity as depicted in the
docking studies. The superimposition of the data set using alignment I is shown in Figure
6-25.
Alignment II. The pyridone ring of elvitegravir and the salicylic acid group of
compound 149 were superimposed (atom-fit) over the pyrimidinone ring of raltegravir
similar to alignment I. However, the docked pose of compound 96 was used as the
bioactive conformation for the chalcone derivatives. As discussed in the docking section,
the halogenated phenyl ring of compound 96 was placed in the opposite (180°) direction.
In this orientation, the carboxylate of compound 96 is directed towards the carbonyl
oxygen of the benzyl carboxamide moiety of raltegravir and both functionalities interact
with the Mg2+ between Asp64 and Glu152. Thus for this alignment, the salicylic acid
group and the carboxylate carbon of compound 96 were respectively superimposed over
the pyrimidinone ring and the carbonyl carbon of the carboxamide moiety of raltegravir.
The superimposition of the dataset using alignment II is shown in Figure 6-26.
Alignment III. Theoretically, overlaying the poses of the compounds docked at the
IN active site should provide a better bioactive conformational alignment than the atomfitting alignments I and II. Thus, to derive a truly docking based 3D-QSAR, all the 103
compounds were docked and their binding poses analyzed. The poses of 98 compounds
that bound similarly were validated by MM-GBSA rescoring which gave better
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Figure 6-25. Superimposition of the data set by alignment I

Figure 6-26. Superimposition of the data set by alignment II
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correlations (ǻGbind r2 = 0.34; ǻEvdW r2 = 0.57) with ST inhibitory activities. These
conformations were then overlayed, to produce an alignment III, which was in effect a
combination of alignments I and II. Alignment III is depicted in Figure 6-27 was used to
build a docking-based 3D-QSAR, model 3.
PLS Results
PLS analysis using the leave-one-out (LOO) cross-validation method was used to
determine predictive ability (using the cross-validated coefficient q2) and the number of
components to use in the final regression models. The optimal number of components
used (5 for both models 1 and 2) was determined by the number of components that
yielded the smallest standard error of prediction. Atom-fit alignments I and II were used
to develop two 3D-QSAR models; model 1 and model 2, respectively. Alignment I may
be more plausible since placement of the hydrophobic phenyl rings of the chalcones into
the cavity should have more contact of the inhibitors with IN than alignment II in which
part of the phenyl ring of the inhibitor is solvent-exposed. However, significant q2 and r2
values were obtained for CoMFA and CoMSIA 3D-QSARs of both models 1 and 2
(Table 6-16). In terms of PLS statistics, the CoMFA of both models performed better
than their CoMSIA counterparts. The CoMFA 3D-QSAR model 1 performed slightly
better than the CoMFA model 2, with q2 and r2 values of 0.82 and 0.94, respectively,
compared to q2 of 0.79 and r2 of 0.93 for CoMFA model 2. Similar q2 values around 0.71
were obtained for both CoMSIA models 1 and 2. On the basis of its extreme residual
value, compound 189 was identified as an outlier in model 1. It was the only compound
in the series which did not have a hydrophobic p-fluoro benzyl ring and thus its structural
uniqueness might be a factor for it being an outlier.
To test the robustness of the predictive capabilities of the models, they were used
to predict the activity of an external test set of 13 compounds which were excluded from
the training set. The residuals of the training and test set predictions for model 1 are listed
in Tables 6-17 and 6-18, respectively. The corresponding residual values for model 2 are
given in Tables 6-19 and 6-20. For model 1, the CoMFA prediction curves for the
training and the test set are shown in Figure 6-28 and the corresponding CoMSIA
predictions in Figure 6-29. The corresponding CoMFA and CoMSIA predictions for
model 2 are shown in Figure 6-30 and Figure 6-31, respectively. As is evident, the
present study gave high correlations between actual and predicted values for the external
test set. CoMFA and CoMSIA gave comparable predictive r2 values of 0.93 and 0.83 for
model 1 and corresponding predictions of 0.90 and 0.82 for model 2. In addition, more
stringent group cross-validation (20 times) was applied to further test the reliability of
models. As shown in Table 6-16, r2cv values of 0.82 was obtained for CoMFA and 0.71
for CoMSIA of model 1. The corresponding values for model 2 were 0.78 and 0.69 for
CoMFA and CoMSIA, respectively. These results demonstrate that both models are
stable and statistically robust. Moreover, low CoMFA and CoMSIA scrambling average
q2 values of 0.17 and 0.18, respectively for model 1 and 0.31 and 0.25 for model 2 also
validate the models’ statistical significance, showing they were not obtained by chance
correlation. The result of bootstrapping further corroborates the robustness of the derived
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Figure 6-27. Docked conformations of the data set compounds used as alignment
III
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Table 6-16.

PLS statistics of 3D-QSAR models

PLS Statistics
q2
r2
S
F
PLS Component
Field
Contribution
Steric
Electrostatic
Hydrophobic
H-Donor
H-Acceptor
Bootstrapping
r2 (20 runs)
Cross-validation
q2 (20 runs)

Model 1
CoMFA
CoMSIA
0.82
0.71
0.94
0.93
0.34
0.36
284.69
240.51
5
5
0.526
0.474

0.94 ± 0.012
0.82

0.105
0.288
0.242
0.224
0.141
0.95 ± 0.016
0.71

Model 2
CoMFA
CoMSIA
0.79
0.71
0.93
0.94
0.38
0.35
222.65
261.51
5
5
0.528
0.472

0.107
0.292
0.223
0.214
0.164
0.95 ±
0.01
0.69

0.90 ±
0.01
0.78
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Model 3
CoMFA
CoMSIA
0.61
0.60
0.93
0.94
0.36
0.33
221.03
263.92
3
3
0.453
0.547

0.95 ±
0.011
0.60

0.122
0.242
0.193
0.232
0.211
0.96 ± .009
0.59

Table 6-17.
of model 1

Residuals of predictions of the training set by CoMFA and CoMSIA

Cpd. Actual
STa pIC50
81
82
83
85
86
87
88
89
90
92
93
94
95
97
98
99
100
101
102
103
105
106
107
108
109
110
111
112
113
114
115
116
117
119
120
121
122
123
124
125
126

4.60
4.85
4.49
4.92
5.30
4.45
5.13
4.72
4.46
4.74
4.79
4.85
4.88
4.27
4.00
4.03
4.60
4.76
4.52
4.38
4.61
4.52
4.53
4.82
4.40
4.23
4.11
4.11
5.04
4.74
4.79
4.74
4.25
4.25
4.95
4.79
4.20
4.28
4.49
4.74
4.22

Residuals
CoMFA CoMSIA
0.48
0.20
0.27
0.17
-0.39
-0.07
0.26
0.22
0.21
0.74
-0.26
0.09
0.18
0.64
0.15
0.12
0.11
0.23
0.20
0.09
0.38
0.18
0.26
0.24
0.32
0.29
-0.34
-0.36
-0.19
-0.35
-0.59
-0.55
0.02
-0.06
0.11
0.13
0.01
-0.04
-0.26
-0.23
-0.12
-0.09
-0.12
-0.09
-0.08
-0.14
0.18
0.19
-0.16
-0.23
-0.20
-0.41
-0.31
-0.17
-0.15
-0.18
0.44
0.13
0.26
0.15
0.03
-0.01
0.30
0.07
-0.03
0.01
-0.23
-0.25
0.10
0.26
0.42
0.08
-0.03
-0.35
-0.17
-0.10
0.00
-0.06
0.00
0.14
-0.52
-0.40
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Cpd.

Actual
STa IC50

149
153
154
155
183
185
186
187
188
189*
190
191
193
195
196
197
201
202
203
204
205
206
207
208
209
210
212
213
214
215
216
217
218
219
220
222
223
224
225
226
227

4.82
4.00
4.00
4.88
8.00
8.39
7.82
7.69
7.58
5.30
7.67
8.39
7.82
7.82
6.92
6.65
7.00
6.69
6.60
6.88
5.39
5.30
6.75
7.20
7.72
6.85
7.36
7.61
8.04
8.08
8.14
4.00
4.74
6.69
5.88
4.61
4.79
4.00
4.00
4.00
4.00

Residuals
CoMFA CoMSIA
0.42
0.44
-0.34
-0.43
-0.28
-0.35
0.12
0.51
-0.21
-0.26
-0.07
0.54
0.40
-0.03
-0.60
-0.37
-0.12
-0.39
-3.16
-2.64
0.35
-0.40
-0.25
0.26
-0.19
-0.05
0.01
-0.25
0.27
-0.01
0.25
0.19
0.66
0.54
0.01
0.04
-0.01
0.04
0.31
0.32
-0.82
-0.79
-0.66
-1.08
0.15
0.14
0.00
0.14
0.46
0.62
-0.01
0.06
-0.05
0.78
-0.30
-0.22
0.28
0.01
0.92
0.20
0.30
0.20
-1.61
-1.41
-1.08
-0.43
0.82
1.17
0.25
0.47
-0.39
-0.73
-0.35
-0.45
-0.23
0.01
0.13
0.16
0.49
-0.04
-0.47
-0.16

Table 6-17.

(Continued)

Cpd. Actual
STa pIC50
4.35
127
4.30
128
4.16
129
4.67
130
a

Cpd.
228
229
230
231

Actual
STa pIC50
4.00
4.00
4.00
4.00

Residuals
CoMFA CoMSIA
0.39
0.60
-0.19
0.18
0.01
-0.50
-0.05
-0.32

ST represents strand transfer; * represents outlier.

Table 6-18.
model 1
Cpd.
84
91
96
204
118
184
192
194
198
199
200
211
221
a

Residuals
CoMFA CoMSIA
-0.16
-0.03
-0.39
-0.16
-0.38
-0.61
0.13
0.11

Residuals of predictions of the test set by CoMFA and CoMSIA of

Actual
STa pIC50
5.04
4.29
5.43
4.76
4.33
7.82
8.04
7.92
7.00
6.16
6.85
5.79
6.22

Residuals
CoMFA
CoMSIA
0.62
0.21
0.05
0.08
0.84
1.11
0.05
0.14
-0.03
-0.15
-0.57
-0.51
-0.16
-0.18
-0.42
0.22
-0.26
0.09
-0.38
0.31
-0.61
-0.39
-0.52
-1.68
0.76
0.66

ST represents strand transfer.
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Table 6-19.
of model 2

Residuals of predictions of the training set by CoMFA and CoMSIA

Cpd. Actual
STa pIC50
4.60
81
4.85
82
4.49
83
4.92
85
5.30
86
4.45
87
5.13
88
4.72
89
4.46
90
4.74
92
4.79
93
4.85
94
4.88
95
4.27
97
4.00
98
4.03
99
100 4.60
101 4.76
102 4.52
103 4.38
105 4.61
106 4.52
107 4.53
108 4.82
109 4.40
110 4.23
111 4.11
112 4.11
113 5.04
114 4.74
115 4.79
116 4.74
117 4.25
119 4.25
120 4.95
121 4.79
122 4.20
123 4.28
124 4.49
125 4.74
126 4.22

Residuals
CoMFA CoMSIA
0.53
0.40
0.30
0.27
-0.53
-0.24
0.29
0.36
0.17
0.57
-0.06
-0.25
0.17
-0.03
0.22
0.15
-0.06
0.11
0.19
0.18
0.25
0.14
0.21
0.26
0.32
0.32
-0.30
-0.29
-0.02
0.00
-0.46
-0.54
0.08
0.05
0.21
0.20
0.01
-0.15
-0.20
-0.21
0.08
0.01
0.04
-0.09
0.03
-0.04
0.30
0.23
0.10
-0.27
0.27
-0.27
0.17
-0.22
0.19
-0.19
-0.24
0.03
-0.14
0.17
-0.13
0.01
-0.06
0.10
0.07
0.04
0.19
-0.14
-0.12
0.42
0.03
0.13
0.27
-0.32
0.24
0.01
0.05
0.08
-0.13
0.26
0.38
-0.26
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Cpd.
149
153
154
155
183
185
186
187
188
189
190
191
193
195
196
197
201
202
203
204
205
206
207
208
209
210
212
213
214
215
216
217
218
219
220
222
223
224
225
226
227

Actual
STa pIC50
4.82
4.00
4.00
4.88
8.00
8.39
7.82
7.69
7.58
5.30
7.67
8.39
7.82
7.82
6.92
6.65
7.00
6.69
6.60
6.88
5.39
5.30
6.75
7.20
7.72
6.85
7.36
7.61
8.04
8.08
8.14
4.00
4.74
6.69
5.88
4.61
4.79
4.00
4.00
4.00
4.00

Residuals
CoMFA CoMSIA
0.07
0.10
-0.62
-0.57
-0.46
-0.44
-0.30
0.29
0.09
-0.29
-0.18
0.49
-0.02
-0.03
-0.12
-0.24
0.32
-0.04
-0.38
0.28
0.50
-0.81
-0.32
0.13
-0.57
-0.21
-0.19
-0.31
-0.38
-0.35
0.15
0.61
0.91
0.84
0.22
-0.05
0.30
0.18
0.59
0.43
-0.59
-0.78
-0.62
-1.05
0.20
0.24
0.13
0.35
0.90
0.90
0.07
0.04
0.26
0.76
0.12
-0.05
-0.02
-0.21
-0.74
0.13
-0.04
0.15
0.66
-0.05
0.60
-0.44
-0.97
1.11
-0.26
0.57
0.49
-0.49
0.14
-0.39
0.08
-0.11
-0.08
-0.05
-0.39
-0.14
0.50
-0.32

Table 6-19.

(Continued)

Cpd. Actual
STa pIC50
4.35
127
4.30
128
4.16
129
4.67
130
a

Cpd.
228
229
230
231

Actual
STa pIC50
4.00
4.00
4.00
4.00

Residuals
CoMFA CoMSIA
0.36
-0.49
-0.19
-0.31
-0.15
0.14
-0.15
0.15

ST represents strand transfer.

Table 6-20.
model 2
Cpd.
84
91
96
104
118
184
192
194
198
199
200
211
221
a

Residuals
CoMFA CoMSIA
-0.24
0.04
-0.47
0.23
-0.37
0.17
0.06
0.35

Residuals of predictions of the test set by CoMFA and CoMSIA of

Actual STa
pIC50
5.04
4.29
5.43
4.76
4.33
7.82
8.04
7.92
7.00
6.16
6.85
5.79
6.22

Residuals
CoMFA CoMSIA
-0.11
0.11
-0.07
-0.01
0.70
1.06
0.19
0.23
-0.73
-0.38
-0.71
-0.79
-0.20
0.10
0.18
0.24
-0.15
0.15
-0.22
0.00
-0.43
-0.38
0.21
-1.57
0.81
0.67

ST represents strand transfer.
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Figure 6-28. Predictions of the training and the test set by CoMFA of model 1
Training and the test sets are represented by blue and red spheres, respectively.

Figure 6-29. Predictions of the training and the test set by CoMSIA of model 1
Training and the test sets are represented by blue and red spheres, respectively.
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Figure 6-30. Predictions of the training and the test set by CoMFA of model 2
Training and the test sets are represented by blue and red spheres, respectively.

Figure 6-31. Predictions of the training and the test set by CoMSIA of model 2
Training and the test sets are represented by blue and red spheres, respectively.
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models. PLS results of model 3, which was developed using the docking derived
alignment, III are also shown in Table 6-16. For estimating predictivity, the same 13
compounds were used as an external test set. The models, which could be developed with
only 3 components, gave q2 and r2 values of 0.61 and 0.93 for CoMFA and the
corresponding values of 0.60 and 0.94 for CoMSIA. Both the CoMFA and the CoMSIA
models gave low standard error of estimate (SEE) and large F values of 0.36, 221.03 and
0.33, 263.92, respectively. Cross-validation and boot-strapping results indicated that both
CoMFA and CoMSIA models were statistically robust. The CoMFA model performed
significantly better in estimating the test set compounds with a predictive r2 value of 0.82
as compared with a predictive r2 value of 0.62 obtained with the CoMSIA model. The
residuals of the training and the test set predictions of model 3 are summarized in Table
6-21 and Table 6-22, respectively. Plots of CoMFA and CoMSIA predictions for the
training and the test set are shown in Figures 6-32 and 6-33. Comparison of the QSAR
models suggests that the atom-based alignment models 1 and 2, gave higher q2 values
when compared with the docking-based alignment model 3. However, models 1 and 2
were derived using 5 components and the higher q2 values might result from over-fitting
of the data points because of the higher number of components used. Thus to check for
any over-fitting, models 1 and 2 were revisited using 3 components. Re-derived model 1
gave q2 and r2 values of 0.67, 0.85 for CoMFA and 0.60 and 0.84 for CoMSIA,
respectively. However, the model gave higher SEE and smaller F values (0.54, 173.69 for
CoMFA and 0.57, 151.09 for CoMSIA) compared to the docking-based model 3.
CoMFA and CoMSIA 3D-QSARs of model 2 when derived with 3 components gave
lower q2 and r2 values (q2 = 0.58, r2 = 0.75 for CoMFA; and q2 = 0.55, r2 = 0.76 for
CoMSIA). Moreover, these models also resulted in higher SEE and smaller F values
when compared to model 3. Thus, in terms of robustness and ability to generalize, the
docking-derived 3D-QSAR models are better than the ligand-based alignments I and II.
Also, compared to our previous pharmacophore-based CoMFA and CoMSIA 3D-QSAR
modeling of the salicylic acid derive IN inhibitors, this structure-based and composite
3D-QSAR approach has generated better models, with best q2 and predictive r2 values of
0.82 and 0.93, respectively, compared to best q2 and predictive r2 values of 0.54 and 0.57,
respectively. Taken together, the results suggest that the docking-based composite QSAR
models are better predictive tools than our previous QSAR models for lead optimization
of the 3-keto salicylic acid series.
Contour Maps
Model 1: CoMFA contour maps. The PLS coefficients derived CoMFA steric
and electrostatic contours mapped around raltegravir are displayed in Figure 6-34 and
Figure 6-35, respectively. The IN-DNA binding site is represented as Connolly surface
which was generated by the MOLCAD program in the SYBYL modeling package. There
are green and yellow contours in the region close to the gem-dimethyl side chain. This is
the region where substantial modifications were made that eventually led to the optimized
gem-dimethyl oxadiazole carboxamide moiety. This side chain is positioned such that the
oxadiazole ring occupies a pocket, which is indicated by a green contour in the cleft

157

Table 6-21.
of model 3

Residuals of predictions of the training set by CoMFA and CoMSIA

Cpd.

Actual
STa pIC50

Residuals
CoMFA CoMSIA

81
82
83
85
86
87
88
89
90
92
93
94
95
97
98
99
100
101
102
103
105
106
107
108
109
110
111
112
113
114
115
116
117
119
120
121
122
123
124
125
126

4.60
4.85
4.49
4.92
5.30
4.45
5.13
4.72
4.46
4.74
4.79
4.85
4.88
4.27
4.00
4.03
4.60
4.76
4.52
4.38
4.61
4.52
4.53
4.82
4.40
4.23
4.11
4.11
5.04
4.74
4.79
4.74
4.25
4.25
4.95
4.79
4.20
4.28
4.49
4.74
4.22

0.19
0.12
0.06
0.37
0.72
-0.14
0.46
-0.01
-0.003
0.41
0.10
0.06
0.25
-0.19
-0.20
-0.65
0.36
0.22
0.23
-0.19
0.14
-0.28
0.17
-0.28
0.52
-0.60
-0.18
-0.52
0.19
0.14
0.20
0.31
-0.26
0.26
0.04
0.11
0.40
-0.13
0.07
0.05
0.02

0.15
0.08
0.02
0.66
0.67
-0.21
0.44
0.03
-0.04
0.30
-0.05
0.16
0.43
-0.46
-0.46
-0.68
0.14
0.29
0.04
-0.34
-0.15
-0.14
0.13
-0.01
-0.07
0.00
0.02
-0.21
0.20
0.20
0.40
0.04
-0.09
-0.12
0.15
-0.03
-0.26
-0.33
-0.12
0.07
-0.10

Cpd.
149
153
154
155
183
185
186
187
188
189
190
191*
193
195
196
197
201
202
203
204
205
206
207
208
209
210
212
213
214*
215
216
217*
218
219
220*
222
223*
224
225
226
227
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Actual
STa pIC50
4.82
4.00
4.00
4.88
8.00
8.39
7.82
7.69
7.58
5.30
7.67
8.39
7.82
7.82
6.92
6.65
7.00
6.69
6.60
6.88
5.39
5.30
6.75
7.20
7.72
6.85
7.36
7.61
8.04
8.08
8.14
4.00
4.74
6.69
5.88
4.61
4.79
4.00
4.00
4.00
4.00

Residuals
CoMFA CoMSIA
0.26
-0.45
0.06
0.08
-0.41
-0.03
-0.53
0.45
-0.20
-0.05
0.52
N/I
0.40
0.006
0.01
0.54
-0.08
0.25
-0.22
-0.16
-0.03
-0.45
-0.10
0.06
0.69
-0.06
0.79
0.58
N/I
0.25
-0.22
N/I
-1.42
-0.02
N/I
-0.55
N/I
-0.32
-0.14
-0.49
-0.003

-0.16
0.11
0.17
-0.20
0.61
-0.03
0.25
-0.19
-0.01
-1.31
-0.22
N/I
0.12
-0.22
-0.02
0.43
0.21
0.03
-0.04
0.13
0.14
0.002
-0.02
-0.43
0.44
0.10
0.34
0.39
N/I
0.06
-0.02
N/I
-0.60
0.49
N/I
-0.50
N/I
0.40
-0.78
0.15
-0.01

Table 6-21.

(Continued)

Cpd.

Actual
STa pIC50

Residuals
CoMFA CoMSIA

Cpd.

Actual
STa pIC50

Residuals
CoMFA CoMSIA

127
128
129
130

4.35
4.30
4.16
4.67

0.01
-0.10
-0.13
-0.20

228
229
230
231

4.00
4.00
4.00
4.00

-0.02
-0.26
0.20
-0.29

-0.05
-0.16
0.20
0.13

-0.51
-0.02
-0.29
0.13

*

Compounds excluded from the dataset because of the lack of common binding mode,
N/I represents not included in the data set, a ST represents strand transfer.

Table 6-22.
model 3

Residuals of predictions of the test set by CoMFA and CoMSIA of

Cpd. Actual
STa pIC50
84
91
96
104
118
184
192
194
198
199
200
211
221
a

5.04
4.29
5.43
4.76
4.33
7.82
8.04
7.92
7.00
6.16
6.85
5.79
6.22

Residuals
CoMFA
CoMSIA
0.52
-0.29
1.06
0.42
-0.01
0.58
-0.66
1.06
0.70
-0.89
0.37
0.25
0.46

0.46
-0.11
0.96
0.02
-0.03
1.69
0.48
1.99
0.28
-0.18
-0.75
-0.77
0.50

ST represents strand transfer.
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Figure 6-32. Predictions of the training and the test set by CoMFA of model 3
Training and the test sets are represented by blue and red spheres, respectively.

Figure 6-33. Predictions of the training and the test set by CoMSIA of model 3
Training and the test sets are represented by blue and red spheres, respectively.
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Figure 6-34. CoMFA steric contour maps of model 1 superimposed on raltegravir
Green and yellow contours illustrate regions where steric bulk has favorable and
unfavorable effects on activity respectively.

Figure 6-35. CoMFA electrostatic contour maps of model 1 superimposed on
raltegravir
Blue and red isopleths indicate regions where an increase of positive and negative charge
is required for activity.
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formed by residues Asn117, Pro142, Tyr143, Asn144 and Pro145. The N-hydroxyalkyl
side chain of the quinolone ring of elvitegravir also occupies the green contour and thus
shows nearly 6 times improved activity relative to the unsubstituted analog (212 vs 215).
The two yellow contours above the pyrimidinone ring indicate that steric bulk is
unfavorable in this region. The N-acetyl substituted piperidine ring of compound 205 fits
into a yellow contour, which might explain the decrease in activity of this compound and
other structural analogs of 4-quinolone-3-carboxylic acids with a bulky phenyl ring, such
as compounds 228 and 229. Moreover, their hydroxyethyl side chains also point towards
the steric disfavored yellow contour region, further supporting a decrease in activity of
these analogs. There are several yellow regions around the hydrophobic phenyl ring,
suggests that steric bulk is not favored at these positions possibly because of clashing
with the donor DNA. This might be one of the reasons fluorine whose size is similar to
hydrogen’s is the most optimal substituent on this ring. The electrostatic map of CoMFA
shows a blue contour close to the pyrimidinone ring, implying that groups that have
electropositive character are favored for activity. This is supported by the presence of
electron-deficient nitrogen-containing ring systems in many different classes of IN
inhibitors including the pyrimidinone ring of raltegravir and the quinolone ring of
elvitegravir, as well as the acidic phenolic hydrogen in this region. There are three red
contours close to the metal-chelating pharmacophore of raltegravir indicating that the
presence of electron rich groups is favored for activity. There is also a red contour at the
ortho-position on the fluorobenzyl group. This is explained by the contour superimposed
on elvitegravir which reveals the ortho-fluoro substituent occupying these red contours.
A distal red contour which is close to the meta-postion on the benzyl group of
elvitegravir again suggests that negative charge is favorable in this region. This is
reflected by the presence of an electronegative chlorine substituent at this position in
elvitegravir and related analogs.
Because the developed QSAR models are developed for potential use in
optimizing our lead amide derivatives to more potent IN inhibitors, CoMFA contours
were also mapped over compound 149. The bromine substituent at the para-position of
the salicylic acid group could be substituted with bulky groups for improvement of
activity as a green contour resides at this region. The CoMFA contours help explain the
loss in activity of compounds 117, 118 and 119, which have cyclopentyl and substituted
polycyclic naphthalene rings placed in steric bulk disfavored yellow-contoured regions.
Model 1: CoMSIA contour maps. CoMSIA steric and electrostatic contours
mapped onto raltegravir are similar to those of the CoMFA model in having two yellow
contours which result from the steric clash with the amide backbone of Tyr143 and the
solvent accessible surface. Like in the CoMFA map, there is a green contour which is
occupied by the carboxamide moiety of the oxadiazole side chain. However, in
compound 206, the side chain is oriented towards the yellow contours and explains the
loss in activity. Another steric bulk-favored green region is occupied by the
p-fluorobenzyl group, which has a positive influence on potency. This is confirmed by
the significant loss of activity of compound 189 which lack of a phenyl at this position.
The green contour is flanked by a large yellow contour suggesting that bulk tolerance
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within the cavity is quite limited. This could be the reason behind the reduced potency of
compounds 112 and 117 in the chalcone series whose methoxy and bulky cyclopentyl
groups fit into the disfavored yellow region. Similarly for compounds 118 and 119, loss
in activity might result from the naphthyl rings placed in the bulk disallowed yellow
region. The phenyl ring in compounds 217, 224, and 227-229 fits into the disfavored
yellow region, and that might account the significant loss in activity of these analogs.
The CoMSIA electrostatic map shows two red contours close together near the
oxadiazole ring which is involved in ʌ-stacking interactions with the phenyl ring of the
Tyr143. Similar to the CoMFA electrostatic contour map, there is a blue contour over the
hydroxyl group of raltegravir. This possibly reflects the ionizable acidic OH group of
raltegravir. Lastly, there are two small red contours around the oxygen of the methoxy
and the hydroxyl groups in elvitegravir, correctly predicting the requirement of electron
rich groups at this location.
CoMSIA hydrophobic contours superimposed on raltegravir (Figure 6-36) show
the presence of two large yellow regions indicating that hydrophobic groups at these
positions are favored for activity. While one of the yellow contours is occupied by the
phenyl ring in raltegravir, the phenyl ring of elvitegravir is oriented towards the second
yellow contour. There is also a small yellow region at the para-position on the phenyl
ring. Indeed, the presence of hydrophobic halogens like bromine in compound 86 or
chlorine in compound 88 suggest the presence of hydrophobic interactions at this
position. There is a hydrophilic region that the ribose and the phosphate regions of the
viral DNA. This voluminous white contour encloses the the carboxamide moiety and
extends up to the central hydroxyl substituent in the pyrimidinone ring of raltegravir. The
reduced potency of compound 206 may be explained by having the hydrophobic methyl
group of its N-methyl carboxamide moiety located in the white region, which is counter
to the preference of a hydrophilic moiety. A yellow contour fits over the methyl and a
white contour fits over the carbonyl group of the oxadiazole carboxamide side chain in
raltegravir in agreement with their hydrophobic and hydrophilic character, respectively.
The H-bond donor-acceptor contour plots mapped onto raltegravir are shown in Figure
6-37. The magenta contour signifies that acceptor groups on the inhibitor are favored at
that location, whereas the red contour encompasses a region where H-bond acceptors are
disfavored, probably because of the presence of the carbonyl oxygen of the amide
backbone of Tyr143 in the receptor. Another magenta contour is merged within the
purple contour suggesting an H-bond acceptor is favored but a donor is disfavored which
relate to groups that interact with the backbone NH of Pro145. It is close to the 8ƍposition of the quinolone ring in elvitegravir indicating that acceptor groups are well
tolerated at this position. There is another red contour above the phenyl ring at the ortho
and meta-positions in raltegravir implying that H-bond acceptors are disfavored at these
positions. One of the purple regions is merged with and complements the magenta
contour at the 8ƍ-position of the quinolone ring. The other purple region appears to
complement the presence of the amino group of Gln148 in the receptor site, signifying
that the presence of H-bond donor at this region is detrimental to activity. Cyan contours
indicate regions where H-bond donor groups increase activity. One of the cyan contours
fits the NH group of the pyrimidinone carboxamide functionality in raltegravir while the
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Figure 6-36. CoMSIA hydrophobic contour maps of model 1 superimposed on
raltegravir
Yellow and white contours enclose areas favorable for hydrophobic and hydrophilic
groups respectively.

Figure 6-37. CoMSIA H-bond contours of model 1
Purple contours indicate regions where H-bond donor decreases activity whereas cyan
contour illustrates regions where H-bond donor increases activity. Magenta isopleths
indicate areas where H-bond acceptor increases affinity while red isopleths indicate areas
where H-bond acceptor decreases affinity.
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other is located in the region close to the hydroxyl of the alkyl hydroxyl group of
elvitegravir.
Model 2 contour maps. The CoMFA steric (Figure 6-38) and electrostatic
(Figure 6-39) contours on raltegravir arising from model 2 have similarities to the
contours obtained in model 1. One green contour again fits into the oxadiazole ring
suggesting that bulk is favored. Nearby yellow regions similar to those in the CoMFA
contour of model 1 indicate sterically disallowed regions. Likewise, there are several red
and one blue contours around the metal-chelating pharmacophore. Similar to the CoMFA
model 1, the contours also explain the loss of inhibitory activity of compounds 189, 206,
217, 224 and 225, and 227-229. In addition, the CoMFA contour map further reveals
green regions around the two meta-positions on the phenyl ring, suggesting that bulky
groups could be added at these positions. One of the green contours is occupied by the
methyl of the methoxy group in elvitegravir, corroborating the increase in activity seen
with the presence of methoxy substituents in compounds 213 vs. 214 and 215 vs. 216.
The CoMSIA steric and electrostatic contours projected onto raltegravir reveal SAR
information similar to CoMSIA isopleths of model 1. However, there is a distant yellow
contour which fits around the phenyl ring of the chalcone derivatives. In alignment II, the
phenyl rings of the chalcones were oriented in the opposite (180°) direction to those in
alignment I, and not within the cavity formed by the displacement of 3ƍ-adenosine of the
viral DNA. The hydrophobic contour of CoMSIA projected on raltegravir (Figure 6-40)
shows two white regions around the metal-chelating pharmacophore and another similar
white region below the NH of the carboxamide moiety in raltegravir and oxygen of the
methoxy substituent in elvitegravir. Again as in model 1, a yellow contour close to the
gem-dimethyl substituent is observed, suggesting a hydrophobic favored region. The Hbond donor and acceptor contours (Figure 6-41) show a large cyan isopleth located on
the hydroxyl group of the hydroxalkyl side chain in elvitegravir. This appears to
complement the red polyhedra observed in the corresponding contour maps of model 1.
There are small cyan and magenta contours close to the pyrimidinone ring of raltegravir
showing the positive role of a H-bond donor. There are two purple contours around the
benzyl groups of raltegravir and elvitegravir implying that H-bond donors are not
tolerated on the phenyl ring. One of the purple contours fits over the meta-chloro
substituent of elvitegravir suggesting the preference for a H-bond acceptor at this
position.
Model 3 contour maps. Contours resulting from docking-based alignment III are
mostly similar to the contours that resulted from models 1 and 2. Since details of these
contours have been described above, only the contours that differ markedly are further
discussed. CoMFA and CoMSIA steric and electrostatic contours are shown in Figure
6-42 and Figure 6-43, respectively. A large green contour observed in the CoMFA map
is directed towards the gem-dimethyl substituent indicating the importance of this
sterically favored group. Large yellow contours near the oxadiazole ring are evident in
both CoMFA and CoMSIA maps, and may have resulted due to the lack of space beyond
the oxadiazole shown by the surface protrusion on the right upper side of the oxadiaxole
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Figure 6-38. CoMFA steric contours of model 2
Green and yellow contours illustrate regions where steric bulk has favorable and
unfavorable effects on activity respectively.

Figure 6-39. CoMFA electrostatic contours of model 2
Blue and red isopleths indicate regions where an increase of positive and negative charge
is required for activity.
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Figure 6-40. CoMSIA hydrophobic contours of model 2
Yellow and white contours enclose areas favorable for hydrophobic and hydrophilic
groups respectively.

Figure 6-41. CoMSIA H-bonding contours of model 2
Purple contours indicate regions where H-bond donor decreases activity whereas cyan
contour illustrates regions where H-bond donor increases activity.
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Figure 6-42. CoMFA steric and electrostatic contours of model 3
Green and yellow contours illustrate regions where steric bulk has favorable and
unfavorable effects on activity respectively; blue and red isopleths indicate regions where
an increase of positive and negative charge is required for activity.

Figure 6-43. CoMSIA steric and electrostatic contours of model 3
Green and yellow contours illustrate regions where steric bulk has favorable and
unfavorable effects on activity respectively; blue and red isopleths indicate regions where
an increase of positive and negative charge is required for activity.
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ring of raltegravir. Similarly, a green common contour is mapped onto the phenyl ring
suggesting that bulk is favored inside the cavity. In the CoMFA map, a yellow contour is
observed close to the benzyl moiety implying the possibility of steric clash with the
surrounding DNA. Electrostatic contours show several red contours close to the metalchelating oxygen atoms implying that electronegative groups increase activity. A blue
contour common in both CoMFA and CoMSIA maps is also present near the metalchelating pharmacophore. These contours which suggest electropositive or H-donor
groups are favored for activity resulted from the acidic phenolic OH residues. A large
blue contour (near the green region) observed in CoMFA is indicative of positive groups
interacting with the surrounding deoxyribose phosphate backbone in the DNA. Both the
CoMSIA hydrophobic, H-bond donor and H-bond acceptor contours are shown in Figure
6-44. There are yellow contours that map onto the hydrophobic phenyl ring and gemdimethyl substituent suggesting that hydrophobic groups are favored at these positions.
There are white hydrophilic regions which map on the carboxamide moiety and on the
oxadiazole ring. The H-bonding contours show two purple contours close to o-position
on the phenyl ring and a red contour close to the m-position indicating that H-bond
donors and acceptors are disfavored at these positions, respectively. There is a purple
contour close to the metal-chelating atoms implying that H-bond donors are disfavored.
An overlapping magenta and red contours suggest H-bond acceptor is favored, while
beside it H-bond donor is disfavored. An overlapping cyan and magenta contours occur
around the NH of the benzyl carboxamide moiety indicating that NH can act as both a Hbond donor and acceptor at this position. Thus, the contour maps of model 3 reinforced
the SAR features explained by contour maps of 3D-QSAR models 1 and 2. This is not
surprising since the docking-based alignment II, was in a way a composite of alignments
I and II.
The two best 3D-QSAR models, 1 and 3, were finally used to predict the amide
derivatives that, were prospectively synthesized in Chapter 4. Thus, compounds in the
correct ionization states were assigned MOPAC atomic charges and predicted for their
ST activities. Comparison of the predicted vs. experimental activities is shown in Table
6-23. Both CoMFA and CoMSIA of the docking-based QSAR model 3 performed better
than their model 1 counterparts; as all the predicted compounds were found to be within 1
log unit of the pIC50 values. Furthermore, the CoMFA, of model 3 predicted three out of
total five compounds used for validation within 0.50 log units. With reference to related
amide, compound 149, used in the training set, the CoMFA of model 3 predicted two
compounds (152, 157) to be more active than the reference compound 149. Upon
biological testing it was revealed that these two compounds were reasonably predicted.
Thus, the final performance of the CoMFA of QSAR model 3, which performed the best,
may be considered acceptable. As the data set used in building the QSAR models
included only four salicylic acid-3-carboxamides, further studies using greater number of
salicylic acid-3-carboxamides derivatives in the training set may improve the predictive
ability of the 3D-QSAR models for the design of related novel 3-keto salicylic acid IN
inhibitors.
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Figure 6-44. CoMSIA hydrophobic and H-bonding contours of model 3
Yellow and white contours enclose areas favorable for hydrophobic and hydrophilic
groups respectively; purple contours indicate regions where H-bond donor decreases
activity whereas cyan contour illustrates regions where H-bond donor increases activity.
Magenta isopleths indicate areas where H-bond acceptor increases affinity while red
isopleths indicate areas where H-bond acceptor decreases affinity.
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Table 6-23.

Comparison of the predicted activities of the 3D-QSAR models guided synthesized compounds

Cpd. X
149a
150
151

COOH
COOH
COOH

Br
Br
Br

152

CONHCH2-4F-Ph
OH

Br

157
158
a

R1

COCHCH2,3,6-tri-Cl-Ph

R2

Actual
Model 1 predicted pIC50
pIC50 CoMFA (Res.)b CoMSIA (Res.)b
4-F
4.82
4.38 (0.44)
4.40 (0.42)
4-Br
4.16
4.45 (-0.29)
4.39 (-0.23)
2,4-di- 5.39
4.44 (0.95)
4.43 (0.96)
F-3-Cl
4-F
5.22
4.61 (0.61)
4.34 (0.88)

COCHCH- 4-F
Ph
Br
4-F

Model 3 predicted pIC50
CoMFA(Res.)b
4.56 (0.26)
4.65 (-0.49)
4.56 (0.83)

CoMSIA(Res.)b
4.98 (-0.16)
5.11 (-0.95)
5.14 (-0.25)

5.18 (0.04)

5.59 (-0.37)

4.67

5.96 (-1.29)

6.03 (-1.36)

5.12 (-0.45)

5.53 (-0.86)

4.00

4.44 (-0.44)

4.16 (-0.16)

4.71 (-0.71)

4.51 (-0.51)

Reference compound used as training set in 3D-QSAR models 1 and 3; b Represents residual values.
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Linear Interaction Energy Activity Model
To compare the three dimensional (3D) molecular interaction field-based
(CoMFA) and molecular similarity indices based (CoMSIA) QSAR models with the
linear interaction approximation218 derived energy parameters, a LIA QSAR model of the
IN inhibitors was developed. LIA estimates the free energy of binding by deriving
electrostatics, vdW, and cavity energy terms using a molecular mechanics force field and
is based on the surface generalized born continuum model of solvation.219 The objective
of building the LIA QSAR model is to correlate the changes in the free energy of binding
of the IN inhibitors in our dataset with their experimental IC50 values; and therefore to
provide a direct estimation of the potencies based on their binding free energies.
Although, unlike the CoMFA and CoMSIA models, the LIA calculations are not highly
dependent on the molecular alignments in calculating the binding free energies, their
accurate estimation is subject to giving a correct binding pose.
Thus, 98 integrase inhibitors of the dataset which shared similar binding modes,
as revealed by the docking studies, were used for building the LIA QSAR model. Same
test set of 13 compounds, docking-based CoMFA and CoMSIA 3D-QSAR models, was
used for prediction. Correlation coefficient r2 of 0.59 was obtained for the training set
with an rmsd of 0.88. Group cross-validation (leave-4-out) q2 of 0.54 indicates that model
can reasonably predict compounds not included in the training set. The model was then
used to predict the activities for the test set compounds. A plot of training and test set
predictions is shown in Figure 6-45. Correlation coefficient r2 of 0.79 between the actual
and predicted activities of the test set indicates that the LIA model has good predictive
ability. This model could estimate the binding affinities of novel HIV-1 IN inhibitors and
aid the virtual screening of IN inhibitors for lead discovery and development.
The vdW, electrostatic and cavity energy terms obtained from the LIA
calculations (Table 6-24) showed correlation of 0.44, 0.09, and 0.44, with the ST IC50s,
in that order. Liaison did not estimate electrostatics accurately probably because of
similar reasons mentioned in the MM-GBSA results. Regression coefficients Į, ȕ, and Ȗ,
for the vdW, electrostatic and cavity energy terms were found to be 0.087, -0.01, and
0.11, respectively. This indicates that the cavity and the vdW energy terms contribute
significantly to activity. The larger value for the cavity term implies that binding of IN
inhibitors is greatly influenced by placement of the ligand into a binding pocket. This is
in agreement with one of the most important binding requirements of potent IN
inhibitors. The crystal structures of the foamy virus IN-DNA complex in the presence of
IN inhibitors, raltegravir and elvitegravir, have revealed that their halogenated benzyl
ring is bound in a cavity formed by the IN-DNA interface after the displacement of 3ƍ
adenosine of the viral DNA. This feature has also been correctly depicted by our
homology models of HIV-1 IN-DNA-inhibitor complex that were discussed previously.
Analysis of the energy terms for raltegravir (compound 193) and elvitegravir (compound
216) explains their similar binding orientation in the IN active site. There is a greater
desolvation penalty for raltegravir as opposed to a smaller penalty for elvitegravir.
Although the halogenated benzyl groups of both dock into the cavity, the amide linkage
gives the benzyl moiety in raltegravir more flexibility to get more deeply buried into the

172

Figure 6-45. Plot of actual and predicted ST inhibitory activities (pIC50s) by the
LIA model
Training and the test sets are represented by blue and red spheres, respectively.
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Table 6-24. Average van der Waals (UvdW), electrostatic (Uele) and cavity energy
(Ucav) terms obtained from the LIA calculations
Cpd.
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122

UvdWa
-3.64
-3.17
-3.91
0.68
-26.95
-24.27
-27.07
-2.52
-10.07
-2.58
-4.31
-7.48
-6.45
-1.17
-2.99
-3.00
0.50
-28.18
-9.72
-7.40
-2.05
-2.28
-0.52
2.10
-0.25
-6.46
-3.92
-0.47
-0.67
-20.29
-30.44
-2.11
-43.47
-43.65
-39.13
-0.30
-5.54
-21.15
-33.45
-1.57
-10.34
-3.24

Ucavb
2.58
3.22
2.59
3.31
4.09
3.66
3.49
3.45
3.88
3.58
3.88
3.92
2.86
3.19
3.09
2.56
2.85
3.10
3.73
3.83
2.76
2.80
2.79
2.60
2.82
2.70
2.76
2.77
2.42
4.07
3.94
3.69
4.33
3.93
4.61
3.28
4.27
4.48
4.25
3.48
3.51
3.46

Uelec
-168.58
-134.91
-170.39
-188.99
49.82
7.71
17.18
-189.98
-131.13
-206.55
-205.05
-137.5
-140.39
-192.54
-212.50
-211.46
-189.28
32.94
-131.34
-136.34
-210.58
-210.01
-192.11
-190.17
-188.10
-131.34
-139.22
-173.17
-223.33
-0.53
-4.52
-206.71
156.91
65.95
114.87
-191.02
-220.24
-22.96
9.11
-187.59
-171.10
-188.87

Cpd. UvdWa
-27.66
130
-13.87
149
-36.41
153
-30.57
154
-21.30
155
-46.92
183
-38.81
184
-32.81
185
-39.26
186
-48.65
187
-36.04
188
-34.42
189
-53.72
190
-51.16
192
-42.67
193
--38.97
194
-50.27
195
-20.29
196
-18.37
197
-33.37
198
-32.74
199
-28.04
200
-32.52
201
-30.96
202
-34.24
203
-35.59
204
-33.56
205
-37.09
206
-32.49
207
-35.37
208
-35.15
209
-34.90
210
-19.66
211
-19.93
212
-31.61
213
-30.97
215
-28.31
216
-24.35
218
-10.23
219
-22.61
221
-19.66
222
-10.92
224
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Ucavb
2.50
4.41
4.65
1.76
3.23
8.80
6.94
6.60
7.60
10.16
7.92
8.61
10.67
9.62
8.66
8.33
8.64
6.17
5.82
6.07
6.44
6.73
6.53
5.92
6.37
7.18
7.26
6.55
5.31
6.67
6.55
7.01
2.74
2.87
2.90
3.30
3.68
3.40
3.51
3.30
3.80
3.45

Uelec
-70.53
-38.58
-7.63
-14.81
-95.56
-82.23
-59.44
-114.88
-58.80
-34.48
-77.39
-96.62
-72.47
-84.71
-60.23
-64.80
8.57
-120.44
-122.33
-50.90
-59.14
-54.86
-66.60
-61.17
-57.75
-56.45
-57.56
-56.89
-73.44
-62.96
-74.77
-63.40
-70.65
-82.47
-26.08
-16.52
-88.37
-81.58
-109.24
-77.11
-54.20
-113.49

Table 6-24.

(Continued)

Cpd.

UvdWa

Ucavb

Uelec

Cpd. UvdWa

123
124
125
126
127
128
129

-2.36
0.47
0.04
-3.29
-20.81
-1.68
-30.26

2.27
3.17
3.43
2.70
2.68
2.55
2.37

-205.83
-193.39
-190.18
-175.25
-100.44
-203.84
2.51

225
226
227
228
229
230
231

a

-34.58
-3.04
-7.43
-7.51
-6.26
-7.09
-6.47

Ueleb

Ucavc

3.40
3.74
4.22
5.05
5.70
5.36
4.87

42.80
-152.21
-68.26
-93.39
-122.54
-74.82
-140.74

Represents van der Waals energy; b represents cavity energy term; c represents
electrostatic energy.
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cavity (see Figure 6-13); than that in elvitegravir (see Figure 6-15). This loss of
desolvation energy is then immediately followed by more favorable electrostatic and
vdW interactions with IN and viral DNA, contributing to potent inhibitory activities. The
electrostatic energy, although not correlated well for the entire data, could be compared
among raltegravir and elvitegravir given that their crystal structure conformations were
used in the LIA calculations. Electrostatic terms were observed to be more favorable for
elvitegravir probably because of the free negatively charged carboxylate that can
participate in stronger electrostatic interactions with the two Mg2+ ions in the integrase
active site. The vdW energy term is more favorable for raltegravir which could be due to
more hydrophobic contacts with residues in the IN active site. Notably, raltegravir has an
extended gem-dimethyl oxadiazole side chain which is involved in vdW contacts with
side chain methylene of Asn117, ʌ-stacking interactions with Tyr143 and vdW contacts
with Pro142. These interactions on the other hand are not observed with the hydroxyl
alkyl chain in elvitegravir. Evaluation of the energy terms for the two most active
chalcone derivatives also gives support to their binding modes. As discussed in the
docking section, these compounds may have two binding poses (Figure 6-18), one that
docks their phenyl ring into the cavity (compound 86) and the other (compound 96)
whose most frequent conformations have their phenyl ring placed away from the cavity,
exposed to solvent. The LIA cavity energy term for compound 76 is less than that of
compound 86, suggesting a binding mode in which their 2,3,6-trichloro-substituted
phenyl ring is placed outside the cavity and interacts with the methylene of Ser119 and
the methine of Gly118. The more favorable vdW energy term for compound 86 also
implies that its halo-phenyl ring docks into the cavity and makes more favorable vdW
contacts.
RACHEL-Guided Design of Compound 137
Receptor-based design was attempted to synthesize amide compound 157.
Analysis of binding interactions of raltegravir (Figure 6-14) revealed vdW interactions
between the methyl on the oxadiazole ring and the side chain methylenes of Asn117.
Moreover, the oxadiazole ring in raltegravir establishes a ʌ-stacking interaction with the
phenyl ring of Tyr143. Tyr 143 is a conserved residue among the family of retroviruses
and literature reports have shown that mutation of this residue (Y143 R/C) decreases viral
susceptibility to raltegravir.220 The binding interactions of elvitegravir (Figure 6-15) also
revealed vdW interactions between its isopropyl moiety and the Tyr143 residue.
Conformation of the most active compound (96) in the chalcone series also showed that
its halogenated-phenyl ring interacted (Figure 6-20) with Tyr 143, Gly118, and Ser119.
In contrast, no interactions with Tyr143 or Asn117 were observed in our synthesized 3keto salicylic acid amides IN inhibitors. Based on these observations and the sterically
favorable requirement, suggested by the 3D-QSAR contours, prompted me to append a
bulky group with an aim of having ʌ -stacking interactions with Tyr143. Thus, to
determine the importance of this site in the inhibition of IN, the amide derivative 149,
was used as a lead to design a compound that could mimic the interactions of the
oxadiazole ring of raltegravir. Towards this end, RACHEL, a lead optimization
program221 in the Sybyl molecular modeling package was used. Compound 149 bound to
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the IN active site (Figure 6-46) suggesting that the bromine at the R1 position could be
substituted and used as a site for modification. Tyr143 was defined as the target site in
the receptor for directing the fragments to grow and make contacts with this residue.
Automated combinatorial optimization was then performed and the compounds were
conformationally searched and iteratively processed within the IN active site. Only those
compounds that dock well in the receptor site were retained as hits. To optimize the size
of the resulting hits, a molecular weight filter (50-200 Da) was applied in the searching
process. After the analysis, a set of 50 hits were obtained, which were then evaluated. On
the basis of drug-likeness and synthetic feasibility only 1 hit (232) was considered for
further evaluation. Compound 232 had a hydrophobic aryl akyl moiety substituted at the
R1 position. The binding interactions of compound 232 (Figure 6-47) revealed that the
phenyl ring of the added fragment is involved in the desired pi-stacking interaction with
Tyr143, and also made vdW contacts with Asn117. Superimposition of the conformations
of raltegravir by shape complementary (Figure 6-48) supported the synthesis and
biological testing of the derived compound.
Docking Studies of Synthesized Phenanthrene HIV-1 IN Inhibitors
To determine the binding modes of phenanthrene derivatives, synthesized in
Chapter 5, docking studies were also conducted on a homology model of a complete
HIV-1-DNA-complex. Docking studies predominantly revealed two distinct binding
modes for the phenanthrene derivatives. The docked conformations of compound 177 are
shown in Figure 6-49 and interactions in Figure 6-50 and Figure 6-51, respectively. In
both orientations, the ȕ-diketo acid chelating pharmacophore interacted with the two
Mg2+ ions in the IN active site, thus contributing to IN inhibition in accordance with the
proposed mechanism of action of ST inhibitors. The phenanthrene ring in one binding
mode interacted with residues Glu92, Ser119, Asn120, and Phe121, in a novel binding
region in the IN active site. In the other mode, the phenanthrene ring made contacts with
Pro142, Tyr143, and Asn117, and Gly118. It is important to note that because of steric
bulk, the phenanthrene ring does not dock into the cavity into which the characteristic
halobenzyl moieties of advanced IN inhibitors, including raltegravir and elvitegravir, are
inserted.93 The interactions of the halobenzyl groups with DNA bases and IN residues
that forms this cavity is one of the most important features contributing to potent IN
strand transfer activities. Structure-based design suggests significant potential for
improvement of potencies of this series of IN ST inhibitors as a halobenzyl moiety could
be appended to occupy this vacant cavity. More importantly, docking studies showed no
significant interactions with Gln148 and Asn155 which are key residues that cause viral
resistance. Since, compound 174 resulted in a significant loss of activity (ST IC50 of 63
μM) its binding pose was also evaluated. It was observed that compound 174
predominantly docked in a different binding mode (Figure 6-52). In this orientation,
while the phenanthrene ring interacted with Thr66, His67, and Leu68, only the acid and
the enolic oxygen of the ȕ-diketo acid motif chelate the two Mg2+ ions. The loss of
potency may be attributed to a disruption of chelation by an adjacent electron
withdrawing fluorine substituent. Structurally similar derivative 175 had similar binding
pose (Figure 6-53) as 174. However, the improved activity of compound 175 might
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Figure 6-46. RACHEL-based design using compound 149 as lead

Figure 6-47. Binding interactions of RACHEL derived compound 232
Mg2+ ions are represented by magenta spheres. Active site residues are represented by
wires. Compound 212 is represented in tubes and shown with grey carbons. Other atoms
in the ligand are colored as follows: O, red; N, blue; F, bright green. H, white.
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Figure 6-48. Superimposition of compound 232 over Raltegravir
Mg2+ ions are shown by magenta spheres. Raltegravir is shown in wires and colored by
element. Compound 232 is shown in tubes and highlighted with green carbons. Other
atoms in ligands are colored as follows: O, red; N, blue; F, bright green. H, white.

Figure 6-49. Binding modes of compound 177 in IN active site
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Figure 6-50. Interactions of compound 177 in one binding mode
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes
and colored by element. Compound 177 is represented in tubes and highlighted with
yellow carbons. Other atoms in the ligand are colored as follows: O, red; Cl, dark green.

Figure 6-51. Second binding mode of compound 177
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes
and colored by element. Compound 177 is represented in tubes and highlighted with
yellow carbons. Other atoms in the ligand are colored as follows: O, red; Cl, dark green.
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Figure 6-52. Binding interactions of compound 174 in the IN active site
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes
and colored by element. Compound 174 is represented in tubes and highlighted with
yellow carbons. Other atoms in the ligand are colored as follows: O, red; F, bright green.

Figure 6-53. Binding interactions of compound 175 in the IN active site
Mg2+ ions are represented by purple spheres. Active site residues are represented by tubes
and colored by element. Compound 175 is represented in tubes and highlighted with
yellow carbons. Other atoms in the ligand are colored as follows: O, red; F, bright green.
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result from favorable hydrophobic contact that the R5 position fluoro makes with the
alkyl side chains of Leu68.
Experimental
Docking Simulations
For prediction of bioactive conformation and binding modes of the synthesized
chalcone and amide compounds; as well as for the QSAR study and the in-silico
screening, we conducted docking simulations using the GLIDE (v5.7) program from
Schrödinger Inc. (Portland, Oregon, USA). The protein and preparation wizard of
Maestro (v9.2) interface in the Schrödinger modeling package was used to prepare the
protein, applying the OPLS-2005 force-field. Compounds were constructed using the 3Dsketcher module in Maestro. The carboxylic acid moiety was constructed as a carboxylate
for docking. The inhibitors were energy minimized using the MacroModel (v9.9)
molecular mechanics program, and prepared for docking using the LigPrep (v2.5) facility
in Maestro. Twenty docking poses were obtained for each molecule, the docking being
terminated if two consecutive solutions were within a rmsd of 5 Å.
MM-GBSA Analysis
Computational methods to predict the binding free energy of a ligand to its
receptor target include rigorous techniques like free energy perturbation (FEP)222 and
thermodynamic integration (TI)223 methods. These methods are more accurate in
predicting binding affinities in certain protein-ligand systems than the use of common
scoring functions, but are computationally intensive and highly time consuming. At the
next level of approximation, is a semiempirical linear interaction energy (LIE) method.
Emperical scoring functions used by various docking programs are designed to include
various approximations in order to determine the binding pose and estimate the binding
affinities of a large number of molecules in short periods of time. Docking procedures
treat proteins as rigid, do not consider protein and ligand desolvation, and ignore the
entropic terms in energy calculations. Although docking algorithms have been highly
successful in reproducing correct binding poses, the approximate scoring functions often
fail to rank order compounds on the basis of their binding affinities. Recent advances in
drug discovery have used a combination of molecular mechanics and continuum
salvation methods to determine and predict the relative binding free energies with better
accuracy; these include Molecular Mechanics/Poisson-Boltzmann Surface Area (MMPBSA)224 and Molecular Mechanics/Poisson-Generalized Born Surface Area (MMGBSA). The MM-GBSA method evaluates binding free energies by minimization and
MD of the protein-ligand complexes. Equation 6-1, Equation 6-2, and Equation 6-3
calculates free energy of binding (ǻGbind) between a ligand and its receptor as;
ǻGbind = ǻH í TǻS = ǻEMM + ǻGsol í TǻS
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(Eq. 6-1)

ǻEMM = ǻEinternal + ǻEelectrostatic + ǻEvdW

(Eq. 6-2)

ǻGsol = ǻGPB/GB + ǻGSA

(Eq. 6-3)

where ǻEMM is the difference between the molecular mechanics energies of proteinligand complex and the sum of the molecular mechanics energies of the free ligand and
the unliganded protein. ǻGsol is the corresponding difference in the solvation energies
and –TǻS is the corresponding differences in conformational entropy upon binding.
ǻEinternal, ǻEelectrostatic and ǻEvdw are internal (bond length, angle, torsion), electrostatic and
van der Waals (vdW) energies, respectively. ǻGPB/GB and ǻGSA are the electrostatic
(polar) and non electrostatic (nonpolar) solvation energies, respectively.
The docking-derived conformations of 98 compounds, which have common
binding modes and were used to build 3D-QSAR model 3, were first subjected to energy
minimization by the local optimization module in the Prime package (v3.0 from
Schrödinger Inc.) and binding free energies were calculated using the OPLS-2005 force
field and the GBSA continuum model. All residues were kept frozen in the Prime
calculations. The entropy penalty upon ligand binding was ignored in estimating the
binding free energies which is calculated in prime-MM-GBSA using Equation 6-4;
ǻGbind = ǻEMM + ǻGGB + ǻGSA

(Eq. 6-4)

3D-QSAR Studies
3D-QSAR methods like comparative molecular field analysis (CoMFA)225 and
comparative molecular similarity analysis (CoMSIA)226 are widely used to guide the
synthesis of novel compounds by identifying the physiochemical properties that are
important for activity, as well as an activity prediction tool. 3D structure building and
CoMFA and CoMSIA studies were performed using the SYBYL program (version X1.1)
on a Dell computer workstation with the Red Hat Linux operating system. All the
molecules were assigned MOPAC partial atomic charges. The CoMFA descriptors, steric
(Lennard-Jones 6-12 potential) and electrostatic (Coulombic potential) field energies,
were calculated using Tripos force field with a distance-dependent dielectric constant,
using the SYBYL default parameters: 2 Å grid points spacing, an sp3 carbon probe atom
with +1 charge, vdW radius of 1.52 Å, and energy cut-off of 30 kcal/mol. The five
similarity indices in CoMSIA, namely, steric, electrostatic, hydrophobic, H-bond donor
and H-bond acceptor descriptors, were calculated using a C1+ probe atom with a radius of
1.0 Å placed at regular grid spacing of 2 Å. A Gaussian-type distance dependence was
used between grid point q and each atom i of the molecule. The default value of 0.3 was
used as the attenuation factor (R). Column filtering was set to 2.0 kcal/mol. CoMSIA
steric indices are related to the third power of the atomic radii, electrostatic descriptors
are derived from atomic partial charges, hydrophobic fields are derived from atom-based
parameters, and H-bond donor and acceptor indices are based on experimental results
(SYBYL program).
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Partial Least Squares Analysis
Partial least square (PLS) regression analysis is widely used to correlate important
structural features with biological activity, and derives a mathematical relationship
between dependent and independent variables, particularly when the number of
descriptors outnumber the number of compounds.227 For the present study, CoMFA and
CoMSIA descriptors were used as independent variables and ST pIC50 (biological
activity) values were used as dependent variable. The predictive value of the models was
evaluated by leave-one-out (LOO) cross-validation. The cross-validated coefficient, q2,
was calculated using Equation 6-5
2

q = 1

_

_

6 (Y predicted Y actual)
6 (Y actual _ Y mean )2

2

(Eq. 6-5)

where Ypredicted, Yactual, and Ymean are predicted, actual and mean values of the target
property (pIC50), respectively. (Ypredicted – Yactual)2 is the predictive sum of squares
(PRESS). Conventional correlation coefficient r2 and its standard error, s, were also
computed for the final PLS models. CoMFA and CoMSIA coefficient maps were
generated by interpolation of the pair wise products between the PLS coefficients and the
standard deviations of the corresponding CoMFA or CoMSIA descriptor values. External
validation of the developed models was performed by determining the predictive r2 of the
test set compounds using Equation 6-6
r2 = (SD – PRESS) » SD

(Eq. 6-6)

where SD is the sum of the squared deviations between the biological activity of the
molecules in the test set and the mean biological activity of the training set.
Linear Interaction Approximation (LIA) Calculations
LIA parameters were also used to develop a QSAR model for the IN inhibitors in
the dataset. The docked conformations of 98 compounds having similar binding modes
were separately subjected to binding affinity calculations in the Liaison module (v 5.7)
from Schrödinger Inc. For the LIA calculations active-site residues surrounding the
ligand were considered flexible. The LIA method uses a Surface Generalized Born (SGB)
continuum solvation model to determine the binding free energy as a linear function of
hydrophobic, electrostatic and cavity energy terms, which are calculated using the
molecular mechanics force field, using Equation 6-7
ǻG = Į ( <UbvdW > í < UfvdW>) + ȕ (<Ubelec > í < Ufelec>)
+ Ȗ (<Ubcav > í < Ufcav>)

(Eq. 6-7)

where < > represents the ensemble average; b means the ligand in the bound form while f
means the ligand in the free form. Į, ȕ, and Ȗ are the coefficients. The vdW, electrostatic
and cavity energy terms are represented by UvdW, Uele, and Ucav. Energy minimization
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sampling using a conjugated gradient technique was used for minimization, with an rmsd
of 0.01 for convergence and a maximum of 1000 steps.
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CHAPTER 7.

CONCLUSIONS

In summary, I have synthesized and evaluated the HIV-1 integrase inhibitory
activities of a series of chalcones and related amides harboring a 3-keto salicylic acid
moiety as a ȕ-diketo acid bioisostere. Consistent with the DKA class of IN inhibitors,
these series of compounds were also generally selective against the IN strand transfer
step. Most of the potent compounds of the series also inhibited HIV replication in cell
culture with moderate antiviral activities, which supports further development of the
series. Following are the three modifications, I believe could be attempted to improve the
activities to submicro and nanomolar levels.
(1) The 3-keto salicylic acid ring may be modified in that the 3-keto group could
be incorporated into a ring system (Figure 7-1) to design bicyclic compounds. As
discussed in the introduction chapter, one of the key features in the development of
potent IN inhibitors is the requirement of coplanar chelating moieties. The 3-keto oxygen
had an angle relative to the core salicylic acid ring. Incorporating it into a ring system
may make the chelating moieties more coplanar and result in a conformation that may
chelate more effectively with the two Mg2+ in the IN active site.
(2) All advanced IN inhibitors have a heterocyclic structural core. Future efforts
could be directed at incorporating a heteroatom, preferentially nitrogen into the ring
system (Figure 7-2).
(3) Position R1 (see Figure 7-1) could be thoroughly investigated. This is the site
where the gem-dimethyl oxadiazole carboxamide group of raltegravir and the isopropyl
hydroxyl substituent in elvitegravir reside. Structure-based design could be used to
improve the HIV-1 integrase inhibitory activity of this series of compounds. Targeting
Tyr143 and Pro145 by putting other groups at the R1 position may improve IN inhibitory
activity. A series of compounds, with amines replacing the bromine at the R1 position,
have been designed and docked in the IN active site. Docking results (Figure 7-3)
revealed that the amino substituents are positioned into a new region making contacts
with Arg263 and Lys264. These amino acids appear to interact with viral DNA and could
be targeted to explore their effect on IN inhibition.
I have also synthesized electronegative groups containing phenanthrene ȕ-diketo
acids as HIV-1 integrase inhibitors. Docking studies suggest that the compounds have
different binding modes than raltegravir and, do not significantly interact with residues
involved in viral resistance (Asn 155, Gln 148). Thus, this series of compounds could be
investigated to circumvent viral resistance associated with current clinically used
integrase inhibitors. However, efforts are needed to prevent their cellular toxicities and to
improve their anti-viral activities. The phenanthrene could be modified to a structurally
related stilbenes that may prevent their intercalation with DNA and thus, may reduce
their toxicities. Docking studies have also revealed that the cavity occupied by the
halobenzyl group in raltegravir and elvitegravir is vacant (see Figure 6-46). Further
optimization could be attempted to append a halo benzyl moiety that could occupy the
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Figure 7-1.

Optimization of 3-keto salicylic acid to a related bicyclic compound

Figure 7-2. Optimization of 3-keto salicylic acid to a 4-carboxamide-3-hydroxy
picolinic acid

Figure 7-3.

Design of new 3-carboxamide salicylic acid IN inhibitors
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vacant cavity.
In computational studies, I have explored the binding modes of potent HIV IN
inhibitors by docking and 3D-QSAR studies using a homology model of HIV IN-DNA
complex. The binding mode of raltegravir and elvitegravir are in accordance with the
foamy virus structure revealing interactions important for inhibitor-IN binding. The parafluorobenzyl group in raltegravir and the halogen-substituted benzyl ring of elvitegravir
insert into the cavity formed by displacement of the 3ƍ-end of the viral DNA and engage
in strong electrostatic and vdW interactions with the DNA-IN interface. The metalchelating pharmacophore of raltegravir and elvitegravir interacted with the two metal
ions (Mg2+) in the IN active site. The models showed the binding contributions of the
gem-dimethyloxadiazole carboxamide moiety in raltegravir and the N-alkyl hydroxyl side
chain in elvitegravir and identified Tyr143 as key residues interacting with IN inhibitors.
To improve our knowledge of the stereoelectronic, hydrophobicity and hydrogen
bonding requirements for IN inhibition, extensive 3D-QSAR studies were conducted
using both the PHASE derived ligand-based and the homology model-guided structurebased molecular alignments. Homology model guided composite 3D-QSAR study,
performed by combining four different classes of IN inhibitors, yielded significantly
improved statistical results than the ligand-based 3D-QSAR study; which was conducted
on synthesized chalcone and amide derivatives. Thus, integration of different scaffolds
proved advantageous in arriving at a single 3D-QSAR model capable of accommodating
diverse IN inhibitors without any bias for a particular functionality. The QSAR model
developed using the docking-based and MM-GBSA validated alignments performed the
best. Both CoMFA and CoMSIA of the docking-based model showed good predictive
ability when evaluated on prospectively synthesized compounds. The CoMFA of
docking-based model 3 has performed the best, and could be further developed by
incorporating more of the synthesized amide derivatives in the training set and then
predicting novel related IN inhibitors.
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